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Chapter
Introduction
1.1 Background
With the advent of several new techniques in the last decades, a huge leap 
has been made in biology to help in the understanding of the workings of the 
living cell. Techniques like Polymerase Chain Reaction, cloning, DNA 
sequencing, protein mass spectrometry and NMR have revolutionized the 
scientific practice in the search of understanding disease and health. Where 
it used to take years to clone and sequence a single gene, for instance, it is 
possible now, to sequence 25 million bases in a 4-hour run [25]. In the field 
of genome sequencing, Carlson’s curve can be considered as the equivalent 
of Moore’s law in informatics [5]. From this curve even faster and cheaper 
sequencing can be expected in future.
The results of these new techniques can show the living cell at various levels. 
General terms which describe these levels are often used to give a global 
indication of the niche in which a researcher is working or at what level an 
experiment is performed. A summary of relevant terms and their explanation 
are given below:
• transcriptomics: The study of expression levels of mRNA molecules 
(transcripts). The expression is dependent on circumstances of the 
population of cells.
• proteomics: The study of function and interaction of proteins in the 
human body. The proteome varies between cell types.
• metabolomics: The investigation of low molecular weight compounds 
in body fluids and tissues. These so called metabolites allow to analyze
5
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the metabolism of an organism.
• genomics: The molecular analysis of the genes in a chosen organism. 
The structure, interaction and functional dynamics of all genes in the 
genome are investigated.
These categories describe investigations on a large scale, with large numbers 
of metabolites, genes and proteins. The categories are generalizations and 
can be divided in subcategories. The term genomics can in turn be 
subdivided in comparative genomics, structural genomics, functional 
genomics and many others. This is much broader than the term 
transcriptomics, which is more specifically defined as the study of levels of 
mRNA molecules. In this thesis, research is presented in the field of 
transcriptomics and genomics. Methods to analyse large multidimensional 
data sets are shown and attention is given to the validation of the results from 
the analyses. The ideas, origin, and applications of these methods are partly 
inspired by methods in the field of chemometrics.
1.1.1 Measuring gene expression: microarray technology
Before we will go deeper into the analysis of gene expression data sets, a 
short description is given of the microarray technique. Microarrays were 
designed to measure gene expression on a large scale [11,30]. The 
expression of thousands of genes can be measured simultaneously on a small 
plastic or glass slide.
First, parts of single-stranded DNA are placed at fixed spots on the surface of 
the slide. The parts are selected to be specific for a single gene and the length 
of these so called probes depends on the type of array which is used. Second, 
the biological sample under investigation is labeled with a radioactive or 
fluorescent label to be able to detect the amount of sample, bound to a 
certain spot. The label is incorporated in the sample when the mRNA in the 
sample is converted to cDNA with an enzyme called reverse transcriptase. 
Third, the sample is allowed to hybridize to the complementary probes on 
the array. The sample can consist of mRNA from all cell-types in a tissue 
sample to specific cultured cell-line, depending upon the biological 
circumstances at which the experiment takes place. Finally, the relative
6
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expression on each spot is determined by scanning the array, hereby 
detecting the intensity of labeled sample, which has hybridized to the spot. 
The data which are used in this thesis are generated with microarrays from 
the company Affymetrix (see Figure 1.1). There are several characteristics 
which are specific for this type of arrays. The probes are generated on the 
surface with photolithography [24]. They have a relatively short length of 25 
bases. For each probe a control sequence is present which is different at the 
central base. This so-called mismatch probe can be used as a measure of the 
background signal for the original probe. Multiple probes are combined into 
a probe-set, which is then used to measure the expression of specific genes.
Figure 1.1: Picture of an Affymetrix array and schematic drawings of probes on the chip. In reality 
the probes are 25 bases long. (Pictures taken from www.affymetrix.com)
1.1.2 Enough data is available.
The introduction of (rapid) sequencing of genomes and large scale gene 
expression measurements were accompanied with roaring statements of 
what could be gained from the results [23]. At the moment substantial 
amounts of data can be generated, but a lot of the answers have to be found 
and promises for the post-genomic era have still to be fulfilled. A lot of hard 
work will have to be done to gain useful information from the data.
One problem is the amount of data which is generated by the experiments. 
The new techniques mentioned before have transformed the biological
7
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science from a data-poor environment, to a data-rich environment. In fact the 
abundance of data can easily overwhelm the researcher when looking for 
solutions in a standard way. Another problem is that the abundance of data 
does not guarantee knowledge. Because of the heaps of information, relevant 
information has to be extracted from it, to find the “needles in the 
haystacks”. Even more challenging is the fact that standard statistical 
methods are not always applicable and new methods will have to be 
developed and tested for this purpose.
An example to illustrate the need for new methods in microarray data 
analysis can be given by a comparison of several gene selection methods 
when inspecting the analysis of a small microarray dataset by Choe et al. [6]. 
The dataset consists of 6 microarray measurements with Affymetrix 
DrosGenomel microarrays. A first group of three replicate arrays measures 
a control sample. For the sample of the second group of three arrays, 1309 
genes are added with a higher expression when compared to the control 
sample. The result is that for this dataset, it is known which genes should be 
found to be differentially expressed in the analysis.
When analysing the differences in gene expression between two conditions it 
is common practice to perform ratio analysis (one of the most simple forms 
of pattern recognition). The first problem which arises is then to determine 
the cut-off for the number of genes which are considered to be differentially 
expressed. One method which has been applied frequently is to take the 
genes which exhibit a two fold regulation (a ratio larger than 2 or smaller 
than -2). A more standard statistical approach would be to apply a two 
sample t-test for each gene. The value of this small dataset becomes 
apparent by inspection of Figure 1.2. The two fold selection method and 
normal t-test acquire an unacceptable amount of false positive genes in the 
process of identifying differentially expressed genes. Multiple hypothesis 
testing (MHT) methods, advocated in microarray literature, are more 
appropriate because the number of false positives is greatly reduced. While 
the number of false positives is diminished a reasonable number of real 
differentially expressed genes is still identified with these methods.
Recapitulating; “Now we have the expression data of thousands of genes, 
what is next?” This was -and still is- a major challenge in gene expression 
analysis depending on the design and nature of the gene expression data at
8
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Figure 1.2: Results from 2-fold regulation in comparison with normal t-test and other MHT methods. 
The percentage of true differentially expressed genes (x-axis) which is found is plotted against the 
percentage of true positives in the group of genes which is predicted to be differentially expressed 
(y-axis). Standard statistical methods return a lot of false positive results; With the 2 fold regulation 
criterion (FS>2) only 40 % of the true DEGs is found, and only 20 % of the “hits” is correct. The two 
sample t-test (t-test) finds more true DEGs (80 %), but here still less than 50 % of the results are true 
positives. (Picture generated by Bart van der Haven)
hand. To position the work presented here, a short overview will be given of 
work which has been done in the field of microarray analysis in section 1.2. 
Next, the goals of the research in this thesis and its scientific contribution are 
explained in brief in section 1.2.2. The more detailed discussion of the 
research articles can be found in the chapters 2, 3, 4, 5 and 6. Finally the 
conclusions which can be drawn are noted and discussed in chapter 7.
1.2 The scientific field of microarray analysis
During the last few years a substantial number of statisticians in the world 
have been occupied in the analysis of gene expression data and contributed 
to the analysis. Not all these statisticians have been working on the exact 
same problem, because the field of microarray research is substantial and
9
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several areas of research exist. Here, I have divided the field in different 
areas of research ranging from planning the experiment to the higher level 
analysis of the expression results.
• Experimental Design: Before the experiment is performed, the setup 
has to be planned with a statistical valid rationale, in order to obtain 
results which allow to find answers to the questions asked.
• Image analysis: The microarrays are scanned and the relative 
expression for each probe has to be extracted. Scratches on the surface, 
differences in probe spot size, artefacts and correction for background 
signal are among the problems which have to be handled in this area of 
research.
• Normalization methods: Generally speaking, the aim of normalization 
is to remove systematic effects in the experiment, which are not 
resulting from response of the system to the experimental factors of 
interest [12].
• Classification/Pattern recognition: In this area, genes with similar 
behaviour or striking patterns of expression are identified. This is done 
to to link them with the altered conditions in the experiment or new 
previously unknown biological function. Also genes allowing for 
classification between diseased and healthy state or genes which allow 
the differentiation between cancer (sub)types can be of interest to the 
researcher [36].
• Genetic network reconstruction: With the expression values as a 
starting point, the metabolic signalling cascades or other systems 
underlying the data are modeled by calculation of the putative relations 
between the genes [31].
• Biological interpretation: The merits of a method of analysis should 
not be based on statistical aspects of the analysis alone, as will be 
explained in section 1.2.2 “biological validation of results”.
Of course this division is artificial and a good analysis of a gene expression 
experiment should be accurate in all fields to obtain relevant results. The 
general goal of the expression experiments is to uncover the role of
10
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previously unknown genes in a biological system of interest. The result of 
many methods of analysis is a list of genes which are indicated as relevant to 
the system.
A general overview of the statistical analysis is given in the paragraphs 
below. Some areas are covered more extensively -  among which is the topic 
biological interpretation -  because these areas are more closely related to the 
scientific setting of the research presented in this thesis.
1.2.1 Statistical analysis of microarray data
Cluster analysis
In general cluster analysis can be considered as a preliminary data 
exploration to give an overview of the most obvious patterns in the data. A 
general description which can be given to explain the term cluster analysis is: 
“the unsupervised grouping of data to automatically summarise and discover 
patterns”. Therefore, cluster analysis is more or less common practice when 
describing microarray results, because of the large amounts of data.
There is a large number of articles using different forms of clustering 
algorithms. The clustering methods are ranging from well-known methods 
like hierarchical clustering [9], k-means clustering [35], model-based 
clustering [38], Self Organising Maps (SOM) clustering [34] up to more 
specific methods with exotic names like for instance weighted Chinese 
restaurant process clustering [27]. The underlying assumption for all cluster 
methods is that genes with similar function exhibit similar expression 
patterns.
The first and most cited paper about clustering was by Eisen et al. [9], 
describing the hierarchical cluster analysis of yeast expression data. Because 
of knowledge about a large number of genes, present in 5 specific clusters, 
these clusters were assigned to the processes cholesterol biosynthesis, the 
cell cycle, the immediate early response, signaling and angiogenesis and 
wound healing and tissue remodeling.
Even though clustering is a technique which is applied frequently in the 
microarray analysis, some problems should be pointed out. Some cluster 
techniques can be time consuming and the biological validation of clusters 
can be difficult. This is of course depending on the cluster method of choice, 
and often clear-cut biological conclusions as drawn by for instance Eisen et
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al. [9] can not be repeated for other gene expression experiments.
Principal Component Analysis
Like cluster analysis, Principal Component Analysis (PCA) [15] has been 
used to analyse microarray data as an explorative technique [13,29]. The 
advantage of PCA is that is very versatile and can be applied to large 
datasets without any problems. The technique can reduce the dimensionality 
of a dataset by compressing the information to a lower number of 
dimensions called Principal Components which contain the important 
information. The selection of the number of components which contain the 
relevant information is an important step for this technique.
An example of reduction of dimensionality of microarray data to so called 
eigengenes and eigenarrays is the study of Alter et al. [1] for a well known 
yeast cell cycle dataset [32]. PCA can also be applied to time-series data and 
an example of this is shown in an article by Hornquist et al. [14].
Due to the large number of genes it is not easy to draw useful conclusions 
from the graphics which can be generated from PCA. It has been mentioned 
in literature that the results can be seriously disturbed by noise in the data or 
large numbers of genes which are not responsive to the experimental 
procedure [14,26].
A technique called Canonical Correspondence Analysis (CCA) can be 
considered as an extension of PCA. There, biological knowledge is explicitly 
shown in the visual representation of the analysis results. CCA has been 
applied in microarray analysis to identify relations between genes and 
experiments in yeast cell cycle dataset and a colon cancer dataset [10,21]. 
Recently it has been used to combine biological annotation information with 
microarray data. Expression data has been combined with GO information, 
and transcription factor site information [4,16].
ANOVAfor microarray data
Analysis of Variance (ANOVA) has been used in statistic analyses in allmost 
all areas of biology. For the analysis of microarray data, it has been applied 
to the fields of nutrition, micro-biology, pathology and plant 
biology [3,8,28]. One of the advantages of ANOVA is that it is possible to 
separate different factors in the experiment. This allows the researcher to 
subtract the modeled effects of disturbing and irrelevant factors and
12
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concentrate on the interesting information. The use of ANOVA to 
microarray data was introduced by Kerr et al. [17-19]. A fixed-effect 
ANOVA model was used, which modeled the factors Gene, Array, Dye, 
Treatment and their interactions. The model of Kerr et al. was later 
expanded by Lee et al. [22] in a two-step model. First, the Array and Dye 
effects were modeled with ANOVA and subsequently removed. Second, 
ANOVA was performed for each gene with the other factors in the 
experiment. Wolfinger et al. [37] introduced a mixed-effect ANOVA model, 
in which they considered the array effect to be random.
1.2.2 Biological interpretation of results
The techniques and methods described in the previous sections certainly 
bring improvements to the data analysis, but in the end, the results of the 
analyses have to be translated back to the biology. Ultimately these 
biological facts will give confidence about results from the data analysis to 
the biologists which performed the experiments. This process can be 
described as biological validation and should be a vital part of the 
introduction of a new data analysis method, to prove the applicability of the 
method in practice.
Biological validation can become a sort of vicious circle sometimes: when 
the results of the analysis agree with current knowledge about a system, one 
could ask what new insights can be gained from the experiments. On the 
other hand, one could begin to doubt the results from an experiment when 
the prior knowledge about a system is not directly reflected in the validation 
process. Therefore, it is useful to mention that biological validation can be 
considered as a test of the outcome of an experiment against current 
knowledge about a biological system at hand.
The ultimate biological validation of the results from methodological 
analysis is of course the confirmation of newly generated hypotheses in the 
wet lab. The term biological validation is used in this thesis as the 
description of methodological results with the prior information which is 
available. Several methods are available which have the objective of 
biological validation. They range from reconstructing genetic networks to 
mining literature databases. Here we will focus more on so-called Gene Set 
Enrichment methods because they are frequently applied and Gene Ontology
13
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Enrichment is used in the research presented further on in the thesis.
Gene Ontology enrichment
Enrichment analysis is a method to identify the biological information which 
is distinctive for a given geneset. The general idea is to identify the 
biological information which is enriched for the geneset based on annotation 
information which is available for these genes. The result is a more general 
biological description of the geneset, which is generated by a specific type of 
analysis.
Currently annotation information stored in the Gene Ontology Database [7] 
is widely used to describe the biological background and results from gene 
expression analysis. Several different programs which can perform GO 
enrichment tests can be used. Some statistical methods which are used to 
calculate the overrepresentation of GO terms are: Hypergeometric test, 
Fisher’s exact test, Pearson x 2 test, Continuous approach, z-score, t-test [2] 
and EASE score [33]. A thorough discussion about GO enrichment tools can 
be found in an article by Khatri et al. [20]. In general, the hypergeometric 
test and Fisher’s test are used in most of the programs. For the results of GO 
enrichment shown later in the thesis, the statistics of the hypergeometric test 
were used.
1.3 Thesis contents
From the preceding sections several problems in microarray analysis can be 
formulated. First, due to the nature of the microarray data new methods will 
have to be found which can handle the amount of data and are able to cope 
with disturbing factors as noise or other systemic effects. Second, the 
decision in biological validation tools is often not checked for stability of the 
results even though large differences could occur depending on the chosen 
cut-offs.
From these problems the goals for the research presented in this thesis can 
be formulated in the following general research questions:
• Is there a way to extend the explorative analysis of data to the biological 
questions for the experiment and to improve the analysis of large 
microarray datasets in general?
14
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• Is it possible to bring advances in analysis of microarray experiments, 
in stability and other aspects, by applying biological information, which 
is available beforehand from external sources?
The contributions in this thesis are diverse, because of the large area of 
research. The topics can be thought of as logical sequential steps, which start 
after data extraction and normalization. In the broad field of microarray 
analysis this thesis adds methodological building blocks to the areas of 
pattern recognition, biological validation and the integration of biological 
information in the data analysis. The new methods are distributed across the 
chapters as follows:
1.3.1 Analysis of microarray datasets
In chapter 2 the improvement of interpretation of ANOVA models with PCA 
is described. In addition to the focus on relevant information in the data, this 
method of data analysis allows to correlate genes with specific factors in the 
data. As a result the method can be considered as an improvement of the 
analysis of large microarray datasets.
The ANOVA method is further investigated and extended by the application 
and comparison of several nonparametric versions of this technique in 
chapter 3. The assumptions of normality which underlie the normal ANOVA 
are rarely met due to the nature of microarray data. The nonparametric 
method allows to refrain from application of data transformation methods to 
attempt to fulfil the requirements of normal ANOVA.
1.3.2 Biological validation and the integration of annotation 
information in data analysis
Methods are introduced in chapter 4 which can improve the interpretation 
and consistency of results of current biological validation methods. 
Furthermore, a method to incorporate prior information in the form of 
biological annotation in the data analysis is shown in chapter 5. There, 
preclustering gene expression data within Gene Ontology classes is applied 
which can correlate specific groups of genes with similar annotation with 
experimental factors.
15
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The ultimate biological validation is experimental evidence which confirms 
hypotheses generated by the analysis of expression data. In chapter 6 an 
example of such validating experimental research is presented. Biological 
evidence is given for the osteogenic properties of Vitamin D. The results 
show that the strong osteogenic effect of Vitamin D is accomplished by 
accelerating the kinetics in the early part of osteogenic differentiation. 
Hypotheses which were generated after analysis of microarray data were 
confirmed.
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2.1. ABSTRACT
2.1 abstract
2.1.1 Motivation:
ANOVA is a technique which is frequently used in the analysis of 
microarray data, e.g. to assess the significance of treatment effects, and to 
select interesting genes based on p-values. However, it does not give 
information about what exactly is causing the effect. Our purpose is to 
improve the interpretation of the results from ANOVA on large microarray 
data sets, by applying PCA on the individual variance components. 
Interaction effects can be visualised by biplots, showing genes and variables 
in one plot, providing insight in the effect of e.g. treatment or time on gene 
expression. Because ANOVA has removed uninteresting sources of variance, 
the results are much more interpretable than without ANOVA. Moreover, the 
combination of ANOVA and PCA allows for simple way to select genes, 
based on the interactions of interest.
2.1.2 Results:
It is shown that the components from an ANOVA model can be summarised 
and visualised with PCA, which improves the interpretability of the models. 
The method is applied to a real time-course gene expression dataset of 
mesenchymal stem cells. The dataset was designed to investigate the effect 
of different treatments on osteogenesis. The biplots generated with the 
algorithm give specific information about the effects of specific treatments 
on genes over time. These results are in agreement with the literature. The 
biological validation with GO annotation from the genes present in the 
selections shows that biologically relevant groups of genes are selected.
2.1.3 Availability:
R code with the implementation of the method for this dataset is available 
from http://www.cac.science.ru.nl under the heading ’’Software”.
Contact: L.Buydens@science.ru.nl
2.2 Introduction
Microarray analysis is not straightforward because of the large number of 
genes which are investigated simultaneously. By incorporating several
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factors of interest (for instance time and different treatments) in the 
experimental design, the interpretation of the data becomes even more 
difficult. The influence of the factors of interest should be separated from 
each other to draw sensible conclusions from the data analysis. By 
application of Analysis of Variance (ANOVA) the different factors are 
modelled separately and significance of interactions between factors can be 
investigated as well [7]. Interpretation of the ANOVA models and resulting 
p-values can be difficult. Here a method is shown which enhances the 
interpretation of ANOVA models by application of Principal Component 
Analysis (PCA) on the ANOVA results. Relevant information is often known 
beforehand to be present in the interaction terms of the ANOVA model. With 
the technique presented here this information can be accessed. The method 
works fast and straightforward, displaying the results in an orderly fashion.
The application of ANOVA to microarray data has been described by Kerr et 
al. and Churchill [4,15-17]. In these papers it is shown how a distinction 
between the effects of different factors can be made with ANOVA. 
Normalization is then performed by removing the disturbing effects from the 
data. Thus, when performing normalization with ANOVA, the aim is to 
make sound estimations of the relative expression of genes by modelling the 
different factors of variation and subsequently correcting for disturbing 
factors [6]. There the ANOVA is split in a normalization model and a gene 
specific model. The residuals of the normalization model are used as the 
normalized signal which is then modeled by the gene specific model. This 
approach was used as well in an article by Wolfinger et al. [30]. Recently 
Juenger et al. [14] used the ANOVA framework to asses sources of 
variability in their expression data of Arabidopsis thalania.
ANOVA can be used for the detection of differentially expressed genes when 
there are more than two conditions in an experiment [6,21,30]. Gene 
selections are made based on significance of an effect, calculated by 
performing ANOVA on a gene-by-gene basis [4]. The selection of genes 
showing differential expression (with a significant effect) can be made based 
on a fixed cut-off, but it is preferred to apply multiple hypothesis testing on 
the results of the significance tests from ANOVA. Tan et al. [26] applied 
ANOVA to detect differentially expressed genes to determine cross-platform 
comparability of three commercial microarray platforms. The number of
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genes which are declared differentially expressed with ANOVA are 
compared between platforms in order to make statements about the level of 
agreement. A recent example of the application of ANOVA to identify 
differentially expressed genes is from Bushari et al. [2]. The authors 
identified 36 differentially expressed genes for groups of mice with different 
diets. The interest was to identify genes which were involved in the effect of 
fescue toxicosis on gene expression in the liver.
Although ANOVA is useful in identifying genes with significant group 
differences, it is not clear which of the groups are responsible for this 
difference [21]. It is highly desirable to get this information from the 
ANOVA results as well. One way of achieving this is analysing the 
individual ANOVA components, the main and interaction effect matrices, 
with PCA. This allows to examine this information in an intuitive way by 
displaying it using biplots. These explicitly show the correlation between 
individual genes and other factors such as time and treatment.
PCA [12] has been applied to microarray data in several publications as a 
data exploration tool [11,23]. An example of reduction of dimensionality of 
microarray data to so called eigengenes and eigenarrays is the study of Alter 
et al. [1]. for a well known yeast cell cycle dataset [25]. PCA allows to 
visualize correlations in data sets by compressing information in a low 
number of dimensions. The method is very flexible and large data sets can be 
handled easily. An important step in PCA is the determination of the number 
of latent variables which contain relevant information. Alter et al. suggest to 
remove components which are thought to be resulting from noise; however, 
the determination of which components in the PCA can be attributed to noise 
is not at all straightforward. Furthermore, Hornquist et al. [9] (for time-series 
data) and Misra et al. [20] (for non time-series data) have recognized that 
PCA can be disturbed by variance resulting from noise in the data, or genes 
which are not affected by the biological experiment. Modelling the different 
factors in the experiment with ANOVA is an approach to solve this.
In this article the combination of the techniques of PCA and ANOVA is 
shown for the analysis of microarray data. Performance of PCA on ANOVA 
models has been described previously for metabolomics data of guinea 
pigs [24], studying the effects of different doses of Vitamin C on the 
development of osteoarthritis. Another example has been published in the
22
CHAPTER 2. INTERPRETATION OF ANOVA MODELS FOR MICROARRAY DATA
field of proteomics [10]. There, the aim was to find consistent biomarkers 
for premature delivery in humans. Besides finding biomarkers from the mass 
spectra, ANOVA-PCA was used to investigate effects of the design of the 
experiment on the data.
ANOVA and PCA have been used on microarray data separately, but we will 
demonstrate the advantages of combining the two methods. The 
combination of PCA with ANOVA will cause PCA to concentrate on the 
variance components that are really important. This avoids the problem, 
mentioned before, of uninformative factors disturbing the picture. Therefore 
the results will be more interpretable, as will be shown below. The aim of 
the analysis presented here is to display the relationships between genes and 
factors in the experiment in an appealing way.
Here, the value of ANOVA-PCA is demonstrated for a multi-treatment 
time-series dataset. In the dataset analysed here, the biological background 
is in the field of osteogenesis. First, the main and interaction components of 
the ANOVA model are calculated with the factors Time, Treatment and 
Gene. Next, the interaction effects are analysed with PCA, showing 
biologically relevant correlations between genes and treatments. Another 
application for the algorithm is making gene selections. The external 
validation of the results is performed with biological annotation information 
from the Gene Ontology (GO) database [5], indicating that biologically 
relevant selections of genes are made.
2.3 Methods and Analysis
2.3.1 Description of the mesenchymal stem cell dataset
The microarray experiment presented here was performed on human 
mesenchymal stem cells, triggered to undergo osteogenic 
differentiation [22]. Dexamethasone can induce the differentiation of stem 
cells to osteoblasts. It is known that BMP2 and Vitamin D3 can potentiate 
osteogenesis in combination with dexamethasone [13]. The biological 
process of interest for the dataset which is used for the analysis in this article 
is skeletal development.
Mesenchymal stem cells are able to differentiate into osteoblasts. Mature 
osteoblasts which mineralize the extracellular matrix are formed after two 
weeks. The experiment was set up as a time-series experiment and the
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expression measurements were taken at 10 time points (at 1, 3, 6, 12, 24, 48, 
72, 120, 192 and 288 hours after after onset of treatment). More 
measurements were taken in the first 24 hours of the time course, because 
the first part is expected to be important for the onset of differentiation.
In addition to sampling multiple time points during the differentiation 
process, another factor of interest is introduced to the experiment by 
inducing osteogenesis of the mesenchymal stem cells with different 
treatments. The three treatments are named after the substances added to the 
culture medium (osteogenic differentiation medium, Cambrex Bioscience, 
Verviers, Belgium). For the first treatment a combination of Vitamin D3 
(VIT) and Dexamethasone (DEX) was used. The second treatment consisted 
of a combination of BMP2 and DEX. The third treatment consisted of 
Dexamethasone only. Furthermore an untreated sample is measured as a 
control at each time point. Thus, four time profiles can be generated for each 
gene on the microarrays. A graphical view of the experimental design of the 
experiment is given in Figure 2.1.
The data can be represented as a cube with the axes Gene, Time and 
Treatment (see Figure 2.1). For each cell in the cube three replicate 
measurements have been performed. The hybridizations were randomly 
assigned to 6 different groups in order to randomize the experimental effects 
of measuring at different time. The hybridizations were performed with 
Affymetrix Human Genome U133 A GeneChips [19].
The normalization of the data was performed with Rosetta Resolver Version 
5 and subsequently the expression data was log transformed [29].
1 3 6 12 24 48 72 120 192 288
VIT □□□ □□□ □□□ □□□ □ □□ □□□ □ □□ □□□ □□□ □□□
DEX □□□ □□□ □□□ □□□ □ □□ □□□ □ □□ □□□ □□□ □□□
BMP □□□ □□□ □□□ □□□ □ □□ □□□ □ □□ □□□ □□□ □□□
U ntr □□□ □□□ □□□ □□□ □ □□ □□□ □ □□ □□□ □□□ □□□
Figure 2.1: Schematic representation of the design of the mesenchymal stem cell dataset. The condi­
tions are indicated on each row. Each column represents a time point (in hours). The dimension genes 
is not shown in the table, but is taken into account in the analysis. Each cell in the table contains three 
replicate arrays.
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2.3.2 Description of the ANOVA model
Analysis of Variance (ANOVA) can be used in microarray data analysis to 
investigate the significance of the effects from factors which could possibly 
influence the gene expression. The ANOVA fixed effects model in which 
three of the possible factors of interest are incorporated is given by 
expression 1. In this model the measured gene expression ( X ij kr) is assumed 
to be the result of the added effects of the factors Time (T), Treatment (S) 
and Gene (G) over time point i, treatment j, gene k and replicate r:
X ijkr =M +  T i +  Sj +  Gk +  TSij (2 1)
+  TGik +  G S jk  +  TSG ijk +  Sijkr
The effect of interactions between factors is also incorporated in the three 
factor ANOVA model shown here (TS, TG, GS and three way interaction 
TSG). The effects are added to a general mean expression value which is 
indicated with ^. Finally the remaining variation is captured in the error 
term e. In the normal application of ANOVA, the sum of squares and mean 
squares are calculated for each factor and interaction. With an F-test the 
significance of the effect of each factor is then calculated. In this application 
of a combination of ANOVA and PCA, however the F-test for significance of 
effects of factors is not performed. Instead of calculating Sums of Squares 
from the main effects and interaction matrices, these matrices are analyzed 
with PCA. The main effects are vectors with a length equal to the number of 
levels in each factor. The interaction matrices consist of the combined effect 
of two factors, when corrected for the general effect of these factors. For 
example, the interaction matrix of the factors Gene and Treatment shows the 
effect of a gene and treatment after the general treatment effect and general 
gene effect have been corrected for. Thus, the interaction effect could be 
interpreted as the response of a gene to the treatments additional to general 
gene and treatment effects. This is of course interesting to the biologists who 
are looking for genes which respond to the treatments incorporated in the 
experiment.
First, the main effect is calculated for each of the factors of interest. The 
three factors used in the ANOVA model are time effect, treatment effect and 
the effect of each individual gene. The main effect is then calculated for each 
factor by subtracting the general overall mean from the mean per Time point,
25
2.3. METHODS AND ANALYSIS
the mean per Gene, and the mean per Treatment
main effect =  y r — y... (2.2)
where y is gene expression, and r is either i... , .j.. or ..k. , depending on the 
effect which is calculated. The next step is the calculation of the interaction 
matrices. The interaction matrices of the interaction between Gene and 
Treatment (GS), Time and Treatment (TS) and Time and Gene (TG) are 
calculated with:
GS =  y .jk. — y.j.. — y ..k. +  y .... (2.3) 
T S =  yij.. — yi... — y .j.. +  y .... (2.4) 
TG =  Vi .k .— yi...— y..k. +  y .... (2.5)
The three factor interaction (GTS) of Time and Gene can be calculated as 
follows:
GTS =  y i j k . — y . j k . — y i j . . — y i.k. +  yi... +  y .j.. +  y ..k.— y .... (2.6) 
The three factor interaction is in fact a data cube. In order to analyse it 
further with PCA the cube has to be unfolded. The two factor interaction 
matrices and the unfolded three factor interaction matrix can now be 
analysed with PCA and interactions can be identified as explained below.
2.3.3 PCA on ANOVA interaction terms
The interaction matrices can be analysed with PCA to identify genes with 
interesting and significant interactions. Genes are interesting for the 
biologist when they can be correlated with for instance a specific treatment 
or time point, depending on the biological question for the dataset. The gene 
is considered to have a significant interaction with e.g. treatment when a 
particular interaction effect is different from the value expected from the 
mean effects of all the genes and treatments. The technique of PCA is 
especially suited to visualize the interesting interactions because it focuses 
on displaying the data in a way that most variance is shown: the interesting 
genes are likely to be among those with large positive or negative values.
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An especially useful graphical representation of the data is the so called 
biplot [8]. In this representation, objects (e.g. genes) and variables (e.g. 
treatments) can be visualized in the same picture, allowing for interpretation 
of the location of scores in the plot. Chapman et al. [3] showed that biplots 
can be used to view the effects of different treatments related to plant 
defence. The first principal component was stated to be correlated to the 
mean response of the genes. In contrast, in the results shown below the data 
are modelled by the ANOVA model and the analysis is performed on the 
resulting interactions and not on the raw data.
2.3.4 Gene selection
In microarray analysis the number of measured genes is substantial and not 
all genes are expected to be involved in the biological process of interest. 
The goal of the osteogenic microarray experiment presented here is to find 
the genes which are involved in the process of mesenchymal stem cell 
differentiation. The aim is therefore to find a meaningful reduced set of 
genes. This set can consist of unknown genes as well as genes known to be 
involved in the process, which can confirm the experimental results. The 
selection can then be used to form new hypotheses and to perform further 
research. Here a method is shown which can be used to make gene 
selections from the results of the analysis with ANOVA and PCA.
Before any validation can take place a selection criterion for the 
identification of groups of interesting genes has to be defined. The selection 
method which will be described here is applied on the scores of the PCA 
performed on the interaction of the factors Gene and Treatment. The 
Hotelling T2 distribution is used to estimate the statistical significance of the 
interactions of the genes in the score plots. Genes which are different and 
interesting to the process, are expected to have a significant interaction when 
they are tested against a critical value for the distribution of the interactions 
of all the probesets. A gene which has a significant interaction is expected to 
have biological relevance because the gene shows a combined effect 
(corrected for general effects).
The Hotelling T2 distribution is used to calculate the critical value T £  :
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T 2 (n — 1)P F
t c  =  7 r  (n — p) a;p,n—p
(2.7)
Here n is the sample size, p is the number of variables used, F is the 
F-statistic with (p, n-p) degrees of freedom and a  is the level at which an 
observation is considered to be statistically significant. By calculating a
chance for this observation to be an outlier by chance alone under the null 
hypothesis. The Hotelling T2 statistic for each observation can be calculated 
with
in which u is the score of the ith observation on the kth Principal 
Component. The variance of the scores is taken into account by s 2u and a is 
the number of PCs considered to be relevant. By making use of the 
F-statistic the group of genes with a significant interaction can be identified 
by predefining the number of Principal Components to be taken into account 
and selecting a confidence level cut-off.
The test described here can be applied to the number of components which 
explain a relevant amount of variance. One option of selecting the number of 
components is to incorporate those components which capture a certain 
percentage of variance in the data (for instance 95 %). The number of PCs in 
the analysis can be determined as well by plotting the percentage of variance 
in each component to see how the variance is distributed (See Figure 2.2).
2.4 Results
Application of the algorithm on the mesenchymal dataset results in main 
effects and interaction matrices (as described in section 2.2). Especially the 
interaction matrices of genes and treatment, and genes, treatment, and time, 
contain interesting biological information. These can be further analysed 
with PCA.
First the interaction between the factors Gene and Treatment is inspected, 
because this is expected to be the most interesting from a biological point of 
view. It is desirable to be able to correlate the interaction of a gene with a
Hotelling T2 statistic for each observation a statement can be made about the
a n,2
(2.8)
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treatment. Other interactions are of interest as well, but for now we address 
the question whether we can make distinctions between the treatments.
Figure 2.2: Plots showing the explained variance for each component of PCA performed on A ) the 
interaction between the factors Gene and Treatment B ) the three factor interaction C) original data, 
averaged over replicates. In 2B and 2C only the first 5 PCs of 40 PCs are shown.
2.4.1 Analysis of the interaction with PCA
The first three components contain more than 95% of the explained variance 
after performance of PCA on the interaction matrix of the factors Gene and 
Treatment (see Figure 2.2A). Because the fourth PC has little variation 
compared to the other PCs the first 3 PCs will be used to construct the 
biplots to make gene selections.
The investigation of the interactions between the factors Gene and Treatment 
is interesting because this can give information about genes which are 
different from the general effects. A normal PCA which does not correct for 
the general effects would be distorted by the general effects. The biplots of 
the two first three principal components from the PCA performed on the 
interaction matrix of the factors Gene and Treatment are displayed in 
Figure 2.3.
The first principal component shown on the x-axis of Figure 2.3A indicates 
variation which distinguishes between the three samples treated with the 
substances (DEX, VIT, BMP) and the untreated sample. This can be seen 
because the arrows, which indicate the loadings, point in opposite directions 
in the plot for treated and untreated. Furthermore, it appears that the BMP
29
2.4. RESULTS
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Figure 2.3: Biplots of a principal component analysis performed on the interaction between the factors 
Gene and Treatment. The arrows indicate the loadings of the treatments (D EX, BMP, VIT, unt). A ll 
22283 probe sets from the dataset were used in the analysis. A group of genes associated with skeletal 
development or known to be involved are indicated with gene symbols instead of points.
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treatment is different from DEX and VIT. The biplot of the second and third 
component (Figure 2.3B) shows the distinction between the different 
treatments and the genes most correlated with a certain treatment.
A number of genes which have a significant interaction ( a  = 10-5, Hotelling 
T2 on first 2 components) and the GO annotation skeletal development (or 
are known to be developed in the process) are displayed in text in Figure 2.3. 
Some examples of genes which are known to be associated with one of the 
treatments will be given to illustrate the advantages of the biplot. For 
instance BGLAP, also known as osteocalcin, is induced by VIT and not DEX 
and BMP [13]. Furthermore FKBP5 is induced by dexamethasone [28]. 
Dexamethasone is present in all treatments and the position of FKBP5 in the 
plot confirms this. In agreement with the data presented in Figure 2.3 DLX5 
and COMP are known to be induced by BMP [18,27].
The results of a general per-gene two way ANOVA can not be associated 
with specific treatments based on their p-value for the interaction between 
Time and Treatment, even if it is low. The sorted p-values of the treatment 
effect of the two way ANOVA for each gene would show the same problem: 
the genes can not be correlated or anticorrelated with a specific treatment.
As can be seen in Figure 2.3 this problem can be solved by performing PCA 
on the interaction matrix because here associations can be made. The 
advantage of the combination of ANOVA and PCA can be shown by 
comparing the results of the technique with results from PCA on the data 
when it is not processed by ANOVA. In order to perform PCA on the 
complete dataset, the data cube with the dimensions time, gene and 
treatment is unfolded by combining the dimension treatments and time.
Thus the resulting data matrix consists of 22693 rows for genes and 40 
columns for ten time points and four treatments. In this analysis the mean of 
the three replicates in each cell was taken. PCA was then applied to the data 
matrix. The results shown in Figure 2.4 are difficult to interpret when 
compared to the results of PCA on interactions (see Figure 2.3). When 
performing PCA on the unfolded mean-centered data matrix, the explained 
variance is almost totally in PC1 (96.5% of explained variance). PC2 and 
PC3 together contain only 2.2% of the explained variance. Furthermore, the 
loadings are pointing in the same direction on PC1, making it difficult to 
associate genes with treatments and time points (see Figure 2.4). When the
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loadings are plotted per treatment, a separation can be seen in PC 2 between 
early and late time points, but this separation is similar for each treatment, 
and PC2 contains only 1.76% variation.
DEX BMP
■=
i ts .
M
O
CL
O _
o It
PC 1 ( 96.52%) PC 1 ( 96.52%)
PC 1 ( 96.52%) PC 1 ( 96.52%)
Figure 2.4: Loading plots of PCA performed on the whole data matrix (without application of 
ANOVA). The arrows indicate the loadings of the 40 variables from the matrix. The four subplots 
show the loadings from each of the four different treatments (D EX , BM P, V IT  and untreated). A ll 
22283 probe sets from the dataset were used in the analysis.
Instead of inspecting the two way interaction matrix of Gene and Treatment, 
one may also focus on the three way interaction between Gene, Treatment 
and Time. This matrix should contain information on which genes show a 
response to treatments over time that cannot be explained by main effects 
and two factor interactions alone. The loading plot of PCA on the unfolded 
three factor interaction matrix can be seen in Figure 2.5. Thus a gene with a 
significant interaction in Figure 2.5 can be associated with an effect of that
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gene at a certain time point for a certain treatment (depending on the 
loadings which correlate with the gene). The first notable difference between 
the three factor interaction plot (Figure 2.5) and the PCA on original data, 
averaged over replicates (Figure 2.4) is the distribution of loadings, which is 
not in one direction but occupies all four quadrants. Furthermore the 
variance is not captured in the first PC alone but more evenly distributed (see 
Figure 2.2B and Figure 2.2C). The loadings are ordered clockwise according 
to the time points. The orientation of the first 5 time points is similar for 
DEX and BMP. This orientation is clearly different from the first 5 loadings 
from the untreated and VIT in the experiment.
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Figure 2.5: Loading plots ofPCA performed on the three factor interaction matrix from the application 
of ANOVA. The four subplots show the loadings from each of the four different treatments (D EX, 
BMP, V IT  and untreated). A ll 22283 probe sets from the dataset were used in the analysis.
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2.4.2 Gene selection
After the application of ANOVA and visual inspection of the biplot of PCA 
on the interaction between Gene and Treatment, interesting genes can be 
selected. An example of a selection of a group of genes according to the 
Hotelling T2 statistic can be seen in Figure 2.6. The scores of the first 2 PCs 
from PCA on the interaction matrix of the factors Gene and Treatment are 
shown. The selected genes are on the outside of the ellipsoidal shape of the 
distribution in the first two Principal Components. These describe 90.2 % of 
the variation in the data. The selection was made as reported before and an a  
= 10-5 leads to a selection of 384 genes in this case.
The GO enrichment analysis of this selection can be seen as a first external 
biological validation of the selection of interesting genes. It will give an 
indication whether the biological function of the selected genes can be 
attributed to the process of skeletal development, or even to the 
differentiation of mesenchymal stem cells.
In Table 1 the GO terms are displayed, which correspond to the gene 
selection. The results are consistent with the biological framework of the 
dataset. The term skeletal development is a good example for this. The terms 
development, organ development, morphogenesis and cell differentiation can 
be linked to the process of osteogenesis as well.
This example was performed using the first two PCs. These were chosen 
because the difference between treated and untreated was clearly visible in 
the biplot (see Figure 2.3A). The selection was made with the first three PCs 
as well: then, the processes development, organ development, skeletal 
development and cell differentiation were found in the first ten terms again. 
The term skeletal development was ranked lower (6th) when compared with 
enrichment after 2 PCs.
The cut-off values which are used as selection criterion for groups of genes 
are known to have effects on the outcome of the biological results of 
expression experiments (Pan et al., 2005). In other words: different cut-offs 
can render quite different biological results. Therefore the enrichment 
process was performed with several gene selections on the first 2 PCs ( a  in 
Hotelling T2 between 10-1 and 10-8). This analysis showed that the top eight 
processes were consistently enriched for a wide range of a  values (data not 
shown).
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Figure 2.6: Example of a selection of genes which was identified with the Hotelling T2 distribution. 
The a  for this selection was 10-5 and 384 genes were selected. Selected genes are represented by the 
points outside the circle.
Next, GO enrichment analysis was performed on genes selected from the 
unfolded three factor interaction. Again the Biological Process category was 
used for the enrichment. This was not done for a wide range of cut-offs but 
at a  = 10-5. The first four PCs were used. The enrichment results were 
comparable with the enrichment results of the selected genes for the two 
factor interaction when the rank of the enrichment of the term skeletal 
development is considered. Several selections were made from the PCA of 
the three factor interaction matrix. For a selection of 228 genes, selected 
from the first 2 PCs with Hotelling T2 the first enriched term was skeletal 
development. Skeletal development was still ranked first for a selection of 
365 genes, selected from the first 3PCs. When the first 4 PCs were used to
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GO identifier full GO term
GO:0007275 development
GO:0048513 organ development
GO:0009653 morphogenesis
GO:0001501 skeletal development
GO:0001568 blood vessel development
GO:0001944 vasculature development
GO:0048514 blood vessel morphogenesis
GO:0030154 cell differentiation
GO:0001525 angiogenesis
GO:0009887 organogenesis
Table 2.1: Table of enriched processes for GO category Biological process in group of 384 genes 
selected with a  = 10-5. The top eight processes are consistently enriched for a wide range of a 
values.
make the selection, 486 genes were selected and skeletal development 
showed as the fourth enriched term in the list (with morphogenesis ranking 
first). Clearly, gene selection based on interaction matrices leads to 
biologically relevant sets. Although the selection of the number of PCs to 
use may lead to differences, the same, biologically relevant, GO categories 
are enriched in the selections. In our example, this is true for both the two 
factor and three factor ANOVA interactions.
2.4.3 Application of ANOVA on selected genes
The results shown before were obtained by applying the combination of 
ANOVA and PCA on all probe sets on the chip, in order to select subsets. 
The resulting gene selections are biologically valid, but it is interesting to 
see the results of the algorithm when it is performed on a selected subset of 
genes. Or, put differently, what happens to the main effects and interaction 
effects when a selection of genes is used in ANOVA-PCA?
Thus the selection of 384 genes mentioned previously was used to perform 
ANOVA and PCA again with just these genes. As expected, the results show 
that the main effects of these subsets are different from the overall main 
effects present in the whole dataset.
When the three factor interaction effect of Gene, Time and Treatment is 
shown for the selection of 384 genes a clear difference can be observed 
between the untreated time-series and the treated samples (see Figure 2.7).
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Figure 2.7: Display of average three factor interaction effect of Gene, Time and Treatment for a set 
of 384 genes selected from the first and second PC of the interaction matrix of the factors Gene and 
Treatment.
A picture of the three factor interaction effect in time over all the genes is 
less informative because it will be disturbed by all the genes which are not 
necessarily involved in the biological process of interest. The untreated 
profile decreases further and longer than the treatment profiles. Furthermore 
the BMP treatment displays a higher peak at 72 hours when compared to 
DEX. For the peak of VIT treatment a shift in kinetics can be seen because 
the maximum of the peak is at 24 hours. The shift in Vitamin D kinetics has 
been confirmed experimentally with in vitro cell-based biological 
assays [22].
2.5 Conclusion
The combination of ANOVA and PCA, as demonstrated here, is a valuable 
tool in microarray data analysis, perhaps even more so than in 
metabolomics: because more information is available on the functions of 
genes, the biological interpretation of the results is more straightforward 
than in the case of metabolites. ANOVA-PCA can be used to split and 
visualize the different components in the ANOVA model, showing relations
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between genes, treatments, and time points. Several genes which are known 
to be induced by specific treatments can be seen to lie close to these 
treatments in the biplots; for genes with an unknown function these plots can 
provide plausible hypotheses to be tested. Furthermore, specific interaction 
matrices can be used to select interesting subsets of genes, identified with the 
Hotelling T 2 test. Such a selection for the current data set is shown to be 
significantly enriched with genes involved in skeletal development, which is 
in line with the biological framework.
The shifted kinetics of Vitamin D induced osteogenesis, which had been 
suspected based on earlier experiments, is clearly visible in the 
ANOVA-PCA results. It has been confirmed using in vitro cell-based 
biological assays citePiek09. Application of either ANOVA or PCA would 
not have shown this as clearly. Many other questions can be addressed as 
well, depending on the nature of the data set and the interests of the 
researcher.
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3.1. ABSTRACT
3.1 abstract
Analysis of Variance (ANOVA) separates the effects of different factors in a 
data set. Typical examples for gene microarray data are the factors time and 
treatment. This separation can improve the interpretability of the results. 
However, the main effects and interactions, calculated in ANOVA, can be 
heavily influenced by outliers, large numbers of non-expressed genes with 
noise, and the heavy-tailedness of the distribution of expression values. 
Robust methods are less affected by these and will improve the analysis.
In this paper, several methods to perform robust nonparametric ANOVA are 
applied to a large multi-treatment time series dataset. The results are 
compared with the results obtained with parametric ANOVA using 
Procrustes Analysis. A further comparison is made by Gene Ontology (GO) 
enrichment analysis of groups of genes identified as significant by inspection 
of the interaction terms in ANOVA. It is shown that there are significant 
differences in the estimates of main effects and gene-treatment interactions. 
ROC curves show an improved representation of current biological 
knowledge for one particular robust form of ANOVA, using a combination 
of rank transformed data, with the median as location parameter.
Keywords ANOVA, Robust Analysis, PCA, ROC curves, microarray
3.2 Introduction
The biological interpretation of high throughput gene expression 
experiments is difficult, because interesting information can be obscured by 
the effect of experimental factors on the data. A popular statistical method in 
the analysis of microarray data is Analysis of Variance (ANOVA). By 
applying ANOVA, a model can be made which separates the experimental, 
biological and residual effects. ANOVA has been applied to analyse 
microarray data in several research fields, for instance to investigate diseases, 
nutrition, microbiology, plant biology and many others [2, 7, 28]. The use of 
ANOVA for microarrays has been proposed by Kerr et al. [22] with a fixed 
effect model. In this model the array effect, dye effect, treatment effect, gene 
effect and interaction effects are modeled for two colour microarrays. The 
model was split in two stages by Lee et al. [24]. The objective of the first 
stage is to normalize and filter out dye and array effects with ANOVA. The
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second stage is a per gene ANOVA on the remaining effects. Wolfinger et 
al. [32] assumed the array effect to be random in a model similar to the 
approach of Lee et al. This results in a two-stage mixed-effect model. 
Regular parametric ANOVA assumes normally distributed data. This 
condition is rarely met for microarray data; Durbin et al. [10] have shown 
that in many cases a mixture of a normal and a lognormal distribution is 
more suited:
Y =  a  +  i e n +  e (3.1)
Here, a  is the background signal, i  is the real expression, and n and e are 
normally distributed error terms. One could imagine that genes that do not 
respond to a certain treatment lead to a normal component in the overall 
distribution, whereas genes that do respond provide the lognormal 
component. Moreover, there is always the possibility of outliers because of, 
e.g., measurement errors.
All this implies that the estimates for the main effects and the interactions 
are influenced by observations that are outlying, either because of true 
biological differences in gene behaviour, or because of measurement errors. 
Durbin et al. [10] stated that before further statistical analysis can take place 
microarray data should be transformed to approach normality, and several 
transformations have been proposed in literature [6,13,18].
Here, we take a different approach, and concentrate on nonparametric forms 
of ANOVA that do not rely on distributional assumptions of the data. 
Nonparametric methods have been applied to microarray data before, for 
instance to identify differentially expressed genes [12,30,33], with good 
results. We compare three different methods for robust ANOVA in the 
analysis of microarray data. The first method simply replaces the non-robust 
mean with the robust median and proceeds as in an ordinary ANOVA. Two 
further methods are based on rank transformations.
The three methods are compared using a large time series dataset with 
several different treatments, designed to investigate the differentiation of 
mesenchymal stem cells to osteoblasts in the process of osteogenesis. Rather 
than focussing on the significance of individual terms, we treat the ANOVA 
as a means to concentrate on the interesting information. For this paper, we 
take the interaction between gene and treatment because it is biologically the 
most interesting term, and use Principal Component Analysis (PCA) for the
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visualisation of this interaction matrix, as in [9]. In the field of agricultural 
sciences this method is known as AMMI (Additive Main effect 
Multiplicative Interaction) [14,34]. The ANOVA-PCA combination can be 
used to select interesting genes based on the scores of the gene-treatment 
interaction [9].
Procrustes Analysis [15] is used to compare the results from the original 
approach with the robust approaches. Furthermore, results from Gene 
Ontology (GO) [5] enrichment calculations [23] are used to draw Receiver 
Operating Characteristics (ROC) curves. These ROC curves can be used to 
assess the agreement between current knowledge about a biological system 
and the enrichment results from the selected genes [8]. Biological 
knowledge about the role of genes known in stem cell differentiation is used 
and discussed in the Supplementary Material.
3.3 Methods and analysis
3.3.1 The mesenchymal stem cell dataset
The microarray experiment used in the examples presented here was 
performed on human Mesenchymal Stem Cells (hMSCs), triggered to 
undergo osteogenic differentiation (E. Piek et al., manuscript in 
preparation, [9]). Dexamethasone induces the differentiation of hMSCs cells 
to osteoblasts. It is known that BMP2 and Vitamin D3 can potentiate 
osteogenesis in combination with dexamethasone [21]. A time series 
experiment was performed and the expression measurements were taken at 
10 time points (at 1, 3, 6, 12, 24, 48, 72, 120, 192 and 288 hours after onset 
of treatment). As onset of osteogenic differentiation is expected during the 
first 24 hours of treatment, frequent sampling was performed within this time 
frame. In addition to sampling multiple time points during the differention 
process, another factor of interest is introduced to the experiment by 
inducing osteogenesis of the hMSCs with different treatments. The three 
treatments are named after the substances added to the culture medium. For 
the first treatment (VIT) a combination of Vitamin D3 and dexamethasone is 
used. The second treatment (BMP) consists of a combination of Bone 
Morphogenetic Protein 2 and dexamethasone. The third treatment (DEX) 
consists of dexamethasone only. Furthermore an untreated sample (UNT) is 
measured as a control at each time point. Thus, four time profiles are
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available for each gene on the microarrays. The hybridizations were 
performed using Affymetrix GeneChips Human Genome U133A [25].
All measurements have been performed in triplicate. The hybridizations 
were randomly assigned to 6 different groups in order to randomize the 
experimental effects of measuring at different points in time. The 
normalization of the data was performed with Rosetta Resolver Version 5 
and subsequently the expression data was log transformed [31]. The 
biological process of interest for the dataset which is used for the analysis in 
this article is skeletal development.
3.3.2 ANOVA and PCA
ANOVA can be used in microarray data analysis to investigate the 
significance of the effects from factors which could possibly influence the 
gene expression. The ANOVA fixed-effects model [22] in which three of the 
possible factors of interest are incorporated is given by expression 3.2. In 
this model the measured gene expression ( X ij kr) is assumed to be the result 
of the added effects of the factors Time (T), Treatment (S) and Gene (G) 
and their interactions over time point i, treatment j , gene k and replicate r:
X ijkr =M +  T i +  S j  +  G k +  T S ij +  (3 2)
T G ik +  G S jk  +  T S G ijk +  ^ijkr
with ¡i the overall mean. The remaining variation is captured in the error 
term s ij kr . In the normal application of ANOVA, the sum of squares and 
mean squares are calculated for each factor and interaction, and the 
significance of the effects is calculated. Here, instead of calculating sums of 
squares, the interaction matrices are analyzed with PCA [9] to identify genes 
with interesting biological behaviour. Because uninteresting sources of 
variance have been removed with ANOVA, the results are much more 
interpretable than a PCA applied to the original data.
The gene-treatment interaction effect can be interpreted as the response of a 
gene to the treatments, additional to general gene, time and treatment effects. 
This is of course interesting to the biologists who are looking for genes 
responding to the treatments incorporated in the experiment. Genes are 
interesting when they can be correlated with for instance a specific treatment 
or time point, depending on the biological question for the dataset. For the
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visualization of these interactions, the technique of PCA is especially suited 
because it focuses on the directions of maximal variance: the interesting 
genes are likely to be among those with large positive or negative values.
In microarray analysis the number of measured genes is substantial; 
however, not all genes are expected to be involved in the biological process 
of interest. The aim is therefore to find a meaningful reduced set of genes. 
This set can consist of unknown genes as well as genes known to be involved 
in the process. One way to make the selection of genes from the results of 
the analysis with ANOVA and PCA is to use the Hotelling T 2 
distribution [9]. For different values of the cutoff parameter, different 
numbers of genes are obtained.
3.3.3 Robust ANOVA
Estimates of main effects and interactions can be severely affected by 
outlying observations. These outliers can be caused either by measurement 
errors, or consist of genes showing a behaviour that is very different from the 
bulk of the genes, e.g. as a result of a treatment. In the latter case, these 
outliers are the most interesting parts of the data. Moreover, ANOVA 
requires normally distributed data, which in practice is not often the case.
We here analyse three ways to perform more robust variants of ANOVA. The 
first relies on robust location estimates, and the other two on rank 
transformations. Combinations are possible, too. The classical, non-robust 
ANOVA will be indicated with the label “CL”.
Robust location
An alternative to the mean as a location parameter, less influenced by 
outliers, is the trimmed mean. When calculating the 20 percent trimmed 
mean for instance, the mean is calculated from the data which remain after 
the upper and lower 20 percent of these data are removed. The most extreme 
form of trimming is taking the median of the data: then, the upper and lower 
50 percent of the data are excluded from influencing the location of the data. 
Thus, when fitting the ANOVA model from Equation 3.2, i  is estimated by a 
trimmed mean or even a median instead of the normal mean. Similarly, 
trimmed means or medians are used for the calculation of the main effects 
and interaction effects. This method will be indicated with “RL” in the
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following. A more refined version for estimating robust effects would be the 
median polish method [27]; in this paper we do not pursue this further.
Rank transformation
Many nonparametric methods apply a rank transformation to the data, to 
decrease the influence of outlying values. For ANOVA, the rank 
transformation has been advocated by Iman [20]: with normally distributed 
data the loss of power, associated with nonparametric methods in general, is 
limited, but for non-normal data, the rank transformation is more powerful. 
Harwell and Serlin [17] suggest to use the rank transformation when the data 
are skewed or heavy-tailed.
In this method, indicated with “RT-CL”, the original values in the whole 
dataset are converted to ranks. For the hMSC dataset this results in values 
from 1 to the number of datapoints: 22283 x 10 x 4. Again, the resulting 
data cube (now containing ranks) is analysed by ANOVA to separate sources 
of variance. Here, too, means can be used as location parameters, but also 
trimmed means or medians. Thus, the rank transformation method can be 
combined with the RL method. We will use means as location parameters 
and denote this method in the following as “RT-CL”.
Aligned rank
An extension of the rank transformation is the aligned rank transformation 
method (AR), suggested by Hartlaub et al. [16]. The AR method was 
invented to reduce the influence of large main effects, resulting in an increase 
of the type I error as reported by [1]. The method was described by Gao & 
Song, Mansouri & Chang and even earlier by Conover & Iman [4,12,26] 
The diffence between the RT-CL and the AR method lies in the fact that in 
the AR method the main effects are subtracted from the data before the data 
are rank transformed. This is done to compensate for the possible 
differences in size of these main effects. In literature this method has shown 
good performance, but the dimensions of the data were substantially smaller. 
Again, this method can be combined with the RL method, even in several 
ways. One can use the RL method for the robust estimation of the main 
effects, subtract these and then do the rank transformation. After the rank 
transformation, one can use either means or a robust location measure. This 
leads to four possible combinations: CL-AR-CL, RL-AR-CL, CL-AR-RL
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and RL-AR-RL. In this paper, we only consider the first of these cases and 
refer to it with ART-CL. The other combinations perform worse, and are 
therefore not taken into account.
3.3.4 Evaluation
In comparing the different approaches, we concentrate on the main effects 
and the interaction between gene and treatment. We use PCA for the 
visualisation of the interaction terms, and compare the different interaction 
matrices by Procrustes analysis [15]. Using a set of 50 predefined GO terms, 
available in the Supplementary Material, we set up ROC plots [3, 8] that tell 
us how well each method reproduces current biological knowledge on bone 
formation.
Main effects
Robust estimates of main effects are expected to be different from the 
classical estimates using the mean. As a result the calculated interactions 
will also differ. Therefore the conclusions from the results are influenced 
depending on the type of robust analysis.
Interaction matrices
Due to the large number of genes it is difficult to identify the changes of 
genes in the score plots from the interaction matrices. In fact we are 
interested in the differences between the plots; we want to know which 
genes have a similar location in the plots and, even more interesting, which 
genes are at different locations.
A technique which can be applied to compare and investigate the topology of 
data points in two multivariate datasets with equal dimensions is Procrustes 
analysis [15]. The goal of Procrustes analysis is to find a transformation, 
either a translation, rotation or reflection, which results in the best match 
between the point configurations in both plots. Thus, Procrustes analysis can 
be applied to investigate the similarity of comparable data tables. An 
indication of the difference between the classical interaction matrix and its 
robust counterparts can be given for each gene, making it possible to identify 
the genes which show the largest difference. In the plots below, we focus -  
rather arbitrarily -  on the twenty genes showing the largest Procrustes error
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(in each case). Moreover, the overall Procrustes error indicates which robust 
interaction matrix deviates most from the classical approach.
Comparison with known biology
Eventually, one is interested in finding new relations and processes, 
influenced by the treatments. The minimal requirement of a new method is 
that the processes which are expected to be found, are indeed returned by the 
analysis (when the experiment has been performed correctly). If that is not 
the case, chances are slim for finding relevant but previously unknown 
relations. A method to evaluate the agreement between current knowledge 
about a biological system and the results found with a microarray 
experiment is the application of ROC plots [8]. Annotation information from 
the Gene Ontology [5] database is used to perform the evaluation of the 
results. The terms associated with the Biological Function branch of GO 
were applied as a description of the genes which are found. Before any GO 
analysis was performed a list of terms expected to be found was composed 
by biological experts [8], available in the Supplementary Material. This set 
is used as a reference for the results of the GO enrichment analysis, which is 
performed next. The terms in the list are considered as positive results and 
can be applied to calculate sensitivity and specificity at different cutoffs in 
the GO enrichment. By plotting one minus the specificity against the 
sensitivity, the ROC curve shows whether the results are better than results 
found by chance alone.
Here we use the ROC plots to compare selected genes found with robust 
methods and the classical application of ANOVA. In both cases, the 
Hotelling T 2 distribution is used to define a threshold ( a  =  0.01). With this 
selection, enrichments are calculated for all processes in the Biological 
Process category. These results are summarised in an ROC plot.
Software
Calculations are performed in R [29]; the GO enrichment calculations are 
performed with the R package GOstats [11]. In-house scripts for the 
nonparametric ANOVA and the ROC curves are available upon request.
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3.4 Results
The results for the RL method using trimmed means are conform 
expectations: they are in between the CL results and the results of RL using 
medians. Therefore we will not discuss trimmed means further, and will in 
the remainder use medians with the RL method. First, the main effects of the 
CL and RL methods are shown; the main effects of the rank based methods 
are comparable in their profile, but are less easily comparable with the 
standard main effects because they are on a much larger scale due to the rank 
transformation. Next, the results of the two factor interaction 
Gene-Treatment are used to make comparisons of the different 
nonparametric methods and the CL method.
3.4.1 Main effects
The main effects for the factors time, gene and treatment are represented in 
Figures 3.1 A, B and C, respectively. From the figure it is clear that the 
robust and classical estimates are different. For the factor time the absolute 
values for the robust method are bigger. The main effect for the factor gene 
is approximately 0.2 larger for the RL method than for the CL method. This 
is the logical effect of the difference between the overall mean and overall 
median (5.563 and 5.337, respectively). Because the averages are taken over 
large numbers of data points the main effects alone are not very informative. 
In contrast to the effects of time and gene, the effect of the factor treatment is 
larger for the CL method. Obviously the differences will result in different 
interaction matrices as well.
3.4.2 Comparison with known biology
When selecting genes based on the methodology presented here one would 
expect certain GO categories to be significantly enriched. Among those are: 
ossification, skeletal development and others [8]. First, gene selections are 
made for each of the nonparametric methods, using the cutoff a  =  1 • 10-2 
for the Hotelling T distribution. The agreement of the resulting gene 
selections with the predefined categories is shown in Figure 3.2. As usual, a 
true positive is a gene belonging to a GO category (or one of its descendants) 
present in the predefined categories. The ROC curve of the RT-CL method is
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running closest to the optimum in the upper left corner. The ART-CL 
method runs below the other methods. This means that a gene selection 
performed with the RT-CL method gives the best balance between false 
negatives and false positives.
3.4.3 Gene treatment interaction
The two-factor interaction of gene and treatment contains information about 
which genes have a specific response to the treatments. It is possible to 
visualise the information in the gene treatment interaction matrix with 
biplots, to correlate genes with specific treatments [9].
As an example of the kind of differences one can expect when comparing 
classical and robust methods, the biplots from the gene-treatment interaction 
matrices of the CL and RL methods are shown in Figure 3.3. The percentage 
of explained variance on the first PC is smaller in the robust case. The 
loadings still show the separation between the three treatments and the 
untreated control in the first PC. However, there seems to be less separation 
between the three osteogenic treatments in the second PC of the RL method. 
In the plots a group of genes is indicated for which the individual Procrustes 
error is largest (see below).
For all methods a separation between the untreated and osteogenic 
treatments can be seen in the loadings, but the shape of the distribution of 
genes and the distance of genes to the center depends on the method. To see 
which methods are similar, we perform Procrustes analysis.
First, a comparison is made between the CL and RL methods. The RL 
interaction matrix is rotated and scaled to find the best match with the CL 
interaction matrix. As a result of the analysis the rotated RL interaction 
matrix can be compared to the original CL interaction matrix. First, the 
distribution of the differences between the rotated and the original is 
depicted in Figure 3.4. Most errors are relatively small compared to the 
outliers in the right tail of the distribution. This means that the relative 
orientation of most genes has not changed, because the bulk is in the center 
of the biplots, relatively irresponsive to the effects of the treatments. One 
would then expect that these elements experience only small changes when 
comparing the two methods.
Second, from the Procrustes analysis the overall Procrustes error can be
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Table 3.1: The overall Procrustes error is calculated as the sum of squared differences between the 
original matrix and the rotated target matrix. The nonparametric methods RL, RT-CL and ART-CL 
are compared with the classical ANOVA PCA.
R L vs CL 71.2
RT-CL vs CL 96.0 
ART-CL vs CL 96.4
calculated by taking the sum of squared differences between the original CL 
data matrix and the rotated RL matrix. The overall Procrustes error is shown 
in Table 3.1. Perhaps not surprisingly the rank-based methods show a larger 
difference with the CL method than the RL method.
Third, to investigate which genes have a large Procrustes difference, when 
compared with the classical ANOVA PCA, we calculate the difference 
between the scores on PCs 1 and 2 of the original interaction matrix and the 
optimal match with the corresponding scores of the interaction matrix from 
the nonparametric method. The difference matrix, obtained after this 
Procrustes rotation, is then inspected with PCA. In Figure 3.5 the scores 
corresponding to the genes are shown for the methods RL, RT-CL and 
ART-CL. In the figures a number of genes is indicated in black for which it 
is known that they are involved in osteogenesis (from literature) and which 
have a large Procrustes difference. Note that these genes are different from 
the genes highlighted in Figure 3.3. There are 7 genes in the set which are 
found by the three methods; OMD, LEPR, IGFBP2, GAS1, COL11A1, 
BGLAP and ADAM12. More detailed information and references for these 
and other genes mentioned here, can be found in the Supplementary 
material. The set of genes MMP7, LEP, IBSP, FRZB, CHI3L1 and CHRDL1 
are present among the set of genes with the largest difference for the 
methods RL and ART-CL. There are three genes which have a large error for 
the RL method; BMP6, LIF and PER1. Finally, the difference for genes 
HEY1 and ID3 is apparent for the RT-CL and the ART-CL methods.
The p-value cutoff for the genes ranked based on the Hotelling T 2 
distribution can also be used when we look specifically at the gene-treatment 
interaction term. The difference between the methods is difficult to 
determine because there is a lot of overlap between the interesting genes 
which are found by the methods. There is a difference between the methods 
though, and it is in the distribution of the interesting genes in the selection.
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To describe these differences, we have chosen to use the 100 most extreme 
genes from the biplot. These are the genes which are most influenced by the 
treatments in the experiment. From the selection of 100 genes for each 
method we will discuss a limited number of genes known to be involved in 
osteogenesis based on literature. The genes BMP6 and CDKN1C are found 
specifically with the RT-CL method. Furthermore the genes PER1, HEY1 
and PTGER2 are only present in both rank based methods (RT-CL and 
ART-CL) whereas COL11A1, CHRDL1, ID3 and IGFBP2 are discovered 
with the classical and RL method.
3.5 Discussion and Conclusion
As explained before in the introduction, the estimates for the main effects 
and the interactions are influenced by outlying observations. These can be 
the result of real biological differences in gene behaviour, or result from 
measurement errors. We have shown that taking a nonparametric approach 
which does not rely on distributional assumptions of the data gives different 
estimates of main effects and interactions, which are not influenced by 
outliers.
Robust ANOVA methods lead to quite different results, compared to 
classical ANOVA, for the data in this paper. This is an indication that the 
assumptions of parametric ANOVA are not justified for this dataset; 
otherwise, the differences would be less substantial. Application of robust 
ANOVA leads to different estimates of main effects and interactions. As a 
result, different biological conclusions will be drawn, e.g., different genes 
will be selected on the basis of the gene treatment interaction. Furthermore, 
the robust methods take slightly different approaches: using the median 
instead of the mean is different from using ranks instead of expression 
values. The sizes of the differences may depend on the data at hand.
When selecting genes with an interesting gene treatment interaction, some 
genes are found with one method, and not with the other. The RT-CL 
method, which is shown to give the best representation of known biology, 
finds the genes BMP6 and CDKN1C for instance. These genes are not 
present in the selections made with the other methods. To give a more 
general picture of the biological results, ROC plots are drawn. For this 
dataset the results from the ROC plots for expected GO categories indicate
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that the rank transformation method with normal means gives results which 
are most in agreement with current biological knowledge of the system. 
From the results it can be concluded that it is not advisable to use the 
ART-CL method.
In addition to the methods that perform robust ANOVA shown in the Results 
section, we have applied several other robust methods as well. The rank 
transformation based methods can also be applied with the robust location 
estimate. The results from these, RT-RL and ART-RL, were much worse 
than the other methods and are therefore not presented here. We also 
evaluated the interaction matrices (obtained from either robust or classical 
ANOVA) using robust PCA (ROBPCA) [19]. The goal of robust PCA is to 
obtain principal components that are not influenced much by outliers in the 
data. Applying robust PCA on the interaction matrices showed no real 
differences with normal PCA, therefore results are not shown. A final 
opportunity for further robust analysis is the Procrustes rotation: by rotating 
the data in such a way that the majority of the points is correctly aligned in 
the two data sets, the differences of the remaining points may stand out more 
clearly. We did not pursue this avenue further, since the standard Procrustes 
analysis provided enough insight already.
Acknowledgements
The first author would like to thank Schering-Plough for financial support.
54
CHAPTER S. ROBUST ANOVA FOR MICROARRAY DATA
A
50 100 150 
time (hours)
200 250
ooo
sorted genes
C
CL RL
dex bmp vit unt dex bmp vit unt
treatment
Figure 3.1: The main effects of the CL and R L method of the factors time (A ), gene (B ) and treatment 
(C).
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Figure 3.2: ROC plot of all methods with genes selected with a  = 1.10-2. The RT-CL method shows 
the best results, because the line is closest to optimum in the upper left corner. The ART-CL method 
shows the worst performance, it finds the smallest number of processes for any given cutoff for GO 
enrichment.
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Figure 3.3: Biplots of interaction matrix from interaction of gene and treatment: the CL method (left) 
and the R L method (right). Genes are represented with points. A group of genes with large differences 
between the methods, which are known to be involved in osteogenesis are indicated with black points. 
Loadings, representing treatments are shown with arrows.
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Figure 3.4: Histogram generated from the Procrustes comparison between results from the CL method 
and the R L method. The 20 genes with the largest difference are shown in the inserted enlarged part 
of the right tail of the distribution.
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Figure 3.5: Results of PCA performed on the difference between the original X  matrix and the rotated 
Y  matrix. Genes with a large difference w ill be on the outside of the plot. Comparisons were made 
with the classical ANOVA PCA as reference. It was then compared with the R L  (A ), RT-CL (B ) and 
the ART-CL (C) and methods, respectively. Each point represents a gene. A group of genes which 
is responsive to osteogenic treatments based on literature and have low p values is shown with black 
points. The threshold for the p-values is p <  1 ■ 10-5 for the Hotelling T 2 distribution on the first 
2PCs.
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CHAPTER 4. BEYOND SINGLE P-VALUE CUTOFFS
4.1 abstract
Currently, a large number of tools are available to calculate GO enrichment 
for gene selections from microarray experiments. It is well known that this 
leads to conclusions that are dependent on the size of different gene 
selections. In this paper we will investigate this effect by varying the 
significance level of both the gene selection cut-off and the GO enrichment 
cut-off. A number of techniques to visualise the resulting enrichment surface 
are proposed. Furthermore, ROC plots are used to assess the agreement of 
the experimental results with current biological knowledge, such as GO 
annotation. Using these techniques, a stable estimate of association of 
expression data with GO terms is generated, which is more robust than the 
results of a single test. The methods introduced in this paper are illustrated 
by application to a human mesenchymal stem cell data set.
4.2 Introduction
The analysis of microarray data is conducted in different stages to condense 
the large number of genes [6,13] into interpretable information. The first 
step after data preprocessing often consists of gene selection, designed to 
filter out irrelevant genes: not all genes are expressed and noise genes can 
disturb the results. The filter algorithm depends on the design of the dataset. 
For instance, genes can be selected based on the significance of deviation 
from the background signal, the significance of deviation from a control 
treatment or significance of the presence of a time effect. The statistical 
method which is used (e.g. a Student’s t-test or Analysis of Variance 
(ANOVA)) gives a p-value for each gene. This p-value represents the 
relevance of the specific gene in the microarray experiment. From now on, 
we will refer to the p-value for Gene Selection as pGS. Irrespective of the 
gene selection method, a cut-off for the p-value determining the number of 
genes in the analysis has to be determined. Generally, predetermined fixed 
values are chosen, and the consequences on the analysis results are not 
investigated.
The biological interpretation of large numbers of selected genes is laborious 
when just the gene names are used. Therefore, additional information, e.g., 
from the Gene Ontology (GO) database [1], is often used in a second stage 
to draw general conclusions for groups of genes which have a similar
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function. One frequently applied approach is GO enrichment analysis. The 
results of this method indicate which biological processes are 
overrepresented in the selected genes. A large number of programs which 
can perform GO enrichment tests are available to the researcher. An 
extensive review about GO enrichment tools was written by Khatri et al. [8]. 
To determine enrichment, most programs use the hypergeometric test or 
Fisher’s test -  the work presented here is based on the hypergeometric test 
but can be applied to any other relevant test as well. The result of GO 
enrichment analysis is a list of GO category names with an associated 
p-value, which represents the significance of the enrichment of a particular 
GO category. This p-value of GO enrichment will be referred to as pGOE; 
again, a cut-off has to be determined.
Determinating the optimal cut-off values for both the pGS and pGOE values 
is difficult. By choosing a very small cut-off for pGS, a low number of genes 
is selected; this may lead to very different pGOE values than when more 
genes are selected, using a higher value for pGS. Moreover, a very low value 
for pGOE will lead to a limited number of enriched processes, while at a 
high cut-off value the risk of finding false positive terms is large. The 
consequences of choosing different cut-offs are not clear for the biological 
conclusions of the analysis. This problem has been recognised earlier by Pan 
et al. [12] and Alexa et al. [2]. Therefore, the first goal of this paper is to 
introduce visualization tools to aid in a well-founded choice of pGS and 
pGOE. The tools can help in the evaluation of the large amount of data 
resulting from enrichment analyses after varying both the pGS and pGOE. In 
addition to finding appropriate pGS and pGOE values, GO processes can be 
identified which are robustly enriched for different choices of pGS and 
pGOE. Three methods to visualise the results of varying pGS and pGOE are 
suggested in this paper: 3d-surface plotting, heatmaps and incorporation of 
information in the GO graph.
The a-posteriori interpretation of findings in GO enrichment analysis is 
important as well. Unexpected results can be informative, but it can be 
tempting to explain enriched terms, which are merely found by chance. 
Hence, the second goal of this paper is to find a method which quantifies 
whether the GO enrichment analysis was successful in representing current 
biological knowledge about the experiment. We propose to use Receiver
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Operating Characteristics (ROC) curves [3] to show the agreement between 
a list of expected enriched terms and the results from the dataset.
All methods mentioned here will be explained in more detail in the Methods 
and Analysis section. As an example, a microarray dataset containing gene 
expression measurements of human mesenchymal stem cells is analysed.
4.3 Methods and Analysis
To help in determining appropriate values for pGS and pGOE, a twofold 
approach is proposed. First, one should visualise the effect of different 
cut-off values for pGS, leading to different numbers of selected genes, on the 
enrichment of specific GO terms. Second, one should investigate how well 
the “known biology” is corroborated by the data.
4.3.1 Visualizations of the enrichment surface
To get an estimate of variance in enrichment results, it is helpful to plot the 
pGOE values across multiple selections of genes, generated by varying the 
pGS. The result is a vector of pGOE values corresponding to the individual 
GO terms, for each level of pGS. These vectors, joined into a matrix, can be 
visualised as a surface. An example for a synthetic data set, used for 
explanatory purposes, is shown in Figure 4.1A. GO terms are ordered 
according to their mean enrichment across all gene selections for easier 
interpretation. Rather than pGOE, 1 — pGOE is plotted; the closer the 
surface is to 1, the more enriched the specific GO term is at that specific 
level of pGS. The enrichment surface allows the user to identify the 
consistency of enrichment. Thus, GO terms which are enriched 
independently of the pGS cut-off can easily be identified.
A more clear way of displaying the enrichment surface is by creating a 
heatmap (see Figure 4.1B). Rather than being sorted on the basis of mean 
enrichment, the enriched GO terms are clustered hierarchically (in this case 
by Ward’s method) to reflect their proximity in the GO graph. This is 
calculated as the fraction of nodes to the root of the directed acyclic graph 
that is shared by two GO terms. The resulting dendrogram is shown at the 
side of a heat map. Thus, one axis represents GO terms, clustered on 
proximity in the GO graph, and the other axis represents gene selections 
based on different pGS levels. By plotting the results in this fashion it is
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size of geneset
Figure 4.1: A ) Example of an enrichment surface (generated from synthetic data for explanatory 
purposes). The height of the plane indicates the significance of the enrichment. A group of GO terms 
which is consistently enriched for all gene sets can be identified and is marked with the character “t” . 
Furthermore, the consistency of enrichment of the most enriched terms can be assessed based on the 
ruggedness of the surface. With normal enrichment analysis one inspects only one cross-section of 
this surface (e.g. the gene set indicated with “s”). B ) Example of the heatmap from the enrichment 
surface in Figure 4.1A. Rows represent GO terms and columns represent gene sets. More enrichment 
is indicated with red and less enriched values are white. The GO terms which are consistently enriched 
can be identified in the map and are marked with the character “c” . Terms which become more 
enriched with increasing gene set size are labeled as “k”, and terms which are less enriched when the 
number of genes increases are indicated with “e” .
possible to investigate whether closely related GO terms are enriched in a 
similar way across a number of gene selections. This definitely seems to be 
the case for the terms labelled “e”. An advantage of the heatmap is that the 
information about the enrichment for specific gene sets and terms can be 
observed at the same time as the consistency of the enrichment.
A final option is to show enrichment information in the GO graph [10,15]. 
By colouring nodes corresponding to GO terms in the graph, one can show 
the enriched processes for a single combination of pGOE and pGS cut-offs. 
Here, we suggest adding information about enrichment of a set of gene 
selections in the graph by plotting pie charts at every node. Each pie shows 
the fraction of pGOEs calculated for the different gene selections for this 
term in different predefined categories. An example is shown in Figure 4.2. 
This gives a natural view of the GO graph with additional information for
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Figure 4.2: A ) Example of a GOgraph, displaying GO enrichment for standard methods. W ith the 
normal analysis, enriched terms (based on a single pGOE) and terms which are not enriched are 
indicated with the colours white and black, respectively. B ) Example of a GOgraph, displaying GO 
enrichment over several pGS cut-offs. The different parts of the pie in each node indicate the fraction 
of pGOE values which falls within a particular categorie. Here the categories are green (0.001 < 
pGOE < 0.01), dark blue (0.01 < pGOE < 0.05) and light blue (pGOE > 0.05).
each node, indicating the enrichment of this term across several selections. 
For instance the bottom node in both figures is indicated as not enriched in 
Figure 4.2A, but when Figure 4.2B is inspected it can be seen that the pGOE 
is varying depending on the pGS cut-off. For 37 percent of the pGS cut-offs 
the pGOE value is between 0.001 and 0.01 (green), 25 percent of pGOEs is 
between 0.01 and 0.05 (dark blue) and 37 percent of the pGOE values is 
higher than 0.05 (light blue).
4.3.2 Agreement of enrichment results with prior knowledge
At the very least, a selected set of genes should reflect known biology. This 
means that processes that are known to be relevant should show up as being 
enriched. Here, the ROC curve is presented as a tool to examine the 
distribution of a set of expected processes among all the processes indicated 
as enriched with GO enrichment analysis. ROC plots have been applied in 
various scientific fields with the purpose of evaluating and validating results 
with prior knowledge [3]. By plotting one minus the specificity against the 
sensitivity, the ROC curve shows whether the results are better than results
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Figure 4.3: A ) Example of the distributions of GO terms from enrichment results which are divided 
in general terms (red curve) and expected terms (black curve). Points in the ROC curve are drawn by 
using results at different pGOEs. Steps are taken from left to right. B ) Schematic example of the ROC 
curve. At each pGOE cut-off, we find a combination of specificity and sensitivity, which is put in the 
ROC plot.
found by chance alone. Sensitivity and specificity are defined as:
nr. true positives
Sensitivity =
Specificity =
nr. true positives + nr. false negatives 
nr. true negatives
(4.1)
(4.2)
nr. true negatives + nr. false positives 
The principle on which the method is based is displayed graphically in 
Figure 4.3. The figure shows the pGOE distributions of terms involved in the 
experimental conditions of interest (expected terms, or positives) and all 
other remaining processes (general terms or negatives) found with GO 
enrichment analysis. When the pGOE cut-off is moved along the x-axis from 
left to right, one would expect the processes of biological interest to be 
found earlier than general or random terms, as is the case in Figure 4.3.
The expected set of GO terms should be defined by expert(s) of the 
biological system under investigation. Not only the species, tissue type or 
cell type are of importance, but other aspects of the dataset should be taken 
into account as well (e.g., time point in the process of investigation and 
treatment of the sample). These GO terms, representing expert knowledge,
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are considered positive results and can be used to calculate sensitivity and 
specificity for a sequence of pGOE values, according to Equations 1 and 2. 
This leads to a ROC curve as shown in Figure 4.3B. Note that experts may 
differ in their definition of expected terms because of personal opinions, 
knowledge and expertise of the biological system at hand. A partial solution 
for this is making a list which is supported by several researchers in a 
combined effort. This way an estimate of performance of the enrichment 
analysis can be made based on current knowledge.
4.3.3 The mesenchymal stem cell dataset
The microarray experiment used in the examples presented here has been 
performed on human mesenchymal stem cells, triggered to undergo 
osteogenic differentiation (E. Piek et al., submitted). Dexamethasone can 
induce the differentiation of stem cells to osteoblasts. It is known that BMP2 
and Vitamin D3 can potentiate osteogenesis in combination with 
dexamethasone [7]. The biological process of interest for the dataset used in 
this article is skeletal development. The hybridisations are performed with 
Affymetrix Human Genome U133A GeneChips [9]. The dataset was used 
previously to demonstrate the advantages of applying PCA on interaction 
terms in ANOVA for a large dataset [4].
Mesenchymal stem cells are able to differentiate into osteoblasts. 
Mineralisation of the extracellular matrix by mature osteoblasts starts around 
12 days after onset of osteogenic treatment. The experiment was set up as a 
time-series experiment and the expression measurements were taken at ten 
time points (at 1, 3, 6, 12, 24, 48, 72, 120, 192 and 288 hours after onset of 
treatment). More measurements were taken in the first 24 hours of the time 
course, because the first part is expected to be important for the onset of 
differentiation.
In addition to sampling multiple time points during the differention process, 
another factor of interest is introduced to the experiment by inducing 
osteogenesis of the mesenchymal stem cells with different treatments. The 
three treatments are named after the substances added to the culture medium. 
For the first treatment (VIT) a combination of vitamin D3 and dexametasone 
is used. The second treatment, DEX, consists of Dexamethasone only. The 
The third treatment consists of a combination of bone morphogenetic protein
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1 3 6 12 24 48 72 120 192 288
VIT □□□ □ □□ J J J □□□ J J J J J J J J J o o a □ □ □ J J J
D E X J J J j j j j j j j j j J J J j j j j j j j j j J J J J J J
B M P JJJ JJJ J J J JJJ JJJ JJJ J J J j j j J J J J J J
Unlr □□□ □ □□ □□□ □□□ J J J □□□ □ □□ □ j j □□□ □□□
Figure 4.4: Schematic representation of the design of the mesenchymal stem cell dataset. The condi­
tions are indicated on each row. Each column represents a time point (in hours). The dimension genes 
is not shown in the table, but is taken into account in the analysis. Each cell in the table contains three 
replicate arrays.
2 (BMP2) and DEX, and is indicated with BMP. Furthermore an untreated 
sample is measured as a control at each time point. Thus, four time profiles 
can be generated for each gene on the microarrays. A graphical view of the 
experimental design of the experiment is given in Figure 4.4.
The gene selections used throughout the article are based on 17 pGS cut-off 
values, evenly spaced between 10-10 to 10-2 . This results in gene sets 
ranging from 90 to 957 genes. The groups of genes are selected by applying 
a multivariate Hotelling T2 test to the two factor interaction of gene and 
treatment, calculated from a three-way ANOVA [4].
4.3.4 Software
The calculations for the hypergeometric distribution were performed in 
R [14] with the package GOstats [5]. R scripts with code to perform all 
analyses and visualizations is available upon request.
4.4 Results
Examples of application of the methods explained in this paper will be 
shown here to indicate the added value of these methods. All calculations 
and examples are from the mesenchymal stem cell dataset. For all 
calculations the GO category Biological Process was used, but the methods 
can be applied to the categories Molecular Function and Cellular Component 
as well.
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Table 4.1: The 25 most enriched GO processes for a set of 957 genes selected with a pGS cut-off of 
0.01. A pGOE cut-off of 0.05 leads to 163 enriched GO categories.
GO identifier G0 term pvalue for 
G0 enrichment
G0:0007275 multicellular organismal development 6.77e-17
G0:0007155 cell adhesion 9.74e-10
G0:0048513 organ development 1.02e-09
G0:0030154 cell differentiation 8.54e-09
G0:0001501 skeletal development 1.33e-07
G0:0009888 tissue development 6.89e-07
G0:0007517 muscle development 3.07e-06
G0:0040007 growth 3.80e-06
G0:0007166 cell surface receptor linked signal transduction 4.62e-06
G0:0009653 anatomical structure morphogenesis 5.91e-06
G0:0007154 cell communication 6.18e-06
G0:0007267 cell-cell signaling 1.73e-05
G0:0006817 phosphate transport 2.14e-05
G0:0006690 icosanoid metabolic process 2.89e-05
G0:0006692 prostanoid metabolic process 5.11e-05
G0:0006693 prostaglandin metabolic process 5.11e-05
G0:0048741 skeletal muscle fiber development 1.7e-04
G0:0048747 muscle fiber development 1.7e-04
G0:0048637 skeletal muscle development 1.7e-04
G0:0009611 response to wounding 2.1e-04
G0:0045595 regulation of cell differentiation 2.3e-04
G0:0040008 regulation of growth 2.5e-04
G0:0045637 regulation of myeloid cell differentiation 3.3e-04
G0:0006820 anion transport 4.1e-04
G0:0045596 negative regulation of cell differentiation 4.8e-04
4.4.1 Enrichment results
For comparison, first the results of a standard GO enrichment analysis, using 
a pGS cut-off of 0.01, are given in Table 4.1. In the 957 genes that are 
selected, 163 enriched GO categories are identified when the cut-off for 
pGOE is set to 0.05. Table 4.1 lists the first 25 of these GO terms. Many -  
but not all -  of these terms seem reasonable; however, it remains unclear 
which of these will show up as enriched when other cut-off choices are 
made.
What is needed is an overview of GO enrichment across several selections of 
genes -  several pGS cut-off values. An example of such a plot, visualizing 
the surface of the pGOEs is shown in Figure 4.5. The GO terms are ranked,
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Figure 4.5: Plot of the enrichment surface. For 25 GO terms the enrichment surface is shown. Enrich­
ment is calculated for different sets of genes. The surface represents 1 — pGOE; the higher the surface, 
the more enriched a term is in the selections of genes. GO terms are ordered by mean enrichment rank.
as explained before, on the basis of the mean enrichment across gene 
selections. The first 25 terms are selected because they represent the most 
interesting part of the surface (before pGOEs are becoming less significant). 
Note that these 25 terms are not necessarily the same as the terms in 
Table 4.1, where only one gene selection is considered. It can be seen that 
the pGS cut-off has significant effects on the results of the enrichment 
analysis. In Figure 4.6A and B cross sections are given, which underline the 
advantage of investigating the enrichment surface. The comparison of two 
gene sets with pGS =  0.00001 and pGS =  0.01 in Figure 4.6A shows that a 
pGOE of 0.01 results in variation in the selected GO terms. This effect is 
also visible in a plot of a single GO term. In Figure 4.6B the pGOE of the 
GO term “GO:0051243” is clearly dependent on the pGS. When a single 
pGS would have been used, selection of a GO term would have depended on 
the choice of pGS. Variation in pGOE could be due to irregular differences 
in the number of selected genes or by the limited number of genes which is 
known for a specific term.
The surface plot can also be visualised in a heatmap, containing additional 
information about the proximity of the GO classes in the GO graph. This
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Figure 4.6: A. Comparison of values of 1 — pGOE for two gene sets with pGS = 0.00001 (282 genes, 
in green) and pGS = 0.01 (957 genes, black), respectively. W ith the example selection cutoff of 
1 — pGOE of 0.99 different GO terms w ill be selected in the processes with a higher rank. B. Plot 
of 1 — pGOE for the GO term “GO:0051243” which is defined as: “negative regulation of cellular 
physiological process” . The enrichment of this term is not constant across different values for pGS. 
At the example cutoff for pGOE (red line) this term is selected with most of the gene sets but is not 
selected with a sets of 196 or 957 genes (pGS of 0.310-6 and 0.01 respectively).
makes it possible to analyze a large number of processes simultaneously. 
Here, we will limit ourselves again to the first 25 terms with the highest 
ranked average enrichment. The matrix of the pGOEs from these terms 
across the gene selections is shown in the heatmap of Figure 4.7. Each cell 
in the matrix is coloured according to the corresponding pGOE, where 
colours range from red (lower p-values, more significant enrichment) to 
white (higher p-values, less significant enrichment). On the left, the 
dendrogram shows which of these terms are close together in the GO tree. 
Thus, the high similarities between the terms organ development 
(GO:0048513), development (GO:0007275) and skeletal development 
(GO:0001501) are much better visible. Furthermore, one can see that the 
term cell differentiation (GO:0030154) becomes relatively less enriched 
when a more limited number of genes is selected.
Another possibility to get an overview across several gene selections is
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Figure 4.7: Heatmap of the enrichment surface of the first 25 most enriched terms, according to the 
ranked average enrichment, showing pGOEs at different selections of genes. The number of genes in 
a selection is shown below each column. Lower pGOEs are indicated with red, and higher pGOEs 
with a light colour. The ordering of the GO terms in the dendrogram is based on the similarity of GO 
terms in the GO graph. GO identifiers of terms discussed in the text are displayed on the right.
plotting the GO graph itself for the these 25 terms. Visualization of enriched 
terms in a graph has been shown before [10,15], but in those cases the 
colouring was based on a single combination of pGS and pGOE cut-offs. By 
representing the nodes in the graph as pie charts, information for this term 
across several gene selections can be shown. An example of such a plot is 
shown in Figure 4.8. Indeed, nodes close together in the branches of the 
graph show similar enrichment behaviour. The three highly similar terms 
identified in Figure 4.7 can be seen in the lower left part of Figure 4.8. This 
part of the graph shows more green pies, which indicates that this related 
group of terms is enriched, independent of varying the pGS cut-off. The 
other two terms, GO:0000188 and GO:0030154, are not uniformly enriched 
over all gene selections and therefore show pies with several colours. In this 
way, a grouping of the terms can be made based on both the GO graph 
topology and enrichment behavior of the terms.
The problem of variability of pGOE between different pGS values can be 
overcome by specific selection of robust terms. Upon first inspection, the 
enrichment surface in Figure 4.5 becomes more bumpy and rough after the 9
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Figure 4.8: GO graph with additional enrichment information: the graph structure of GO is used to 
show the relations between enriched terms. Information about the enrichment across several gene 
selections in each node is represented as a pie chart. The fraction of pGOEs lower than 10-3 in the 
gene selections is green, the pGOEs between 10-3 and 10-2 are dark blue, pGOEs between 10-2 and 
5.10—2 are cyan and, finally, pGOEs higher than 5.10—2 are grey. Nodes which are not in the first 
25 terms are indicated with white circles - it is possible that these terms w ill be coloured when more 
terms are used.
Table 4.2: Thirteen robustly enriched GO processes for pGOE < 0.01.
GO identifier GO term
G0:0007275 multicellular organismal development
GO:0048513 organ development
GO:0001501 skeletal development
GO:0007517 muscle development
GO:0009653 anatomical structure morphogenesis
GO:0048519 negative regulation of biological process
GO:0048741 skeletal muscle fiber development
GO:0048747 muscle fiber development
GO:0030154 cell differentiation
GO:0048523 negative regulation of cellular process
GO:0045445 myoblast differentiation
GO:0009887 organ morphogenesis
GO:0042692 muscle cell differentiation
most enriched (on average) GO terms. This indicates that these 9 terms are 
consistently enriched and that there will be more variability in other terms. 
This rather subjective observation can be formalized using the following 
selection criterium: a term is selected when the percentage of pGOE < 0.01 
is larger than 90 percent. This leads to the selection of 13 terms, shown in
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Table 4.2. When compared with the standard results, the number of 
categories has decreased drastically (13 versus 163). The terms “cell 
adhesion”, “cell surface receptor linked signal transduction” and “cell 
communication” -  ranked 2, 9 and 11 in the standard results, respectively -  
are not selected because their pGOE becomes less significant at smaller 
pGS. This obviously makes the interpretation of these terms much easier. 
Moreover, the plot in Figure 4.5 immediately shows why some terms are no 
longer being identified as (robustly) enriched.
4.4.2 Agreement with prior knowledge: ROC plots
The agreement of knowledge about a biological system and the results found 
in the dataset can be tested with ROC curves. Based on the knowledge that 
the experiment underlying the dataset involves the process of osteogenesis, 
we have generated a list of 30 processes which are expected to be enriched, 
available in Table 4.3 in the Supplementary Material.
Only one set of 957 genes is analysed here to show the application of the 
ROC plot, but the plot can also be used to evaluate the results for several 
gene selections. By calculating the true positives, false positives, true 
negatives and false negatives for several pGOE cut-off values, the ROC 
curve can be drawn (see Figure 4.9A). Based on the ROC plot, 0.01 would 
be a good choice of the pGOE cut-off. In that case, allmost 50 percent of the 
expected terms is identified as enriched, while the percentage of false 
positives is remains acceptable at approximately 5 percent. The advantage of 
using prior information becomes clear, when a comparison is made with the 
standard results. In contrast with the standard approach, the ROC plots allow 
for an objective assessment of pGOE cut-off values, based on sensitivity and 
specificity.
To have an indication of the influence of the set of expected terms on the 
stability of the results, the curve is drawn ten times, with a different group of 
three terms removed from the expected terms each time. The result is shown 
in Figure 4.9B. Clearly, the conclusions from this plot are fairly independent 
of what terms exactly are used. To assess the significance of these results, the 
same procedure for generating an ROC plot was repeated with 30 random 
(non-enriched) GO terms. Additionally, the procedure was repeated, but with 
a random selection of genes (but now again with the original list of expected
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Figure 4.9: A ) ROC plot of expected terms. For a set of 957 genes the ROC curve is shown. The 
pGOE cut-off is plotted along the curve. B ) Ten ROC curves, each time with a different group of 
three terms removed from the set of expected terms. As can be seen, the ROC curve is not critically 
disturbed by changes in the group of expected terms.
terms). The latter was achieved by randomising pGS values. Representative 
results for such experiments are shown in Figures 4.10A and B. As can be 
seen in the plots, the results fluctuate around the straight line, which is an 
indication of the results expected by chance. In fact, Figure 4.10B shows 
that the processes in which we are interested are underrepresented in random 
groups of genes with similar size. This can be explained by the fact that, in 
general, genes associated with processes involved in bone development are 
present in small numbers compared to all other genes on the array. In 
summary, the results in Figure 4.9 show that expected processes are to a 
large extent present in the enrichment data. The randomized experiments, 
shown in Figure 4.10, indicate that this effect is significant.
4.5 Discussion
Gene selection profoundly influences enrichment analysis: selecting a 
different number of genes can lead to quite different conclusions. Note that a 
multiple-testing correction does not alleviate the problem: one still faces the 
problem of choosing appropriate thresholds. In this paper, we have proposed 
several visualization methods to help identify robust enrichments. All
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1 - specificity 1 - specificity
Figure 4.10: A ) ROC plot of 200 analyses based on random terms rather than on terms expected to 
be enriched. The resulting curves are shown in black. The average, shown in red, lies on top of 
the diagonal. For comparison, the “real” ROC curve is displayed in green. B ) ROC plot of sets of 
957 random genes (equal sized set as Figure 4.10). For this plot the genes were selected at random, 
without considering the statistics from the test which was used previously to select and sort the genes; 
the average ROC curve is below the diagonal in this case.
visualizations are representations of the same enrichment data, generated by 
calculating pGOE at varying pGS values. The information gained from the 
different visualizations is different though. The surface plots (Figures 4.1 
and 4.5) can identify which processes are most robustly enriched, but do not 
show the biological relations between the terms. The latter can be identified 
with the heatmaps (Figures 4.1 and 4.7) and the GO graph with pie 
charts(Figures 4.2 and 4.8). The pie charts give the best representation of the 
original GO graph, while the heatmap shows the relation between GO terms 
based on distances between nodes in the GO graph. By representing the pie 
charts in the GO graph the information about the size of the gene sets is lost; 
if one is interested in that, the other visualizations are to be preferred.
A visualization displaying the relation between the experimental data and 
prior knowledge about the experiment is the ROC method. By application of 
this method a choice of pGOE cut-off can be made for which the selected 
gene set represents the anticipated biological processes best. It is therefore 
preferred to the usual practice of picking a single point in the large space of 
enrichment data. Although the method relies on a predefined list of
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important terms, it still allows for unknown or unexpected terms to show up. 
One should be aware that this is strongly dependent upon the prior 
information used to make the graph.
In the dataset used here, standard GO enrichment analysis would have 
resulted in 163 enriched processes. This is a substantial number of terms 
which can be reduced drastically by selecting only terms which are robustly 
enriched across a number of pGS values. Moreover, several terms which are 
in the top enriched processes are not at all robustly enriched, and vice versa. 
These terms are given a much lower rank when drawing the surface plot, as 
proposed here. Furthermore, the relation between terms in the GO graph 
with the heatmap and the pie GO graph can be shown simultaneously with 
robustness of GO enrichment information; this is not possible with current 
methods.
In this paper, we focus on GO enrichment information, because this is the 
most complete and most frequently used form of annotation. Other forms of 
biological information are available; an example is the KEGG database [11] 
containing pathway information. Our visualization methods can be applied 
to the statistics of enrichment calculations, independent of which source of 
biological information was used.
By using the methods shown here, a better overview of results and 
consequences in enrichment analysis can be given. Furthermore, 
incorporating expected GO terms in the analysis can help to find out whether 
the enrichment results generated with the dataset match with prior 
expectations. When this is not the case, it is possible that the biological 
knowledge about the system under investigation is not complete.
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Supplementary material
GO identifier Go term
G0:0030154 cell differentiation
G0:0001501 skeletal development
G0:0045595 regulation of cell differentiation
G0:0001503 ossification
G0:0031214 biomineral formation
G0:0045597 positive regulation of cell differentiation
GO:0030500 regulation of bone mineralization
G0:0016049 cell growth
G0:0001558 regulation of cell growth
G0:0046849 bone remodeling
G0:0046850 regulation of bone remodeling
G0:0030278 regulation of ossification
G0:0000902 cellular morphogenesis
G0:0030282 bone mineralization
G0:0016055 Wnt receptor signaling pathway
G0:0008284 positive regulation of cell proliferation
G0:0008283 cell proliferation
G0:0007050 cell cycle arrest
G0:0043062 extracellular structure organization and biogenesis
G0:0030198 extracellular matrix organization and biogenesis
G0:0042127 regulation of cell proliferation
G0:0045786 negative regulation of progression through cell cycle
G0:0030501 positive regulation of bone mineralization
G0:0001649 osteoblast differentiation
G0:0045778 positive regulation of ossification
G0:0045667 regulation of osteoblast differentiation
G0:0045669 positive regulation of osteoblast differentiation
G0:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
G0:0030111 regulation of Wnt receptor signaling pathway
G0:0000074 regulation of progression through cell cycle
Table 4.3: Table of GO processes expected to be enriched before enrichment calculations are per­
formed. These 30 terms were used as a reference set to make the ROC plots.
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5.1. ABSTRACT
5.1 abstract
Background: Gene expression data can be analyzed by summarizing groups 
of individual gene expression profiles based on GO annotation information. 
The mean expression profile per group can then be used to identify 
interesting GO categories in relation to the experimental settings. However, 
the expression profiles present in GO classes are often heterogeneous, i.e., 
there are several different expression profiles within one class. As a result, 
important experimental findings can be obscured because the summarizing 
profile does not seem to be of interest. We propose to tackle this problem by 
finding homogeneous subclasses within GO categories: preclustering. 
Results: Two microarray datasets are analyzed. First, a selection of genes 
from a well-known Saccharomyces cerevisiae dataset is used. The GO class 
“cell wall organization and biogenesis” is shown as a specific example. After 
preclustering, this term can be associated with different phases in the cell 
cycle, where it could not be associated with a specific phase previously. 
Second, a dataset of differentiation of human Mesenchymal Stem Cells 
(MSC) into osteoblasts is used. For this dataset results are shown in which 
the GO term “skeletal development” is a specific example of a 
heterogeneous GO class for which better associations can be made after 
preclustering. The Intra Cluster Correlation (ICC), a measure of cluster 
tightness, is applied to identify relevant clusters.
Conclusions: We show that this method leads to an improved 
interpretability of results in Principal Component Analysis.
5.2 Background
With the advent of large gene expression experiments, new methods of 
analysis have become necessary to extract relevant information from the 
data. Exploratory data analysis methods like cluster analysis are regularly 
used to examine the expression profiles [8, 26, 28]. Other methods use 
annotation information and look for overrepresentation in sets of 
significantly regulated genes [1, 17, 25]. A next step would be to associate 
relevant profiles with annotation information and experimental variables 
simultaneously. In this paper we will show advances in finding associations 
between annotation categories and experimental variables in microarray 
experiments.
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One of the most extensive and systematic methods of categorizing 
information about genes is the Gene Ontology (GO) database [27]. A 
problem when relating GO classes with expression profiles is the fact that 
the genes in these functional classes can have diverse expression profiles. 
This could mean that a class is not responding to the experimental factors 
and is not related to the specific biological settings. However, a second 
possibility is that interesting subgroups are silenced by other heterogeneous 
or anti-correlated expression profiles present within the class. This may 
obscure interesting relations. To address this problem, we propose to cluster 
the expression profiles of genes in every category, and select relevant 
clusters before applying Principal Component Analysis (PCA; [15]).
PCA has been applied frequently to explore the microarray data in a 
low-dimensional space [14, 22]. Either genes or arrays are described with so 
called Principal Components, in order to assess relations between arrays or 
to identify genes with similar expression profiles. The technique is very 
versatile and can easily cope with large datasets. Work done by Alter et 
al. [3] is an example of the application of PCA to reduce the dimensionality 
of microarray data. PCA was applied to the Yeast Cell Cycle dataset of 
Spellman et al. [24], with each gene as an individual object. We will use the 
same dataset, but will focus on improvements in the application of PCA to 
find relations between specified classes of genes and phases in the cell cycle.
The work by Goeman et al. [12] is an example of the direct association 
between annotation information and data analysis. A global test is 
introduced, determining the relation between a global expression pattern of a 
group of genes and a clinical outcome of interest. The global expression 
pattern summarising a group of genes is a method to perform research, based 
on previous research stored in databases like for instance GO. A second 
example of summarization of annotation categories is from Chen and 
Wang [6]. In this paper, gene expression data with prior biological 
knowledge are integrated by constructing “supergenes” for each gene 
category by summarizing information from genes related to outcome using a 
modified principal component analysis (PCA) method. Instead of using 
genes, these supergenes representing information from each gene category 
were used in further analysis. Both methods [6,12] indicate that analysing 
the data on the level improves the results of predictions.
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Figure 5.1: Example of heterogeneous expression profiles within a single GO class. Expression pro­
files for genes annotated with the term G0:0007047 are depicted here for the cdc15 synchronization 
of the Saccharomyces cerevisiae Cell Cycle dataset [24]. From the first subpicture, containing all pro­
files simultaneously (A ), it is clear that there is big variation within the profiles. More homogeneous 
subgroups, with shifted or even anti-correlated profiles in time, can be identified (B , C, D).
Here, we show that summarizing a GO category in a single profile or 
supergene can give problems for certain classes, and can be improved. An 
example of a heterogeneous GO category is shown in Figure 5.1. The 
expression data are from the Saccharomyces cerevisiae dataset [24] and all 
the profiles belonging to the genes annotated with G0:0007047 (“Cell wall 
organization and biogenesis”) are shown in Figure 5.1A. At first glance, 
there are several particular profiles distinguishable, but it would be hard to 
give a suitable general description for this category. Previously, Busold et 
al. [5] also included GO information in their analysis and touched upon this 
problem by discarding of the categories like the one described here. Thus
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with the criteria of Busold et al. [5] this category would not be included in 
the analysis, because the whole category has a low mean correlation over all 
the genes. The fact that this category is discarded is surprising, because 
organization of the cell wall is expected to be important in the cell cycle.
We propose to perform clustering of expression profiles present in individual 
GO classes before applying PCA. This is a reversal of the order with respect 
to more common analyses, where clusters of genes with similar expression 
profiles are mapped to GO terms. An indication of the improvements of GO 
class descriptions after cluster analysis is given in Figure 5.1B, C and D. 
After clustering with model-based clustering [10] these three new subgroups 
with more distinct profiles can be formed for this class. The new subclasses 
will not be discarded because the mean correlation of each newly formed 
class is higher and the role of this process will not be obscured any longer. 
The advantages of the cluster analysis will be shown by comparing results 
from PCA performed with and without preclustering. The Saccharomyces 
cerevisiae dataset and a Mesenchymal Stem Cells (MSC) dataset will be 
used. The intra-class correlation of clusters will be analyzed to identify 
better defined subgroups, and two specific examples of GO categories 
benefiting from the clustering will be given.
5.3 Methods
All calculations are performed in R [21]. GO information is obtained from 
the R data packages “Yeast” and “hgu133a”.
5.3.1 Datasets
Two datasets are used to show the advantages of the method proposed here. 
The first dataset is the well known Saccharomyces cerevisiae Cell Cycle 
dataset of Spellman et al. [24], from here on referred to as the Yeast Cell 
Cycle (YCC) dataset. The focus is on a subset of 800 genes involved in the 
cell cycle [24]. From this set, genes are selected for which GO annotation 
information is available. Only GO classes which contain at least 4 genes are 
considered, which are members of the Biological Process definition in GO. 
The 24 time points of the cdc15 synchronization method in the experiment 
are used. As a result of these choices, a data matrix of 24 time points by 348 
genes is obtained.
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The second gene expression experiment analyzed in this paper, was 
performed on human mesenchymal stem cells, triggered to undergo 
osteogenic differentiation (E. Piek et al., manuscript in preparation). This is 
a time series dataset with multiple osteogenic treatments: Dexamethasone 
(DEX), Bone Morphogenetic Protein (BMP), Vitamin D3 (VIT) and an 
Untreated control (UNT). The hybridizations were performed with 
Affymetrix Human Genome U133 A GeneChips [20]. The dataset was used 
previously to demonstrate the advantages of applying Principal Component 
Analysis (PCA) on interaction terms from an Analysis of Variance for a 
large dataset [7]. The MSC dataset has four dimensions (genes, treatments, 
time points and replicates). Rather than focussing on the expression values, 
as in the YCC dataset, we analyze the “Gene-Treatment” two-way 
interaction matrix from the ANOVA model, described in de Haan et al. [7].
It represents the relations of genes with specific treatments -  in this case, we 
want to extend this to describe the relation of specific GO (sub)classes and 
treatments. Starting from the interaction matrix, genes are selected having 
GO annotations, where the corresponding GO classes contain at least 4 
genes and have the definition Biological Process. This gives us a data matrix 
of 4 treatments times 11974 genes. Furthermore, a subset of this set is 
considered containing 50 relevant GO categories. These categories have 
been defined beforehand by domain experts.
5.3.2 Principal Component Analysis and biplots
Principal Component Analysis [15] can be used to give a succinct overview 
of the structure in a high-dimensional data set using a small number of 
Principal Components (PCs). These PCs are linear combinations of the 
original variables X1, X 2 ,..., Xz, chosen in such a way that PC 1 describes 
the largest fraction of variation in the data, and subsequent PCs describe 
maximal portions of the remaining variation. An essential requirement is 
that all PCs orthogonal to each other. Thus, only the first few PCs need to be 
considered to get a good overview of the data. In our datasets, the variables 
X1, X 2 ,..., Xz represent time points or treatments. The data of n objects, 
each measured at m time points or treatments, can be written as an n by m 
matrix X. In our case, each object represents the mean profile of a GO 
category (or subgroup within a GO category identified with preclustering).
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The matrix X is then decomposed by singular value decomposition (SVD), 
as follows:
X  =  U  • A • VT (5.1)
where U (an n by n score matrix) and V (an m by m loading matrix) are 
orthogonal and A is an n by m matrix containing the so called singular 
values. The superscript T means the transpose of the matrix V . For the 
biplot [11], the n x 2 matrix U2 of the first 2 PCs represents the objects in the 
data. The m x 2 matrix containing the first 2 loading vectors represents the 
variables in the data. A biplot is then constructed by plotting U2 and V2 in 
the same graph.
5.3.3 Combining experimental data with GO information
In order to relate GO information with experimental data, either expression 
profiles or interaction effects from ANOVA, we should combine both 
entities. Here, we use matrices to represent expression information (E ) and 
GO category information (G). In both matrices, rows correspond to genes. 
Columns in E  indicate time points (as in the YCC dataset) or interactions 
(the MSC data). In matrix G, columns represent GO terms in a binary 
coding: if a gene is annotated for a specific GO term the corresponding value 
in the matrix is 1, otherwise it is 0.
By combining the E  and G matrices, categorical information about groups 
of genes is obtained:
X  =  E T G (5.2)
The resulting data table X  is then scaled column-wise so that the sum of 
each column is one. The X matrix can now be considered to contain the 
mean expression profiles -  or interaction profiles -  for all GO categories of 
interest.
Finally, PCA is performed on the X table containing combined information 
sources. The results can be visualized with a biplot [11]. In the biplots the 
GO classes are shown as points; cell cycle phases and treatments are 
indicated as arrows. The biplot allows the GO terms to be correlated with the 
treatments or the cell cycle phases.
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5.3.4 Preclustering
In order to prevent interesting profiles within one GO category to cancel out, 
we propose to perform a cluster analysis on all GO categories of interest 
individually, provided they contain enough genes. The actual clustering is 
performed on the submatrix of the gene expression matrix E, that 
corresponds to all columns and genes within a go cluster. Based upon the 
results of the gene expression clustering, new GO groups (one per cluster) 
are added to the GO matrix. This step is indicated with the term 
“preclustering”. In the remainder of the paper, we will only consider GO 
(sub)categories containing at least four genes.
In principle, any clustering method can be used. We have chosen to cluster 
the genes, present in each GO class, with model-based clustering [10] 
because this is one of the few methods giving an indication of the optimal 
number of clusters automatically. When this optimal number equals one, the 
category is not split; if it is larger than one, the GO class is split into several 
subclasses. Model-based clustering is available in several R packages, such 
as flexmix and mclust. Which method is used is not very important - the 
main motivation is to achieve an automatic assessment of the optimal 
number of clusters. In our scripts, we have used the 2002 version of mclust 
(available as mclust02). Model-based clustering has been applied to gene 
expression data before (e.g., [28]). The data are described as a mixture of 
(normal) distributions. The method applies a number of different models, 
identified by more or less stringent constraints. Parameters for these models 
include different variations of shape, volume, and orientation of the clusters. 
Selection of the best model is performed using the Bayesian Information 
Criterion (BIC, [23]). This index corrects for several parameters used in the 
clustering -  for instance the number of clusters -  to enable a fair comparison 
between the results of different models. The clustering of the model with the 
best BIC was chosen with a minimum of 1, and maximum of 8 clusters; it is 
not to be expected that a higher number of clusters is needed in practice, but 
one can easily check whether the results improve upon increasing this upper 
limit.
The steps in the preclustering algorithm are displayed below:
• 1. Construct the E matrix of expression values and the G matrix
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containing GO category information.
• 2. Set maximum number of clusters and minimum number of genes in 
cluster (here 8 and 4 respectively)
• 3. For each GO class:
3a. Select the submatrix from  matrix E that contains only the genes 
from  that particular GO class.
3b. Perform gene-wise clustering of the submatrix and select the best 
clustering.
3c. Accept only clusters with at least the minimum number of genes.
• 4. Define a new G matrix containing either the original GO classes or, 
when clusters have been detected, the GO subclasses - one column is 
used for each (sub)class.
• 5. Multiply E and the new G matrix to obtain the X  matrix.
• 6. Perform column-wise scaling ofX  by dividing by the number of genes 
in each subclass.
• 7. Perform PCA on the scaled X  matrix and show the biplot.
Of course, the best clustering model will not necessarily result in interesting 
clusters only. From a GO class, clusters which contain noise or have a less 
interesting profile, can also be formed. Therefore a measure is used to assess 
the cluster quality of each individual cluster. One way to do this is to 
calculate the volume for each cluster, available from the model-based 
clustering. Small volumes indicate tight clusterings. An alternative measure, 
independent of the clustering method, is to use the mean of all the (Pearson) 
correlations between the genes within a cluster, the Intra Cluster Correlation
Here, Ci is an element in the lower triangle of the correlation matrix of the 
genes in a cluster. The measure is also used by Busold et al. [5] but was not 
specifically given a name. By using the IC C  it is possible to assess the 
quality of the newly formed subgroups from a GO class: high values indicate 
tight clusters. An additional advantage of the IC C  over a measure like
(ICC  ):
(5.3)
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cluster volume is that uninteresting clusters around zero, which may cover a 
small volume and therefore would seem interesting according to the volume 
criterion, usually show only low IC C  values.
The result of the preclustering stage is a new set of GO categories, nested in 
the original categories. These new categories now are used as matrix G in 
Equation 5.2 to obtain matrix X , the focus of attention. As a consequence, 
one original GO category now may have several representatives in this 
matrix, and in that case will show up multiple times in PCA plots. The 
matrix E containing the expression values is not changed by the 
preclustering algorithm.
5.4 Results and Discussion
In this section, we will compare the results of PCA using the original GO 
categories with the results of PCA on the preclustered GO data. Besides the 
restrictions mentioned previously in paragraph 3.1, all GO classes are taken 
into account, no cuts were made to exclude parts of the GO tree. In Table 5.1 
the number of GO terms before and after preclustering is summarized for the 
datasets. Besides the number of unchanged original GO categories, the 
number of original GO categories split into new subgroups based on the 
clustering is shown. Furthermore the number of new subgroups containing 
more than 4 genes is given -  these are used for further analysis.
Table 5.1: Number of GO categories, before and after preclustering. Only categories containing more 
than four genes are considered. The header # > 4 means the number of groups which contains more 
than 4 genes.
Dataset # genes # GO cl. # split # new # > 4 total 
YCC 348 68 12 29 14 70 
MSC 11,974 922 553 1,933 1,284 1,653 
MSC (50 cl.) 1,252________24 24 100 79 79
Clearly, for the MSC data set and the relevant subset of 50 GO categories, 
many GO categories are heterogeneous with respect to the expression data. 
For the subset, for example, all GO categories are split, leading to 100 new 
categories. Of these 100, 79 contain more than four genes. For the much 
smaller and simpler YCC data set, there is still a group of 12 GO categories 
that is split, leading in total to 70 categories each containing more than four
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genes.
5.4.1 YCC data
To investigate whether the new GO subcategories generated with 
preclustering show relevant cluster structure, the ICCs of the original GO 
classes and the new subgroups are compared in Figure 5.2. For most classes 
(56, see Table 5.1) the IC C  has not changed. These classes lie on the 
diagonal, and consist of GO terms for which the optimal number of clusters 
is determined to be 1: no meaningful subclasses are formed. However, 
several new subclasses with an increased IC C  can be observed above the 
diagonal line. These are examples of groups of genes having a specific 
profile, which is cancelled out to some extent when the GO category as a 
whole is taken into account. In some instances, a new subclass with fewer 
than four genes is found. Such a class will not be taken into account and is 
not shown in the figure. Note that in this case there is no subclass showing a 
decrease in IC C .
As an example of a heterogeneous GO class benefiting from preclustering 
the term “cell wall organization and biogenesis” is taken. The three 
subclasses are shown with asterisks in Figure 5.2. The expression profiles 
and clusters for this term can be seen in Figure 5.1 in the introduction. The 
term is chosen because it is expected to be involved in the cell cycle, where 
the cell wall has to be organized and assembled during cell division. The 
new subclasses generated with clustering have an increased IC C  compared 
to the IC C  of the whole class. The profiles are more specific now and will 
not cancel out in the analysis.
The results of PCA of the YCC dataset with the normal GO classes, and 
PCA of this dataset after clustering of profiles within GO classes can be seen 
in Figure 5.3. This allows for a comparison of the results and shows the 
advantages of preclustering GO classes in PCA. The 24 time points of the 
cdc15 experiment are shown as loadings, and are connected by lines. The 
fact that the cell cycle is passed through more than once results in a large 
number of time points associated with the same phase (G1, S, G2, M or 
G1/M). A separation of phases can be seen in both Figure 5.3A and 
Figure 5.3B. The G1 phase is separated from the M and G2 phases on the 
x-axis and the M phase is separated from the G2 and S phase on the y-axis.
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ICC original GO class
Figure 5.2: Plot showing the relation between the IC C  of the grouped genes from original GO classes 
(x-axis) and the new subgroups (y-axis). Each point represents a class. The GO term G0:0007042 is 
marked with three asterisks, one for each subclass.
The explained variance in the first two Principal Components (PCs) is more 
than 70 percent.
The consequences of preclustering are shown by a number of differences 
between Figures 5.3A and 5.3B. The term “cell wall organization and 
biogenesis”, represented with a star, is used as an example showing 
interesting changes. When the whole GO class is used (Figure 5.3A), the 
term seems uninteresting and is close to the center of the PCA biplot. It is 
hard to associate it with a specific phase of the cell cycle. When the different 
profiles are separated by the clustering however, the new subgroups can be 
associated with phases G1, M, and between M and G2.
5.4.2 MSC data
For the MSC dataset similar questions about the comparison between normal 
PCA and PCA after preclustering of GO classes can be asked. The 
corresponding I C C  plot is shown in Figure 5.4. The original number of 922
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Figure 5.3: Visual representation of PCA results for the YCC dataset. The PCA results without (A ) 
and with preclustering (B ) are shown. Several categories for the preclustered PCA are more outward 
and at a different location than for the PCA without preclustering. Categories (PCA scores) are shown 
as points, which can be correlated with phases of the cell cycle (connected by lines). Dark points 
have a IC C  which is larger than 0.2. Specifically marked is the category “cell wall organization and 
biogenesis” (GO:0007047, represented by star symbols). Cell phases are indicated by names (G1, S, 
G2, M  and G1/M) also used by [24].
GO classes has increased to 1653 subclasses after preclustering, indicated 
with gray dots. As shown previously, not all classes are divided into 
subgroups and the unchanged classes are appearing on the diagonal. A
95
5.4. RESULTS AND DISCUSSION
considerable number of newly formed classes has an increased IC C . Many 
of these subclasses have a low IC C  for the original GO classification, which 
results in vertical band of points at around x =  0. The plot also tells us that a 
number of new subclasses are formed with a lower IC C  than the original 
GO classes. These subclasses arise when a group of less related expression 
profiles remains after relevant profiles are split off in the preclustering.
Because of the large number of GO terms for this dataset we will focus on 
the terms involved in cell differentiation and osteogenesis. Out of a list of 50 
GO terms which could be expected to be responsive to the conditions and the 
setup of the experiment, 24 terms were present in our dataset 5.2, taking into 
account our criteria for the minimum number of genes in a class. For these 
24 classes, clustering of the expression profiles in the original GO classes 
gives rise to 79 classes. These subclasses are marked with black dots in 
Figure 5.4. A large number of new subclasses show an increased IC C ; they 
all lie in the vertical band described above. There is also a number of new 
subclasses which has a decreased ICC.
For the MSC dataset, PCA results with and without preclustering are shown 
in Figures 5.5A and B. One should remember that in contrast to the YCC 
dataset, where expression values are used, here, the interaction values from 
the ANOVA model are analyzed. Four loadings are shown as arrows, 
corresponding to the three osteogenic treatments and the untreated control 
(DEX, BMP, VIT and UNT). The first two PCs describe 89.4 percent of the 
total variation in Figure 5.5A, and 94.2 percent in Figure 5.5B. A separation 
between GO terms associated with the untreated control and the osteogenic 
treatments can be seen in the first PC for both Figures 5.5A and B. The 
direction of the UNT arrow is opposite of the three treatments [7]. In the 
second PC, a separation between VIT and the two other treatments can be 
observed.
The number of subclasses associated with cell differentiation and 
osteogenesis has increased from 24 original GO classes to 79 subclasses, as 
mentioned before. The GO term “skeletal development” is shown as an 
example of a category which benefits from preclustering. The group is 
marked with a star symbol in Figure 5.5A. After preclustering, six 
subclasses are identified. As can be seen in Figure 5.5A, the original term 
could not be associated with a specific treatment and is present in the center
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ICC whole GO class
Figure 5.4: Representation of the IC C  for GO categories evaluated with PCA for the MSC dataset. 
The IC C  values of the whole GO class are on the x-axis and the IC C  of the corresponding sub­
group^) are on the y-axis. A group of classes expected to be involved in the MSC dataset is marked 
with black dots, other classes are marked with grey dots.
of the plot. This has changed dramatically after clustering, as shown in 
Figure 5.5B. One subgroup is still in the center of the plot, but the other 
subclasses can be associated with individual treatments. Two subgroups can 
specifically be correlated with osteogenic treatments, one for VIT and one 
for BMP. These groups are even lying on the corresponding arrows for the 
loadings. A number of genes within the subgroups corresponds with 
information known from biological literature. The new subgroup lying on 
the arrow of the BMP contains the gene MSX1 for instance, which has been 
proven to be induced by BMP in mice [4]. An example of a gene present in 
the newly formed subgroup lying on the loading of the VIT treatment is 
MSX2, which is known to be regulated by vitamin D [19]. Finally, there are 
two subgroups which lie in the direction of the untreated arrow and one final 
class which could possibly be correlated with DEX.
To give additional statistical evidence of the improvements of preclustering,
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Figure 5.5: Visual representation of PCA results for the MSC dataset, without (A ) and with preclus­
tering (B ). The dots (scores) represent GO categories or subgroups, and the arrows (loadings) are the 
treatments with which the categories can be correlated (indicated with D EX, BM P, V IT  and UNT). 
Only a subset of GO classes is depicted, to focus on cell differentiation and osteogenesis. In Fig­
ure 5.5A the 24 original GO classes are shown and in Figure 5.5B the 79 subclasses. The stars 
identify the GO term GO:0001501 (skeletal development).
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the identification of the 24 terms mentioned previously was generalized. The 
generalized procedure was used for both unclustered and preclustered X 
matrices of the MSC dataset (containing 922 and 1653 profiles, 
respectively). From the first 2 PCs of the X matrix, interesting profiles were 
selected from the outside of the scores in steps of decreasing 
”interestingness”. The larger the distance from the center, the more 
interesting a profile can be. The selection was based on the Mahalanobis 
distance of a group or subgroup to the center of the data. To assess the 
relevance of a selection, the set of 24 GO terms in Table 5.2 is used as a 
reference. At each step the selectivity and specificity of the selection can be 
determined from the number of reference GO terms, which are either present 
or not present in the selection.
Now a comparison between unclustered and preclustered data can be made 
by drawing ROC curves -  see Figure 5.6. The preclustered method is clearly 
more sensitive and specific, compared to the data where no preclustering has 
been performed. This means that newly formed preclustered profiles are 
more to the outside of the data in the first 2 PCs, and are more readily 
marked to be interesting.
5.4.3 Discussion
We have shown a simple and general method to relate expression levels, 
either directly, or after an ANOVA, to GO categories at all levels in the 
hierarchy simultaneously. The crucial step is the realization that genes, 
although they are in the same GO category, may show different profiles. As 
a result, the application of preclustering leads to more differentiated 
information. The method is generic; we have opted to use model-based 
clustering, but in principle any other clustering method can be used, 
provided that it is possible to automatically generate a reasonable estimate of 
the number of clusters. The method may be adjusted in a number of ways. 
The lower limit on the number of genes for a GO category to be considered 
in the analysis is rather arbitrary. For other problems and datasets this can be 
adjusted depending on the questions for the specific dataset. The same is 
true for the cutoff for selecting GO categories. It is possible to inadvertently 
remove categories which are of interest to your dataset, but are very small. 
Other techniques have been proposed for relating measurements to
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1-specificity
Figure 5.6: ROC plot to exemplify the improved identification of interesting terms by performing 
preclustering. The sensitivity and specificity of identification of 24 relevant GO terms was calculated 
to draw the lines. The curve generated from the pleclustered data (grey line) is more sensitive and 
specific than the original data without preclustering (black line).
annotation information. An example of relating class information and 
experimental factors is shown by Jeffery et al. [16], who use transcription 
factor binding sites information. These are sites in the promoters of genes to 
which a transcription factor can bind. The transcription factors play an 
important role in the regulatory networks of gene expression. A method 
called Correspondence Analysis (CA; [13]) was applied to relate classes and 
experimental information. CA is similar to PCA; the algorithm can reduce 
the multidimensional data matrix to a lower dimension containing the 
important information from the data. In the standard way of applying CA, 
the dependency of values in the rows on the columns of a contingency table 
for two sets of conditions is investigated. After scaling of both the rows and 
columns, PCA is applied to the scaled data.
For the analysis of gene expression data, the first articles which applied CA 
treated the matrix with expression values as a contingency table. The aim
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was then to associate genes with variables. Kishino et al. [18] applied CA to 
show the relationship between genes and tissues of a dataset which was 
designed to investigate colon cancer [2]. Fellenberg et al. [9] also showed 
the possibility to investigate the associations between genes and variables. 
The application of CA to incorporate GO information as class information in 
the visualization of results was shown by Busold et al. [5]. Datasets 
investigating glucose metabolism and from human pancreatic 
adenocarcinomas were used.
For our data, CA and PCA would lead to very similar results, because of the 
fact that the column means and row means, used for scaling in CA, are very 
similar, something that is also true for the data used in, e.g., [9]. In 
Figure 5.6, the CA curves would completely overlap with the PCA curves 
and therefore have been left out. Since PCA is more easy to interpret, we 
prefer it for this case. Preclustering of GO information as presented here 
could also reveal interesting findings otherwise discarded in methods using 
class information like CA.
GO information (and other annotation information) is to some extent 
limited, because not all genes are annotated. This will have a limiting effect 
on the size of clusters for less well known GO categories; if a certain GO 
category in the database is not described correctly, or extensively enough, it 
will obviously be hard to link this GO category with the experimental factors 
of interest. However, the number of annotations will increase rapidly so that 
the method will only gain in importance.
With the division of GO classes in clusters with similar profiles, it is possible 
that one of the new classes gets a high IC C , but remains in the center of the 
biplot. Such a subgroup will contain relatively flat profiles; nevertheless, it is 
beneficial that it is clustered separately, to prevent other interesting 
subgroups to be obscured. One final result of the preclustering is that a 
category can be found more than once in the same PCA biplot. This can 
make it more difficult to draw conclusions for a single GO category as a 
whole. On the other hand, the results will be more indicative of what is 
really happening within a GO class.
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5.5 Conclusions
The advantages of clustering heterogeneous GO classes have been shown 
here for two real gene expression datasets, the well-known YCC dataset and 
the MSC dataset. The results show that preclustering yields an increased 
number of interesting groups deviating from the center of the PCA biplot. In 
this center the less interesting groups with flat profiles are present. In future, 
more formal selection criteria could be used to identify interesting GO 
classes and newly formed subclasses, based on statistical significance.
These properties of preclustering allow for a better association of GO 
categories with phases or treatments, because interesting subgroups which 
are obscured by different profiles are separated from each other. New 
meaningful relations are discovered which would not have been found 
otherwise with PCA. For the GO processes “cell wall organization and 
biogenesis” (GO:0007047) and “skeletal development” (GO:0001501) this is 
explicitly shown.
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6.1. ABSTRACT
6.1 Abstract
Bone marrow-derived human mesenchymal stem cells (hMSCs) have the in 
vitro capacity to differentiate into osteoblasts, chondrocytes or adipocytes, 
depending on the applied stimulus. In order to identify novel regulators of 
osteogenesis in hMSCs, osteo-transcriptomics was performed whereby 
differentiation induced by dexamethasone (DEX), DEX+bone 
morphogenetic protein 2 (BMP2), and DEX+ Vitamin D3 (1,25(0H)2D3) 
was studied over a course of 12 days. Microarray analysis revealed that 2095 
genes were significantly regulated by DEX+1,25(0H)2D3, of which 961 
showed accelerated expression kinetics compared to treatment by DEX 
alone. The majority of these genes were accelerated 24-48 hrs after onset of 
osteogenic treatment. Gene ontology (G0 ) analysis of these 
1,25(0H)2D3-accelerated genes indicated their involvement in biological 
processes related to cellular differentiation and cell cycle regulation. When 
compared to cells treated with DEX or DEX+BMP2, treatment with 
DEX+1,25(0H)2D3 clearly accelerated osteoprogenitor commitment and 
osteoblast maturation, as measured by alkaline phosphatase (ALP) activity 
and calcification of the matrix. Cell cycle progression, as observed after 
initial growth arrest, was not significantly accelerated by 1,25(0H)2D3 and 
was not required for onset and progression of osteogenesis. However, 
expression of c-Myc was accelerated by 1,25(0H)2D3, and binding sites for 
c-MYC were enriched in promoters of genes accelerated by 1,25(0H)2D3. 
Lentiviral overexpression of c-MYC strongly promoted 
DEX+BMP2-induced osteoblast differentiation and matrix maturation. In 
conclusion, our studies show for the first time that 1,25(0H)2D3 strongly 
accelerates expression of genes involved in differentiation of hMSCs and, 
moreover, identify c-MYC as a novel regulator of osteogenesis.
6.2 Introduction
Postnatal mesenchymal stem cells (MSCs) residing in the bone marrow are 
critically important for repair and regeneration of skeletal tissue throughout 
adult life. These MSCs are multi-potent and may undergo self-renewal 
whereby they divide, remain immature and sustain the stem cell pool. 
Alternatively, depending on the biological signals they receive, they can be 
triggered to undergo commitment to one of a selective number of
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differentiation lineages, including bone, cartilage, and fat [25]. Although the 
mechanisms that control MSC fate decisions are still incompletely 
understood, a number of growth factors and hormones have been identified 
that control lineage-specific differentiation of MSCs in an orchestrated and 
temporal manner [3]. In the case of human bone marrow-derived 
mesenchymal stem cells (hMSCs), glucocorticoids are essential for in vitro 
osteogenesis. Thus, physiological concentrations of the synthetic 
glucocorticoid dexamethasone (DEX) inhibit proliferation of hMSCs, induce 
osteoblast commitment, maturation, and phenotypic marker gene expression, 
as well as extracellular matrix mineralization [9]. Glucocorticoids signal via 
the glucocorticoid receptor, a member of the steroid hormone receptor 
subclass of nuclear receptors, which regulates gene expression as a dimer by 
binding to glucocorticoid responsive elements in promoters of target genes, 
for example bone sialoprotein (BSP) [23]. Bone morphogenetic proteins 
(BMPs) were originally characterized by their potent ability to induce 
ectopic bone formation following injection at extraskeletal sites. BMPs 
induce osteoblast differentiation and matrix maturation in vitro in a wide 
variety of rodent and human cell systems, including primary calvarial cells 
and various osteoblastic cell lines (reviewed in [39]). In addition, BMPs 
induce osteogenesis of various mesenchymal progenitor and stem cells, 
including mouse and rat MSCs [1,6], although it has been suggested that 
BMPs need glucocorticoids to efficiently initiate osteogenic commitment of 
rat mesenchymal stem cells [26]. Likewise, BMPs poorly induce osteoblast 
differentiation of human MSCs but they strongly enhance DEX-induced 
osteogenesis of these stem cells as based on analysis of known phenotypic 
osteoblast markers, including induction of alkaline phosphatase (ALP) 
activity and mineralization of the matrix [13,18]. BMPs signal via 
heteromeric complexes of type I and type II serine-threonine kinase 
receptors, which propagate downstream signalling mainly via the canonical 
Smad1/5/8 pathway. Upon receptor-mediated phosphorylation of these 
BMP-Smads, they associate with Smad4, translocate to the nucleus, and 
cooperate with tissue-specific transcription factors, such as RUNX2, to drive 
osteogenic target gene expression. In addition, BMPs can activate the 
mitogen-activated protein kinases (MAPK) c- JUN N-terminal kinase (JNK), 
Extracellular Regulated Kinase (ERK)1/2, and p38 to control
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osteogenesis [12,39]. The active vitamin D metabolite 1a,  
25-dihydroxyvitamin D3 (1,25(OH)2D3) plays an important role in skeletal 
homeostasis. 1,25(OH)2D3 controls bone metabolism indirectly through its 
effects on calcium and phosphate (re)absorption in kidney and intestine. 
Furthermore, 1,25(OH)2D3 acts directly on osteoblasts and osteoclasts in 
bone tissue, whereby anabolic as well as catabolic effects have been reported 
on osteoblast differentiation and bone formation (reviewed in [35]). Studies 
in rats have shown that treatment with 1,25(OH)2D3 results in increased 
numbers of osteoblast (precursors), suggesting that 1,25(OH)2D3 may 
promote early stages of osteoblastogenesis in vivo [15]. This is supported by 
in vitro studies using hMSCs, whereby 1,25(OH)2D3 is able to induce 
expression of both early as well as late stage markers of osteoblast 
differentiation, including ALP, osteopontin, bone sialoprotein, and 
osteocalcin [5,18]. Furthermore, 1,25(OH)2D3 enhances DEX-induced 
osteogenic differentiation of human pre-osteoblasts and mesenchymal stem 
cells, resulting in elevated activity of ALP and increased mineralization of 
the matrix [5,18,35]. 1,25(OH)2D3 signals via de nuclear hormone vitamin 
D receptor (VDR) which, in cooperation with the retinoid X receptor (RXR), 
binds to vitamin D responsive elements (VDRE) in promoters of 
1,25(OH)2D3 target genes, and thereby induces expression of osteoblast 
markers such as osteocalcin. In order to compare the mechanisms by which 
BMP2 and 1,25(OH)2D3 promote DEX induced osteogenic differentiation, 
and to identify novel key regulators involved in osteogenesis of hMSCs, we 
performed a genome-wide osteo-transcriptomics time-series analysis. We 
previously described a bioinformatics analysis of this microarray data set 
which suggested that BMP2 enhanced average gene expression intensities, 
while 1,25(OH)2D3 accelerated average expression kinetics [11]. In the 
present study we performed a systematic approach to identify all genes for 
which individual gene expression kinetics were accelerated by 1,25(OH)2D3, 
with the aim to understand the functional implications of these accelerated 
genes for the process of osteogenesis, and to get insight into the 
transcriptional mechanisms by which 1,25(OH)2D3 accelerates gene 
expression. Our study shows that over 45% of all genes regulated by 
DEX+1,25(OH)2D3 show accelerated expression kinetics. Many of these 
genes are involved in differentiation and cell cycle regulation, including
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c-MYC which we identified in this study as a potential transcriptional 
regulator of accelerated genes. We reveal that 1,25(OH)2D3 functionally 
accelerates osteoblast commitment and differentiation, and that 
overexpression of c-MYC strongly promotes DEX+BMP2-induced 
osteogenesis. This shows, for the first time, an important role for the 
proto-oncogene c-MYC in osteogenesis of hMSCs.
6.3 Materials and methods
Culture and treatment of human mesenchymal stem cells Human 
mesenchymal stem cells (hMSCs), harvested from normal human bone 
marrow, were purchased from Lonza (Walkersville, MD) at passage 2. Cells 
were tested by the manufacturer and were found to be positive by flow 
cytometry for expression of CD105, CD166, CD29, and CD44, and negative 
for CD14, CD34 and CD45. We confirmed multipotency of all donor batches 
based on in vitro osteo-, chondro- and adipogenic differentiation capacities. 
The cells were expanded for no more than 5 passages in “mesenchymal stem 
cell growth medium” (MSCGM; Lonza, Walkersville, MD) at 37 °C in a 
humidified atmosphere containing 7.5% CO2. Microarray studies, and 
bioassays performed in parallel to monitor differentiation efficiency, were 
performed with hMSCs from donor 1F1061. Subsequent studies were 
performed with hMSCs from 5 different donors, including 4F1127, 5F0138, 
6F3400, 6F4085, 7F3458. For osteogenic differentiation, 2.0 x 104 cells per 
cm2 were seeded in MSCGM. The next day, cultures were sub-confluent and 
cells were switched to osteogenic differentiation medium (DM) composed of 
high-glucose containing Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (Lonza Walkersville, Inc.), 100 
U/ml penicillin, 100 g/ml streptomycin, 10-7 M dexamethasone (DEX), 0.2 
mM ascorbate and 10 mM -glycerophosphate, in the absence or presence 
of 250 ng/ml bone morphogenetic protein 2 (BMP2; R&D Systems) or 10-8 
M 1 , 25-dihydroxyvitamin D3 1,25(OH)2D3; Calbiochem). These 
osteogenic treatments will be further referred to as DEX, DEX+BMP2, and 
DEX+1,25(OH)2D3, respectively. Cells treated with DM in the absence of 
dexamethasone (further referred to as DEX) were used as negative controls 
and are also referred to as “untreated”. Medium was refreshed every 3 days. 
Aphidicolin (Sigma-Aldrich), a DNA polymerase inhibitor which blocks
111
6.3. MATERIALS AND METHODS
cells at the Sphase in the cell cycle, was dissolved in dimethyl sulfoxide 
(DMSO) and diluted to indicated concentrations in the various media. 
hMSCs were seeded as described above and the next day (t=0 hrs), as well as 
at t=24 hrs, cells were treated with the various media in the presence of 
DMSO or aphidicolin, which remained on the cells until day 5 when assays 
were performed.
RNA isolation RNA was extracted using TRIzol according to the protocol 
provided by the manufacturer (Invitrogen). RNA was precipitated with 0.8 
M sodium acetate/1.2 M NaCl and isopropanol, and after air-drying 
dissolved in 10 ^l DEPC-treated H2O. RNA concentrations were determined 
by measuring absorbance at 260 nm. The quality of the RNA samples was 
evaluated by capillary electrophoresis on an Agilent 2100 Bioanalyzer 
(Agilent Technologies).
Microarray processing and identification of significantly regulated genes In 
total, 132 RNA samples were obtained from triplicate experiments of 44 
biological conditions (4 treatments including DEX , DEX, DEX+BMP2, 
DEX+1,25(OH)2D3), each measured at 11 time points (0, 1, 3, 6, 12, 24, 48, 
72, 120, 192 and 288 hrs after onset of treatment). For each sample, 5 ^g of 
RNA were reverse transcribed into double-stranded cDNA, and used as a 
template for the preparation of biotin-labeled cRNA, as previously 
described [33]. A total of 10 ^g of biotin-labeled cRNA was hybridized to 
the Human Genome U133A Array (Affymetrix), after which hybridization 
signals were amplified using a streptavidin-biotin amplification procedure. 
(Due to failure of biotinylated cRNA synthesis, four samples were not 
hybridized, including 2 samples for time point 0 hrs, 1 sample for time point 
3 hrs for the DEX+1,25(OH)2D3 treatment, and 1 sample for the DEX 
treatment at 120 hrs). A total of 128 arrays were hybridized and scanned 
with a GeneChip G3000 scanner (Affymetrix). Data were quantified using 
GCOS 1.2 software (Affymetrix). Normalization and statistical analysis of 
the data were performed using the error model developed for Affymetrix 
GeneChips [38], carried out using Rosetta Resolver Version 4.0. One array, 
hybridized with a t=0 hrs sample, failed and was excluded for further 
analysis. Therefore, data obtained from 127 arrays, among which 9 arrays 
representing t=0 hrs, were used for further analysis. A gene pre-selection 
step excluded genes that did not have a significant expression level above
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background (p-value <10-3) in at least 2 out of 127 arrays, or that did not 
have a significant modulation of expression over time (p-value <10-3 
calculated by ANOVA using time as factor). To identify genes differentially 
and significantly regulated during osteogenesis, expression ratios (and 
corresponding p-values) were calculated for each time point (except time 
zero) and for each osteogenic treatment relative to untreated time-matched 
controls using Rosetta Resolver Version 4.0. To correct for multiple 
hypothesis testing, the qvalue [31] was calculated for each p-value, 
indicating the significance of the corresponding ratio. Genes were selected 
as significantly expressed compared to untreated controls if the qvalue 
<10-4. This resulted in a selection of genes significantly regulated during 
osteogenesis for each of the (3x10 =) 30 biological conditions tested, i.e. for 
each combination of osteogenic treatment (DEX, DEX+BMP2, 
DEX+1,25(OH)2D3) and 10 different time points (except time zero), based 
on triplicate experiments (with the exception of the 3 hr time point 
DEX+1,25(OH)2D3 treatment and the 120 hr time point DEX treatment, 
which were in duplicate). Furthermore, if a gene belonged to one of the 10 
selections (time points) corresponding to a certain osteogenic treatment, it 
was said to belong to the total selection of genes significantly regulated 
during osteogenesis induced by that osteogenic treatment. In this way it was 
observed that 1748 genes were significantly regulated by DEX, 1930 genes 
were significantly regulated by DEX+BMP2, and 2095 genes were 
significantly regulated by DEX+1,25(OH)2D3.
Microarray data analysis To identify genes with expression kinetics that 
were significantly accelerated by at least 1 time point following treatment of 
the cells with 1,25(OH)2D3, we developed an algorithm to objectively detect 
accelerated and decelerated genes among the 2095 genes that were found to 
be significantly regulated by DEX+1,25(OH)2D3. The exact details of the 
algorithm (e.g. thresholds and exceptional cases) can be found in the 
Supplemental Materials. In short, a gene is said to be accelerated (“early”) 
by 1,25(OH)2D3 when it reaches its extremum (minimum or maximum 
expression level) at an earlier time point in DEX+1,25(OH)2D3-treated cells 
than in DEX-treated cells. Similarly, a gene is said to be decelerated (“late”) 
by 1,25(OH)2D3 when it reaches its extremum at a later time point in 
DEX+1,25(OH)2D3-treated cells than in DEX-treated cells. For genes for
113
6.3. MATERIALS AND METHODS
which the time point at which the extremum is reached is identical in the 
DEX- and DEX+1,25(OH)2D3-treated cells, the change in expression 
directly preceding or following the extremum is considered (“fast” or 
“slow”) (see Supplemental Materials). For all genes identified as being 
accelerated or decelerated expression profiles were visually inspected and 
false-positives were excluded from further analysis.
The web-based platform Gene Ontology Tree Machine (GOTM) [40] was 
used to identify enriched GO terms (biological process category) [2] and 
KEGG (Kyoto Encyclopaedia of Genes and Genomes)-annotated pathways 
in (sub)sets of significantly regulated and/or accelerated genes. The 
enrichments were expressed as corrected p-values (hypergeometric 
distribution, Benjamin-Hochberg) to indicate significance of deviation from 
random distribution.
For hierarchical clustering of selected subsets of genes, the complete linkage 
(maximum) clustering method and cosine correlation similarity measure 
were performed using Spotfire DecisionSite for Functional Genomics 
version 9.0 (http://www.spotfire.com). For each time point in combination 
with osteogenic treatment, expression intensities were expressed as base-10 
logarithm of the ratios compared to time-matched untreated samples and 
visualized in a heatmap.
Promoter analysis Promoter analysis was performed to identify transcription 
factors that potentially regulate subsets of genes with accelerated expression 
profiles in the presence of 1,25(OH)2D3. Using the software platform “R”, 
we developed a promoter analysis function that computes the enrichment of 
the occurrence of specific transcription factor binding sites (TFBS) in the 
promoter sequences of any selected set of genes. For further details, see 
Supplementary Materials.
Alkaline phosphatase assays To quantify alkaline phosphatase (ALP) 
enzymatic activity hMSCs were seeded in 96- well tissue culture plates and 
cultured for different time intervals under osteogenic differentiation 
conditions as described above. ALP activity was measured enzymatically as 
described by Van der Plas et al. [34] and corrected for differences in cell 
number based on neutral red staining [20]. For histochemical analysis of 
ALP activity, cells were fixed with 3.7% formaldehyde. After washing with 
phosphate-buffered saline (PBS), cells were incubated for 1 hour at 37 °C in
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a mixture of 0.1 mg/ml naphtol AS-MX phosphate (Sigma- Aldrich), 0.5% 
N,N-dimethylformamide, 2 mM MgCl2, and 0.6 mg/ml Fast Blue BB salt 
(Sigma-Aldrich) in 0.1 M Tris-HCl, pH 8.5.
Flow cytometry hMSCs were seeded in 24-well tissue culture plates and 
cultured for the indicated time periods under osteogenic conditions, as 
described above. For quantitative measurement of ALP expression, 
trypsinized cells were resuspended in phosphate-buffered saline (PBS) 
supplemented with 1% newborn calf serum (NCS; Hyclone) and incubated 
for 30 min with 2 g/ml anti-ALP monoclonal antibody (MAB1448, R&D 
systems). After washing the cells in PBS/1% NCS, they were incubated with
5 g/ml goat-anti-mouse immunoglobulins/RPE goat F(ab’)2 (R0480, 
DakoCytomation) for 15 min in PBS/1% NCS. After washing, cells were 
resuspended in ice-cold PBS/1% NCS after which ALP expression, as 
detected by RPE fluorescence, was measured on a FACSCaliburTM  (Becton 
Dickinson) flow cytometer. Mineralization assays To measure calcium 
deposition in the extracellular matrix, hMSCs were seeded in 24- well tissue 
culture plates and cultured for different time intervals under osteogenic 
differentiation conditions as described above. Cells were subsequently 
washed twice with PBS after which calcium was extracted from the 
extracellular matrix by treatment with 150 ^l of 0.5 M HCl. Calcium 
concentrations were measured in a colorimetric assay using ocresolphtalein 
complexone as chromogenic agent according to the protocol provided by the 
manufacturer (Sigma-Aldrich). For von Kossa staining, hMSCs were 
cultured under osteogenic differentiation conditions as described above. 
After 4 weeks, cells were washed twice with PBS and fixed for 10 min with 
3.7% formaldehyde in PBS. Subsequently, cells were washed three times 
with water and incubated in 2% silvernitrate solution for 10 min on a light 
source. After incubation silvernitrate was replaced by PBS.
Thymidine incorporation assay To measure S-phase progression during the 
course of osteogenesis, hMSCs were seeded in several 24-well plates which 
were cultured in parallel for different time periods. During the last 24 hrs of 
a particular time period, 1 ^Ci of [3H]-thymidine (MP Biomedicals), 
suspended in 50 ^l of Ham’s F12 medium, was added to 400 ^l of 
osteogenic differentiation medium in each well of one 24-well plate. 
Cumulative 24 hrs incorporation of [3H]-thymidine from day 1 to day 2 after
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onset of osteogenesis is indicated by ‘1-2’ days, etc. Cells were fixed for 15 
min in methanol, air-dried, and solubilized for 30 min at 37 °C in 1 ml of 0.2 
M NaOH. Incorporation of [3H]-thymidine into cellular DNA was measured 
in a liquid scintillation fi-counter.
Lentiviral constructs The lentiviral cloning vector 
pRRLSIN.cPPT.PGK-GFP.WPRE (Addgene) was digested with AgeI and 
SalI to replace the GFP cDNA sequence by a multiple cloning site 
(AgeI-BamHI-AsuII-NdeI-XbaI-SalI) following insertion of the annealed 
oligonucleotide-pair MCS-FW:
5’-ccggtggatccttcgaagcgtaccatatggcctactctagag-3’, MCS-RV: 5’- 
tcgactctagagtaggccatatggtacgcttcgaaggatcca-3’. This vector was designated 
pRRLSIN. cPPT.PGK-MCS.WPRE). A control lentivirus 
(pRRLSIN.cPPT.PGK-HA.WPRE) containing the hemagglutinin (HA) 
epitope sequence was generated by insertion of the annealed 
oligonucleotide-pair HA-FW:
5’-ctagatacccatacgatgttccagattacgcttgactcgagg-3’ and HA-RV: 
5’-tcgacctcgagtcaagcgtaatct ggaacatcgtatgggtat-3’ into the XbaI-SalI sites of 
pRRLSIN.cPPT.PGK-MCS.WPRE. Full length human c-MYC cDNA was 
purified following BamHI and SalI digestion of pBABE-puro-cMYC, 
provided by Dr. M. van Lohuizen (Netherlands Cancer Institute, Amsterdam, 
the Netherlands), and cloned in pRRLSIN.cPPT.PGK-MCS.WPRE to 
generate pRRLSIN.cPPT.PGK-cMYC.WPRE.
Lentiviral infections Lentiviruses were produced in 293T cells (ATCC) by 
calcium phosphate cotransfection of the above described lentiviral constructs 
with third generation lentiviral packaging vectors pRSV-Rev, pMDLg/pRRE 
and the envelope plasmid pMD2.G (Addgene) according to the protocol 
described by the Tronolab (http://tronolab.epfl.ch). Virus concentrations 
were determined using the Murex HIV Antigen mAB kit according to the 
protocol provided by the manufacturer (Abbott Murex, Dartford, UK). For 
infection, hMSCs were seeded at a density of 1.5 x 104 cells per cm2. The 
next day, cells were infected overnight with 40 ng of virus per 3.0 x 104 
seeded cells in culture medium containing 8 g/ml of polybrene. After 16 hrs 
cells were washed with PBS and treated with osteogenic stimuli as indicated.
Apoptosis assay hMSCs were seeded in 96-wells plates, infected with 
HA-control or c-MYC lentivirus, and treated with osteogenic stimuli as
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described above. After 5 days of treatment, apoptosis was measured using 
the Caspase-GLO 3/7TM  assay according to the protocol provided by the 
manufacturer (Promega).
Statistical analysis Statistical analysis of microarray gene expression profiles 
(Figures 6.2B and 6.3A) was performed using student’s t-test. For all other 
data, statistical analysis was performed using Welch’s t-test.
6.4 Results
The effect ofBMP2 and 1,25(OH)2D3 on DEX-induced osteogenesis of 
hMSCs hMSCs can be induced to differentiate into osteoblasts by treatment 
with 10-7 M DEX. However, under these conditions not more than 50% of 
the hMSC population differentiated to osteoblasts as revealed by 
histochemical staining of alkaline phosphatase (ALP)-positive cells, as well 
as by flow cytometric analysis of cells stained for ALP surface expression 
after 9 days of treatment (Figure 6.1A). The nature of the ALP-negative cells 
remains unclear, but no adipocytes were detected in the osteogenic cultures 
(data not shown), in agreement with previous data from Cheng et al. [9]. 
Histochemical staining and flow cytometric analysis of ALP-positive cells 
indicated that co-addition of BMP2 or 1,25(OH)2D3 strongly potentiated 
osteoblast differentiation induced by DEX, resulting in cultures that 
contained more than 70% ALP-positive cells after 9 days of treatment 
(Figure 6.1A). In addition, these flow cytometry studies showed that BMP2, 
and to a lesser extent also 1,25(OH)2D3, enhanced average ALP surface 
expression levels compared to DEX-treated cultures; in the presence of 
BMP2 the average intensity of ALP staining per cell was three-fold 
increased (Figure 6.1A).
Mineralization of the extracellular matrix was also strongly enhanced by 
BMP2 or 1,25(OH)2D3 (Figures 6.1B and 6.1C). Compared to DEX-treated 
cultures, the amount of calcium deposited in the extracellular matrix was 2 
fold-increased in the presence of DEX+1,25(OH)2D3, and three-fold 
increased in the presence of DEX+BMP2. In conclusion, BMP2 and 
1,25(OH)2D3 strongly potentiate DEX-induced osteogenesis of hMSCs. 
Osteogenic microarray study To get insight into the mechanisms by which 
BMP2 and 1,25(OH)2D3 promote DEXinduced osteogenesis of hMSCs, in 
particular onset and progression of osteoprogenitor commitment and
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Figure 6.1: (A ) BMP2 and 1,25(OH)2D3 potentiate DEX-induced A LP activity of differentiating 
hMSC cultures. hMSCs were treated for 9 days in the absence (D EX  ) or presence of 10-7M D EX, 
250 ng/ml BMP2 or 10-8M 1,25(OH)2D3. Efficiency of osteogenesis was assessed by histochemical 
staining of the cells for A LP activity. The percentage of A LP positive cells and the average A LP 
expression per cell, indicated by X-mean, was quantified by flow cytometry using a primary mouse 
monoclonal anti-ALP antibody and a secondary goat-anti-mouse immunoglobulin R-phycoerythrin 
(RPE)-conjugated F(ab’)2. X-mean values indicate average RPE fluorescence intensities per cell and 
represent average A LP expression levels per cell.
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Figure 6.1: (B , C) BM P2 and 1,25(OH)2D3 potentiate DEX-induced matrix mineralization as mea­
sured by (B ) the amount of calcium deposited in the extracellular matrix after 2, 3 or 4 weeks of 
culture or (C ) von Kossa staining after 4 weeks of osteogenesis. White bars, D EX  ; Light grey bars, 
D EX; Dark grey bars, DEX+BMP2; Black bars, DEX+1,25(OH)2D3. Data shown are representative 
of at least three independent experiments. Average expression values ± SD from biological duplicates 
performed in one experiment are shown in (B ).
osteoblast maturation, triplicate genome wide expression studies were 
performed as a function of time (t=0, 1, 3, 6, 12, 24, 48, 72, 120, 192 and 
288 hrs) and treatment (“DEX” (negative control), DEX, DEX+BMP2, or 
DEX+1,25(OH)2D3). For each time point and treatment, significantly 
differentially expressed genes (denoted here as regulated genes) were 
selected based on the criteria as described under Materials and Methods. We 
observed that a total of 2762 genes on the array were regulated during 
osteogenesis compared to the negative control DEX , of which 1748 genes 
were regulated by DEX, 1930 genes were regulated by DEX+BMP2, and
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2095 genes were regulated by DEX+1,25(OH)2D3. A total of 1224 genes 
was commonly regulated by all three treatments, as listed in Table 6.1.
Table 6.1: Overview of the number of significantly differentially expressed genes per time point and 
per osteogenic treatment as revealed from osteo-transcriptomics gene expression analysis. In addition, 
the total number of genes regulated per treatment (TOTAL), and the number of genes regulated by all 
three treatments (0 ) are indicated.
T IM E  PO INT (HRS)
1 3 6 12 24 4S 72 120 192 28 S T O T A L 0
D E X 14 157 285 431 749 1193 1297 835 1001 1185 1748
DEX+ BM P2 15 146 277 429 804 1314 1607 962 930 145S 1930 1224
DEX+1,25(OH)iD 3 8 142 362 723 1252 1243 1080 712 832 756 2095
Table 6.1 shows that for DEX and DEX+BMP2, maximum numbers of 
regulated genes (1297 and 1607 genes, respectively) were reached at 72 hrs, 
followed by a strong decline at 120 hrs. However, for DEX+1,25(OH)2D3 
maximum numbers of significantly regulated genes were already reached 
after 24-48 hrs of treatment, and the decline commenced at 72 hrs and lasted 
during the remaining of the differentiation period (Table 6.1). These results 
indicate that general transcriptional activity is accelerated in the presence of 
1,25(OH)2D3. These findings support our previous bioinformatics 
analyses [11] in which 1,25(OH)2D3 was shown to accelerate average gene 
expression of 384 genes identified as being most differentially expressed 
among the DEX , DEX, DEX+BMP2 and DEX+1,25(OH)2D3 treatments. 
Osteogenic differentiation ofhMSCs as revealed from microarray data 
analysis To investigate if the gene selections shown in Table 6.1 represent 
the process of osteogenesis over time, we analyzed our sets of genes by 
functional gene annotations according to Gene Ontology (GO) for the 
biological process “skeletal development”. GO enrichment was calculated 
based on the gene selections made for each of the 30 biological conditions (3 
osteogenic treatments and 10 time points per treatment) presented in 
Table 6.1, and the p-values were plotted per treatment over time 
(Figure 6.2A). As can be seen, for all osteogenic treatments the lowest 
p-value of enrichment for “skeletal development” was reached at 120 hrs. 
The genes that contribute to enrichment of “skeletal development” in the 
DEX+BMP2 gene selection at 120 hrs are listed in the legend of 
Figure 6.2A. In figure 6.2B, expression profiles of a selected set of genes 
generally known to be involved in skeletal development are presented.
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mRNA expression of ALP commenced at 48 hrs in the presence of 
DEX+1,25(OH)2D3 and continued to increase during the remaining of the 
differentiation period examined. Compared to DEX-treated cultures, 
induction of ALP expression was accelerated and enhanced by 
1,25(OH)2D3. From 120 hrs onwards, BMP2 was more potent than 
1,25(OH)2D3 to enhance DEX-induced ALP expression. mRNA of bone 
sialoprotein (IBSP) and osteopontin (SPP1) was first significantly induced at 
120 hrs in the presence of 1,25(OH)2D3. Expression of osteocalcin 
(BGLAP) was suppressed by DEX and by DEX+BMP2, and was strongly 
induced after 24 hrs in the presence of 1,25(OH)2D3. Collagen 1A1 
(COL1A1) was highly expressed in hMSCs and its expression did not 
increase during osteogenesis of hMSCs. Similarly, mRNA levels of RUNX2, 
a key transcriptional regulator of osteogenesis, did not change during 
differentiation of hMSCs. Expression kinetics of several of these 
osteo-differentiation markers, including ALP, BGLAP, COL1A1 and 
RUNX2, is differently regulated in hMSCs compare to primary rat calvarial 
osteoblasts and the mouse MC3T3-E1 cell line, in agreement with published 
studies on expression of bone markers during osteoblast differentiation of 
hMSCs [9,18,27]. Expression of CEBPB and FOS, known transcriptional 
regulators of osteogenesis, was rapidly induced upon osteogenic treatment. 
Interestingly, and similar to what was observed for ALP, 1,25(OH)2D3 
accelerated and BMP2 enhanced expression of CEBPB and FOS, in 
agreement with our previous bioinformatics study which indicated that 
1,25(OH)2D3 accelerated average expression kinetics, while BMP2 
enhanced average gene expression intensities [11].
In order to get insight into pathways involved in osteogenesis of hMSCs, we 
analyzed the 1748 genes selected for DEX, 1930 genes selected for 
DEX+BMP2 and 2095 genes selected for DEX+1,25(OH)2D3 (Table 6.1) by 
functional gene annotations according to KEGG (Supplemental Table S1). 
The most significantly over-represented KEGG pathway in all three gene 
selections was “focal adhesion”. Other KEGG pathways enriched in all three 
gene selections included “adherens junction”, “ECM-receptor interaction”, 
“TGF-beta signaling pathway”, and “Wnt signaling pathway”, all known to 
play important roles in regulation of osteogenesis. BMP2 particularly 
enhanced enrichment of the KEGG pathways “gap junction” and “cell
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Figure 6.2: Osteogenic differentiation of hMSCs as revealed from microarray analysis. (A ) Pro­
filing of enrichment values of the Gene Ontology term (category biological process) Skeletal De­
velopment over time for each osteogenic treatment based on gene selections derived from tripli­
cate microarray experiments. The genes that contribute to enrichment of Skeletal Development in 
the DEX+BMP2 gene selection at 120 hrs include IGFBP4, RPS6KA3, FRZB, COL11A1, PRELP, 
FBN1, IGF2, KLF10, EXT1, FGFR3, TNFRSF11B, GHR, COMP, TUFT1, MSX1, COLlOAl, MATN3, 
BMP6, BGLAP, IBSP, INHBA, POSTN, SPARC, DLX5, TWIST1, ALP, TBX3, and NPR3. o, D EX ; •, 
D EX; □, DEX+BMP2; ■, DEX+1,25(OH)2D3.
communication”, while 1,25(OH)2D3 had an impact mainly on regulation of 
genes involved in the “cell cycle” pathway. Altogether, analysis of our 
microarray dataset with respect to enrichment of biological processes, 
pathways and osteogenic marker gene expression indicates that our 
microarray dataset represents the process of osteogenesis, and that BMP2 
and 1,25(OH)2D3 differently potentiate osteoblast differentiation of hMSCs. 
Identification of genes with accelerated expression kinetics in the presence of 
1,25(OH)2D3 Based on the observation that 1,25(OH)2D3 accelerates 
(average) gene expression kinetics during osteogenesis of hMSCs (Table 6.1, 
Figure 6.2B; ALP, CEBPB and FOS) [11], we made a full survey of 
1,25(OH)2D3-accelerated genes. As outlined in detail in the Materials and 
Methods, algorithms were developed to identify genes for which (local) 
minimum (MIN) or maximum (MAX) expression was accelerated (defined 
as “early”) or decelerated (“late”) by 1,25(OH)2D3 by at least one time 
point. In addition, algorithms were defined to identify genes for which 
(local) minima or maxima were identical in the DEX and 
DEX+1,25(OH)2D3 gene profiles, but the expression profile preceding or 
following MIN or MAX was accelerated (“fast”) or decelerated (“slow”) by 
1,25(OH)2D3. The set of genes used for this analysis involved the 2095
SKELETAL DEVELOPMENT
TIME (HRS)
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Figure 6.2: Osteogenic differentiation of hMSCs as revealed from microarray analysis. (B ) Overview 
of expression kinetics of the bone markers alkaline phosphatase (A LPL; 215783_s_at), bone sialo- 
protein (IBSP ; 207370_at), osteopontin (SPP1; 209875_s_at), osteocalcin (BG LA P; 206956_at), col­
lagen 1A1 (Col1A1; 202311 _s_at), RUNX2 (221283_at), C/EBPB (212501 _at) and FOS (209189_at) 
during osteogenesis as revealed from microarray analysis. o, D EX  ; •, D EX; □, DEX+BMP2; ■, 
DEX+1,25(OH)2D3. Average expression values ± SD from triplicate microarray experiments are 
shown; * p < 0.05; ** p < 0.01; *** p < 0.001 compared to D EX  at the same time point.
genes significantly regulated by DEX+1,25(OH)2D3.
1 As the algorithm used to identify accelerated or decelerated genes requires expression intensities of the two preceding
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Table 6.2: Overview of the number of 1,25(OH)2D3-accelerated (EARLY, FAST) or decelerated 
(LATE, SLO W ) genes per time point as revealed from microarray gene expression analysis1. 0  
indicates the number of accelerated or decelerated genes with both a maximum and minimum. ND= 
not determined.
TIME POINT (HRS) TOTAL 
# GENES
0
# GENES3 6 12 24 48 72 120
MAX EARLY 9 12 38 192 169 21 ND 441 584
58FAST 4 1 11 29 79 14 5 143
MIN EARLY 2 15 44 129 71 19 ND 280 435
FAST 3 8 9 22 103 4 6 155
MAX LATE ND 19 31 8 5 3 3 69 91
7SLOW 8 7 6 1 0 0 0 22
MIN LATE ND 5 9 9 5 3 5 36 59
SLOW 5 3 1 4 1 2 7 23
Table 6.2 shows the number of accelerated or decelerated genes in the 
presence of 1,25(OH)2D3 for each of the seven time points between 3 hrs 
and 120 hrs. In total, 584 genes showed an early or fast (local) maximum, 
and 435 genes displayed an early or fast (local) minimum between 3 and 120 
hrs. Of all these accelerated genes, 58 genes showed both an accelerated 
maximum and an accelerated minimum. In total, (584+435-58=) 961 unique 
genes were found to be accelerated by 1,25(OH)2D3 compared to treatment 
with DEX only. The largest subsets of accelerated genes were found at 24 
hrs and 48 hrs. In contrast, only 91 genes showed a late or slow (local) 
maximum, and 59 genes displayed a late or slow (local) minimum between 3 
and 120 hrs by 1,25(OH)2D3. Of all these decelerated genes, 7 genes showed 
both a decelerated maximum and a decelerated minimum. In total 
(91+59-7=) 143 different genes were decelerated by 1,25(OH)2D3. Of all the 
2095 genes regulated by 1,25(OH)2D3 over 45decelerated expression 
kinetics compared to DEX-induced expression profiles. In Figure 6.3A, 
examples of various genes showing accelerated expression kinetics are 
presented. c-MYC displays an early MAX at 72 hrs, ALDH2 has a fast 
MAX at 48 hrs, CDK4 exerts an early MIN at 24 hrs, while TUBA1B 
displays a fast MIN at 48 hrs. Accelerated expression of these genes was 
confirmed by real-time quantitative RT-PCR using RNA from an
(decelerated) or two subsequent time points (accelerated) for each individual treatment, we were not able to determine 
accelerated or decelerated genes at 1 hr, 192 hrs and 288 hrs, nor could we identify early genes at 120 hrs, and late genes at
3 hrs.
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independent osteogenic time-course experiment, as shown for c-MYC in 
Supplemental Figure S1. An example of an accelerated cluster is given in 
Figure 6.3B, showing a heatmap of the 129 genes with an earlier minimum 
at 24 hrs in the presence of 1,25(OH)2D3 compared to the minimum reached 
at 48 hrs in DEX- and DEX+BMP2-treated cells. Supplemental Table S2 
provides the list of genes corresponding to this group of accelerated genes. 
In conclusion, 1,25(OH)2D3 has a major impact on gene expression kinetics 
during early phase osteogenesis of hMSCs, resulting in accelerated 
expression kinetics of over 45DEX+1,25(OH)2D3, of which the majority is 
accelerated after 24-48 hrs of treatment.
Figure 6.3: A. 1,25(OH)2D3 accelerates gene expression during osteogenesis of hMSCs. Exam­
ples of various types of accelerated gene expression kinetics. c-MYC (202431 _s_at): Early M AX 
72 hrs; CDK4 (202246_s_at): Early M IN  24 hrs; ALDH2 (201425_at): Fast M AX 48 hrs; TUBA1B 
(213646_x_at): Fast M IN  48 hrs. Average expression values ± SD from triplicate microarray experi­
ments are shown; * p < 0.05; ** p < 0.01; *** p < 0.001 compared to D EX  at the same time point. 
o, D EX  ; •, D EX; □, DEX+BMP2; ■, DEX+1,25(OH)2Ds.
Biological processes accelerated by 1,25(OH)2D 3 To get insight into the 
biological significance of the large set of genes accelerated by 1,25(OH)2D3, 
GO enrichment analysis was performed to identify biological processes 
overrepresented in the various accelerated gene selections (Table 6.3(a), data
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Figure 6.3: B. 1,25(OH)2D3 accelerates gene expression during osteogenesis of hMSCs. Heatmap of 
129 genes displaying an earlier minimum at 24 hrs in DEX+1,25(OH)2D3-treated cells in comparison 
to the minimum at 48 hrs in DEX- and DEX+BMP2-treated cultures. Average expression intensities 
based on triplicate microarray experiments for each time point and treatment (D EX, DEX+BMP2, 
DEX+1,25(OH)2D3) are expressed as 10-log ratios compared to time-matched untreated (D EX  ) con­
trols. Genes are ordered on similarity based on the hierarchical clustering result indicated on the left. 
In Supplemental Table S2, the corresponding list of hierarchically clustered genes is shown.
not shown). GO analysis of the sets of genes displaying an earlier maximum 
at any of the seven time points between 3 and 120 hrs indicated that various
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GO terms related to “cellular differentiation”, “development” and 
“morphogenesis” were significantly enriched. Table 6.3(a) also provides an 
overview of genes contributing to enrichment of these biological processes. 
These results suggest that 1,25(OH)2D3 may accelerate the process of 
osteogenesis by regulation of genes known to be involved in bone formation, 
such as TGFB2, DLX5, HDAC5, GHR, as well as via several other 
differentiation genes of which the role in osteogenesis is unknown or poorly 
understood, such as NRP2, HSPA2, FZD4, PSEN1. GO analysis of the sets 
of genes with an earlier minimum indicated that biological processes related 
to “RNA metabolism” (24 hrs) and “regulation of the cell cycle” (48 hrs) 
were enriched (Table 6.3(a)). For the fast MIN gene selections biological 
processes related to the “cell cycle” and “microtubule-based processes” were 
most prominently enriched (Table 6.3(a)). The cell cycle-annotated genes 
mainly involve positive regulators of cell cycle progression, such as BIRC5, 
CDC20, CDC2, CCNH and MCM2, MCM3, MCM6 and MCM7, and 
covered all phases of the cell cycle. Altogether, GO analysis suggests that 
accelerated gene expression kinetics by 1,25(OH)2D3 may result in 
accelerated differentiation and/or cell cycle kinetics during the process of 
osteogenesis.
Effect of 1,25(OH)2D3 on osteogenic commitment, maturation and 
mineralization To monitor whether 1,25(OH)2D3 may affect the kinetics of 
osteogenesis, ALP protein expression and activity was measured as a 
function of osteogenic treatment over time. As shown in Figure 6.4A, ALP 
enzymatic activity was induced from day 4 on by DEX or DEX+BMP2 
compared to the negative control DEX , while ALP activity was already 
increased on day 3 in the presence of DEX+1,25(OH)2D3. During the first 5 
days of osteogenesis, ALP enzymatic activity remained higher in 
DEX+1,25(OH)2D3-treated cultures compared to DEX- or 
DEX+BMP2-treated cultures. After 6 days, ALP activity became similar in 
DEX+1,25(OH)2D3- and DEX+BMP2-treated cultures. Flow cytometric 
analysis confirmed the enhanced onset of ALP protein expression by 
1,25(OH)2D3 (Figure 6.4B); in the presence of DEX+1,25(OH)2D3 45% of 
the cell population was positive for ALP expression on day 3, compared to 
20% ALP-positive cells following treatment with DEX or DEX+BMP2. 
During the first 6 days, the percentage of ALP-positive cells remained higher
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Figure 6.4: 1,25(OH)2D3 accelerates osteogenesis of hMSCs. (A-C) 1,25(OH)2D3 accelerates os­
teoblast differentiation. (A ) A LP enzymatic activity was measured over time and corrected for neu­
tral red uptake as a relative measure for cell numbers. (B ) The percentage of ALP40 positive cells 
and (C) the average A LP expression per cell was determined over time by flow cytometry. (D, E ) 
1,25(OH)2D3 accelerates matrix mineralization as measured by the amount of calcium deposited in 
the extracellular matrix over time. White bars or o, D EX ; Light grey bars or •, D EX; Dark grey 
bars or □, DEX+BMP2; Black bars or ■, DEX+1,25(OH)2D3. Data are representative of three in­
dependent experiments. Results shown in (B,C ) are from a single experiment whereby 5000 cells are 
measured per sample. Bars (A ) and line graphs (D ,E) represent means ± SD of biological duplicates 
from one experiment; * p < 0.05; ** p < 0.01; *** p < 0.001 compared to D EX (D ) or D EX (E ) at 
the same time point.
in the presence of DEX+1,25(OH)2D3 than in the presence of DEX or 
DEX+BMP2 (Figure 6.4B). Furthermore, both 1,25(OH)2D3 and BMP2 
enhanced the average ALP protein expression level per cell compared to 
treatment with DEX alone (Figure 6.4C). As shown in Figure 6.1A, after 9 
days of osteogenesis the percentage of ALP-positive cells in DEX+ 
1,25(OH)2D3-treated cultures became very similar to that seen in 
DEX+BMP2-treated cultures, while the average ALP expression per cell in 
DEX+BMP2-treated cultures was almost 2-fold increased. To investigate the 
effect of 1,25(OH)2D3 on the kinetics of onset of matrix mineralization the 
amount of calcium deposited in the extracellular matrix was measured over 
time during the early phase of hMSC matrix mineralization [16]. Calcium
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deposition was detected from day 7 on following treatment with 
DEX+1,25(OH)2D3 (Figure 6.4D). There was a clear acceleration by at least 
one day in the onset of calcium deposition in cultures treated with 
DEX+1,25(OH)2D3 compared to DEX or DEX+BMP2 (Figure 6.4D, 6.4E). 
Accelerated deposition of calcium in the presence of 1,25(OH)2D3 
correlated with a strong increase in the expression of genes known to be 
expressed during matrix mineralization, such as IBSP, SPP1 and BGLAP 
(Figure 6.2B) [29]. As shown in Figure 6.1C, at later stages of matrix 
mineralization DEX+BMP2 more potently enhanced deposition of calcium 
compared to cultures treated with DEX+1,25(OH)2D3. Together, these 
studies indicate that, compared to DEX- or DEX+BMP2- treated cultures, 
1,25(OH)2D3 promotes osteogenic differentiation of hMSCs by accelerating 
onset of osteoblast differentiation and matrix mineralization. At later stages 
of osteogenesis, BMP2 becomes more potent than 1,25(OH)2D3, to enhance 
DEX-induced ALP activity and calcium deposition in the extracellular 
matrix.
Effect of 1,25(OH)2D3 on cell cycle kinetics The fact that the KEGG cell 
cycle pathway is enriched in the set of 2095 genes regulated by 
DEX+1,25(OH)2D3 (Supplemental Table S1) and the observation that 
1,25(OH)2D3 accelerates expression kinetics of many cell cycle-related 
genes according to GO analysis (Table 6.3(a)) suggests that regulation of the 
cell cycle may be important for osteogenesis. We therefore monitored 
kinetics of hMSC proliferation as a function of osteogenic treatment over 
time. Cellular proliferation of hMSCs was followed in parallel cultured 
plates during the course of osteogenesis by consecutive 24 hrs measurements 
of [3H]- thymidine incorporation into newly synthesized DNA 
(Figure 6.5A), as well as by cell counting (Figure 6.5B). In agreement with 
the fact that DEX is a potent inhibitor of cellular proliferation of hMSCs [9], 
our data show that upon treatment of hMSCs with DEX, DEX+BMP2 or 
DEX+1,25(OH)2D3, DNA synthesis was strongly inhibited during the first 4 
days compared to DEX treated cells (Figure 6.5A). [3H]-thymidine 
incorporation in DEX cultures reduced as cells grew confluent. Following 
this period of growth arrest, cells re-entered the cell cycle as shown by a 
transient increase in [3H]-thymidine incorporation reaching peak levels after
4-5 days of treatment. Despite the fact that 1,25(OH)2D3 accelerated
129
6.4. RESULTS
expression of many of these cell cycle-related genes, 1,25(OH)2D3 only 
weakly enhanced [3H]-thymidine incorporation after 72 hrs, thus marginally 
affecting the kinetics of cell cycle re-entrance. Also studies in which the 
number of cells was counted over time as a function of the different 
treatments did not show selective increase in cell numbers by 1,25(OH)2D 
(Figure 6.5B), together indicating that 1,25(OH)2D3 has only minor effects 
on kinetics of cell cycle progression during osteogenesis. To further establish 
the role of the cell cycle in onset of osteogenesis, cells were treated with 
aphidicolin, a DNA polymerase inhibitor which blocks cells at the S-phase 
in the cell cycle (data not shown). Aphidicolin did not affect onset of 
osteoblast differentiation as measured by relative induction of ALP activity 
(Figure 6.5C), indicating that the temporary expansion of differentiating 
hMSCs does not appear to be essential for onset of osteogenesis.
MYC binding sites in promoter regions of accelerated genes For the majority 
of genes showing accelerated expression in the presence of 1,25(OH)2D3, 
the accelerated kinetics occur after 24-48 hrs of treatment, indicating that 
they are most likely not direct target genes. We hypothesized that 
identification of transcription factors that drive accelerated gene expression 
in response to 1,25(OH)2D3 may be potentially novel regulators of 
osteoblast differentiation, as 1,25(OH)2D3 initiates a transcriptional program 
that results in accelerated onset and progression of osteogenesis. To get 
insight into the transcription factors that are possibly involved in accelerated 
expression kinetics, we performed transcription factor binding site 
enrichment analyses on promoters of accelerated genes (Supplemental Table 
S3, and data not shown). Interestingly, binding sites for several transcription 
factors, known to be involved in osteogenesis, were found to be significantly 
enriched, including ID1, NF-Y, PRRX2, ARNT-AHR citeRyan07, 
tenBerge98, Zhang08. In addition, binding sites for FOS, MYC and E2F1 
were significantly over-represented in the accelerated gene selections 
(Supplemental Table S3). These findings, together with the fact that 
expression kinetics of c25 MYC, FOS and CDK4, the latter controlling E2F 
transcriptional activity, are accelerated by 1,25(OH)2D3 (Fig 6.2B,
Figure 6.3A) makes these transcription factors interesting for further 
analysis.
The role ofc-MYC in osteogenesis of hMSCs Based on our observations that
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Figure 6.5: Cell cycle progression is not required for onset of osteogenesis. (A ,B ) 1,25(OH)2D3 
weakly enhances re-initiation of cell cycle progression following a period of growth arrest as measured 
by (A ) [3H]-thymidine incorporation into newly synthesized DNA over consecutive 24 hr intervals in 
parallel cultured plates (“ 1-2” days indicates incorporation measured from day 1 to day 2 after onset 
of osteogenesis, etc.) and by (B ) counting cells over a period of 7 days. (C ) Inhibition of cell cycle 
progression by aphidicolin does not affect onset of osteoblast maturation as measured by A LP activity. 
hMSCs were treated with osteogenic media on day 0 and day 1 in the presence of DMSO (control) or 
aphidicolin, which remained on the cells until day 5. A LP enzymatic activity was measured on day 
5 and was corrected for neutral red uptake. White bars or o, D EX ; Light grey bars or •, D EX; Dark 
grey bars or □, DEX+BMP2; Black bars or ■, DEX+1,25(OH)2D3. Data shown are representative 
of at least two independent experiments. Line graph in (B ) represents the average of four counts of 
single samples for each time point and treatment of a representative experiment. Line graph (A ) and 
bars (C ) represent means ± SD based on biological duplicates from a single experiment; * p < 0.01 
compared to DMSO for the same osteogenic treatment.
expression of c-MYC is enhanced and accelerated by 1,25(OH)2D3, that 
DNA binding sites for c-MYC are enriched in several subsets of genes 
showing accelerated expression kinetics, and that 1,25(OH)2D3 accelerates 
osteogenic differentiation of hMSCs, we hypothesized that c-MYC might be 
a key regulator of osteoblast differentiation. To test this hypothesis, hMSCs 
were infected with c-MYC encoding lentivirus. Infection of hMSCs with 
control eGFP lentivirus revealed that under the conditions used, over 90% of
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the hMSCs expressed eGFP for at least three weeks (data not shown). 
Real-time PCR analysis revealed that c-MYC expression levels increased 
5-fold following transduction of hMSCs with lentiviral c-MYC (data not 
shown). In comparison, a 3-fold increase in endogenous c-MYC expression 
was observed upon treatment with DEX+1,25(OH)2D3 (Figure 6.3A). As 
shown in Figure 6.6, overexpression of c-MYC was not sufficient in itself to 
induce osteogenesis of DEX cultures. Furthermore, c-MYC was not able to 
enhance ALP expression in cells treated with DEX or DEX+1,25(OH)2D3.
In contrast, c-MYC strongly promoted ALP activity induced by 
DEX+BMP2 as early as three days after onset of treatment (Figure 6.6A), 
which could not be accounted for relative differences in cell numbers as 
measured by neutral red uptake (Figure 6.6B). Flow cytometric analysis of 
ALP protein expression in c- MYC overexpressing hMSCs revealed that at 4 
days of treatment with DEX+BMP2 already more than 60% of the 
c-MYC-overexpressing cell population was positive for ALP expression, 
compared to only 30% in the control population. Average ALP protein 
expression per cell was only slightly increased (Figure 6.6C and 6.6D). 
Calcification of the extracellular matrix was significantly promoted when 
c-MYC infected cells were treated with DEX+BMP2 or DEX+1,25(OH)2D3, 
resulting in a 114% and 33% increase in calcium deposition, respectively 
(Figure 6.6E). Apparently, overexpression of c-MYC particularly synergizes 
with BMP2 to enhance osteoblast differentiation and matrix maturation of 
hMSCs, and to a lesser extent enhances 1,25(OH)2D3-induced matrix 
mineralization. This suggests that endogenous c-MYC protein expression 
levels may be limiting differentiation in cells treated with DEX+BMP2 but 
not, or to a lesser extent, in cells treated with DEX or DEX+1,25(OH)2D3. 
The observation that neutral red uptake was not changed following 
overexpression of c-MYC (Figure 6.6B) suggests that the potentiating 
effects of c-MYC on osteogenesis occur in the absence of effects on cellular 
proliferation. Still, [3H]-thymidine incorporation was clearly increased upon 
overexpression of c-MYC, whereby the fold increase of [3H]-thymidine 
incorporation into c-MYC overexpressing hMSCs compared to control cells 
was similar for all three osteogenic treatments (Figure 6.6F). As neutral red 
uptake did not increase upon c-MYC overexpression, we next examined the 
effect of c-MYC on induction of apoptosis in osteogenic cultures. As shown
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in Figure 6.6G, overexpression of c-MYC caused a 4-fold increase in 
caspase 3/7 activity in cells treated with DEX or DEX+1,25(OH)2D3, a
5-fold increase in cells treated with DEX, and a 6-fold increase in cells 
treated with DEX+BMP2. These results indicate that c-MYC enhances both 
cellular proliferation and apoptosis during all treatments, while c-MYC 
particularly potentiates DEX+BMP2-induced osteogenesis.
Figure 6.6: (A , B, C and D) c-MYC potentiates DEX+BMP2-induced osteogenesis of hMSCs. (A ) 
c-MYC enhances A LP enzymatic activity induced by DEX+BMP2 as measured after 3 days of treat­
ment. (B ) In parallel with the A LP assay, neutral red uptake as a relative measure for cell numbers 
was measured. (C, D) c-MYC potentiates osteoblast differentiation induced by DEX+BMP2. After 
4 days the percentage of A LP positive cells (C ) and the average A LP expression per cell (D ) was 
quantified by flow cytometry. White bars or o, D EX  ; Light grey bars or •, D EX; Dark grey bars or 
□, DEX+BMP2; Black bars or ■, DEX+1,25(OH)2D3. A ll data presented are representative of at 
least two independent experiments. Results shown in (C, D) are from a single experiment whereby 
5000 cells are measured per sample. Bars (in A and B ) represent means ± SD of biological duplicates 
from representative experiments; * p < 0.01; ** p < 0.005; *** p < 0.001 for MYC-infected cells 
compared to eGFP- or HA-infected cells for the same treatment.
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Figure 6.6: (E, F  and G) c-MYC potentiates DEX+BMP2-induced osteogenesis of hMSCs. (E ) c- 
M YC enhances matrix mineralization induced by DEX+BMP2 and DEX+1,25(OH)2D3. The amount 
of calcium deposited in the extracellular matrix was quantified on day 13. (F) Effect of overexpres­
sion of c-MYC on cellular proliferation of hMSCs. [3H]-thymidine incorporation into newly syn­
thesized DNA was measured over consecutive 24 hr intervals in parallel cultured plates. Ratios of 
[3H]-thymidine incorporation in MYC-infected cells over control cells are plotted over time for the 
various treatments; “0-1” days indicates incorporation measured between day 0 and day 1 after on­
set of osteogenesis, etc. (G ) Effect of c-MYC overexpression on apoptosis of hMSCs. Induction of 
apoptosis was measured after 5 days of osteogenic treatment by performing a Caspase-GLO 3/7 assay. 
White bars or o, D EX  ; Light grey bars or •, D EX; Dark grey bars or □, DEX+BMP2; Black bars or 
■, DEX+1,25(OH)2D3. A ll data presented are representative of at least two independent experiments. 
Bars (in E  and G) represent means ± SD of biological duplicates from representative experiments; 
* p < 0.01; ** p < 0.005; *** p < 0.001 for MYC-infected cells compared to eGFP- or HA-infected 
cells for the same treatment.
6.5 Discussion
BMP2 and 1,25(OH)2D3 are potent inducers of osteoblast differentiation in a 
wide variety of osteoblastic models systems [36,39]. However, few studies 
have directly compared the effects of BMP2 and 1,25(OH)2D3 on 
DEX-induced osteoblast differentiation of hMSCs [18], and little is known 
about the molecular mechanisms by which they commonly enhance 
DEX-induced osteoblastogenesis. Our present comparative genome-wide
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expression analysis provides the first insight into the global transcriptional 
mechanisms that underlie the potentiating effects of BMP2 versus 
1,25(OH)2D3 on DEX-induced osteogenesis of hMSCs. Our previous [11] 
and present microarray studies reveal a novel role for 1,25(OH)2D3 in 
acceleration of gene expression kinetics during osteoblast differentiation of 
hMSCs, particularly by induction of genes involved in differentiation and 
cell cycle regulation. Moreover, our microarray time-series analyses indicate 
that 1,25(OH)2D3 and BMP2 employ different mechanisms to enhance 
DEX-induced osteoblast differentiation. Thus, in contrast to 1,25(OH)2D3, 
BMP2 particularly augments the amplitude of DEX-induced gene expression 
and does not affect expression kinetics. Additionally, as can be expected 
from the different signalling pathways they elicit, 1,25(OH)2D3 and BMP2 
drive different transcriptional programs, as illustrated for example by 
differential regulation of the osteoblast maturation marker osteocalcin, but 
also by our finding that c-MYC expression is enhanced and accelerated by 
1,25(OH)2D3, but not by BMP2. These observations, together with our novel 
finding that overexpression of c-MYC mainly enhances 
DEX+BMP2-induced osteoblastogenesis, support the hypothesis that 
1,25(OH)2D3 and BMP2 drive different osteogenic programs, and possibly 
different types of bone cells, in DEX-treated hMSCs. Our observation that 
1,25(OH)2D3 speeds up the kinetics of gene expression as early as 12 hrs 
after onset of treatment, suggests that the osteogenic program is initiated 
faster, and accordingly that the different stages of differentiation commence 
earlier compared to DEX or 28 DEX+BMP2-treated cultures, as confirmed 
by our functional validations. The majority of genes was accelerated after 
24-48 hrs of treatment, too late to be direct 1,25(OH)2D3 target genes. We 
therefore suggest that 1,25(OH)2D3 may directly, and independent of DEX, 
control expression of (immediate) early regulator(s) of osteoblast 
differentiation, such as CEBPB and c-FOS [21,32], two of the earliest genes 
accelerated by 1,25(OH)2D3 (Figure 6.2B), and known direct target genes of 
1,25(OH)2D3 [8,10]. In turn, these regulators may set the pace for 
subsequent downstream target events (in cooperation with DEX which is 
required for osteoblastogenesis of hMSCs), for example by accelerated 
regulation of genes involved in developmental processes (Table 6.3(a)), 
including c-MYC. In contrast to 1,25(OH)2D3, BMP2 may not be able to
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initiate early osteogenic events in hMSCs independent of DEX, in agreement 
with published studies [13]. After DEX has primed immature hMSCs for the 
osteogenic lineage, BMP2 may then synergize with DEX to enhance 
osteogenic gene expression, possibly because DEX induces expression of 
BMP receptors or, alternatively, induces expression and/or activity of 
transcriptional regulators that cooperate with the BMP2 signalling pathway. 
We have no indications that under the osteogenic conditions used, 
differentiation into other lineages (cartilage, fat) occurs, but it still should be 
realized that the expression profiles measured over time may represent the 
integration of mRNA levels contributed by different cell populations (stem 
cells and more mature progenitors) at different stages of differentiation, 
inherent to gene expression analysis of differentiating stem cells. Although 
1,25(OH)2D3 can exert direct anabolic effects on osteoblast differentiation in 
vivo [15], little is known about how this is achieved. In contrast to the 
osteogenic effects of DEX on hMSCs cultured in vitro, prolonged treatment 
of patients with glucocorticoids results in bone loss, and eventually in 
development of glucocorticoid-induced osteoporosis. This is due, in part, to 
altered growth factor signalling, resulting in a decrease in the number and 
function of osteoblasts and an increased activation of osteoclasts [7,28]. 
1,25(OH)2D3 is prescribed for prevention and treatment of bone loss in 
patients with (glucocorticoid-induced) osteoporosis [36], primarily because 
1,25(OH)2D3 promotes bone mineralization indirectly via increased uptake 
of calcium and phosphate by the kidneys and intestines. Our studies suggest 
that 1,25(OH)2D3, together with glucocorticoids, may enhance bone 
formation by directly accelerating osteoblast differentiation of local MSCs. 
1,25(OH)2D3 is known to be a potent inhibitor of cell cycle progression in a 
wide variety of (osteoblastic) cell system, in part via downregulation of the 
proto-oncogene c-MYC [14]. In contrast, our studies show that 
1,25(OH)2D3 accelerates induction of cell cycle-related gene expression 
during the course of differentiation, despite the fact that 1,25(OH)2D3 does 
not significantly affect kinetics of cell proliferation of hMSCs. It is therefore 
unclear why so many cell cycle-related genes display accelerated expression 
kinetics by 1,25(OH)2D3. c-MYC is a known regulator of genes involved in 
cell cycle regulation, DNA replication, and RNA metabolism [19,22], 
biological processes enriched in our 1,25(OH)2D3-accelerated gene
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selections. In addition, it is becoming increasingly clear that c-MYC is an 
important regulator of stem cell fate decisions, being able to induce 
differentiation independent of its role as cell cycle regulator [22]. We 
therefore propose that accelerated c-MYC activity by 1,25(OH)2D3 in 
hMSCs primarily results in accelerated osteoblast differentiation. As a 
“side-effect” of accelerated c-MYC activity, expression of many cell 
cycle-related c-MYC target genes is accelerated, but the degree of 
modulation of these genes by 1,25(OH)2D3 appears to be insufficient to have 
a strong impact on cell cycle progression. Depletion of c-MYC in cranial 
neural crest cells of Xenopus laevis and in mouse embryos results in loss of 
branchial arches and a failure to form cartilage in facial skeletons, indicating 
a role for c-MYC in skeletogenesis [4,37]. c-MYC is known to be temporary 
induced during the proliferative stage of osteoblast differentiation in a 
variety of in vitro osteoblastic cell systems [28,30] as well as in bone in 
response to parathyroid hormone injection [24]. It has recently been shown 
that overexpression of c-MYC in MC3T3-E1 cells enhances expression of 
osteocalcin and ALP [41]. Our studies indicate that overexpression of 
c-MYC is not sufficient to induce osteogenesis in DEX cultures, indicating 
that c-MYC is not an osteogenic commitment factor in itself. Furthermore, 
overexpression of c-MYC does not enhance osteoblast maturation induced 
by DEX, indicating that c-MYC can not substitute for 1,25(OH)2D3. Thus, 
additional factors must be regulated by 1,25(OH)2D3 to enhance 
DEX-induced osteogenesis, possibly in cooperation with c-MYC. 
Furthermore, overexpression of c-MYC has no effect on 
DEX+1,25(OH)2D3-induced ALP activity, suggesting that the endogenous 
c-MYC expression levels induced by 1,25(OH)2D3 during early stages of 
osteogenesis are sufficient to fully support 1,25(OH)2D3-enhanced onset of 
osteoblast differentiation. Overexpression of c-MYC does synergize with 
1,25(OH)2D3 to enhance the late phase of osteogenesis, i.e.calcification of 
the matrix. Thus, endogenous c- MYC appears limiting for optimal 
DEX+1,25(OH)2D3-induced mineralization, in agreement with reduced 
expression levels of endogenous c-MYC at late stages of differentiation 
(Figure 6.3A). We are currently investigating whether loss of endogenous 
c-MYC expression affects DEX+1,25(OH)2D3-induced osteoblast 
differentiation. Furthermore, the fact that c-MYC synergized with BMP2 to
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enhance osteoblast differentiation and matrix mineralization suggests that 
endogenous c-MYC levels may be limited under BMP2-induced osteogenic 
conditions, and that BMP2 additionally regulates factors that can cooperate 
with overexpressed c-MYC. BMP signalling via Smad1 is known to 
suppress c-MYC expression [17]. Nevertheless, BMP2 strongly potentiates 
DEX-induced osteogenesis of hMSCs, most likely through efficient 
activation of alternative pathways, for example by enhancing expression 
and/or activity of RUNX2 [12]. We are currently studying the molecular 
mechanisms that underlie the synergy between BMP2 signalling and c-MYC 
to enhance osteogenesis.
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Table 6.3: Overview of the 1,25(OH)2D3-accelerated genes that contribute to enrichment of a selec­
tion of GO terms in the sets of genes of which maximum (M A X) or minimum (M IN ) expression 
shows “EA R LY ” or “FAST” kinetics. For each GO term, p-values of enrichment are indicated.
Acceleration GO process Gene Symbol Sequence Code Gene Name
MAX Notch signalling pathway ADAM10 202603_at a disintegrin and metalloproteinase domain 10
EARLY p-value: 4.26E-03 PSEN1 203460_s_at presenilin 1
24 HRS PSFL 22103 _s_at hypothetical protein DKFZp564D0372
Organ Development HDAC5 202455_at histone deacetylase 5
p-value: 4.34E-03 EXT2 202012_s_at exostosin-2
PRELP 37022_at Human prolargin gene
SORT1 212797_at ESTs, Moderately similar to sortilin precursor
FXR1 201637_s_at fragile X mental retardation syndrome-related protein 1
Organ Development CITED2 207980_s_at Cbp/p300-interacting transactivator 2
Morphogenesis ENG 201809_s_at endoglin
ANPEP 202888_s_at alanyl (membrane) aminopeptidase (CD13)
PTCH 209815_at patched (Drosophila) homolog
BTG1 200920_s_at B-cell translocation gene 1
BTG1 200921 _s_at B-cell translocation gene 1
TGFB2 220407_s_at transforming growth factor, beta 2
ZNF22 218005_at zinc finger protein 22(KOX 15)
NRP2 214632_at neuropilin 2
NRP2 219367_s_at neuropilin 2
SOCS5 208127_s_at KIAA0671 gene product
SOCS5 209648_s_at KIAA0671 gene product
Morphogenesis IMP-2 218847_at IGF-II mRNA-binding protein 2
p-value:7.11E-03 CPM 206100_at carboxypeptidase M
FBN2 203184_at fibrillin 2
DKK3 214247_s_at dickkopf (Xenopur laewis) homolog 3
Acceleration GO process Gene Symbol Sequence Code Gene Name
MAX Development COL7A1 204136_at collagen, type VII, alpha 1
EARLY p-valye: 2.77E-03 COL7A1 217312_s_at collagen, type VII, alpha 1
48 HRS CSF1 207082_at colony stimulating factor 1 (macrophage)
DHCR24 200862_at 24-dehydrocholesterol reductase
DIAPH2 205726_at diaphanous (Drosophila, homolog)2
DLX5 213707_s_at distal-less homeobox 5
FOXC1 213260_at cDNA FLJ11796 fls (FKHL7)
FOXO3A 204131 _s_at forkheadbox O3A
FOXO3A 210655_s_at forkheadbox O3A
FLNB 208614_s_at filamin B, beta(actin-binding protein-278)
ANGPTL2 213001_at angiopoietin-like 2
ANGPTL2 213004_at angiopoietin-like 2
ANGPTL2 219514_at angiopoietin-like 2
GHR 205498_at growth hormone receptor
ANGPT1 205608_s_at angiopoietin 1
ANGPT1 205609_at angiopoietin 1
FLJ140001 212970_at Homo sapiens mRNA; cDNA dKFZp43E033
FLJ140001 212985_at Homo sapiens mRNA; cDNA dKFZp43E033
APBB2 213419_at amyloid beta (A4) precursor protein binding
HSPA2 211538_s_at heat shock 70kD protein 2
IGFBP4 201508_at insulin-like growth factor binding protein 4
LAMB1 211651 _s_at Human laminin B1 mRNA, complete cds
LAMC1 200771 _at laminin, gamma 1 (formerly LAMB2)
MEIS1 204069_at Meis1 (mouse) homolog
GADD45B 207574_s_at growth arrest and DNA-damage-inducible, beta
GADD45B 209304_x_at growth arrest and DNA-damage-inducible, beta
GADD45B 209305_s_at growth arrest and DNA-damage-inducible, beta
PAPPA 201981 _at ESTs, Highly similar to TNHUA prothymosin alpha
SIX1 205817_at sine oculis homeobox (Drosophila) homolog 1
SOX9 202936_s_at SRY (sex determining region Y)-box 9
STAT3 208991 _at signal transducer and activator of transcription 3
KIAA1547 212770_at KIAA1547 protein
VEGFC 209946_at vascular endothelial growth factor C
FZD4 218665_at frizzled (Drosophila) homolog 4
CREG1 201200_at cellular repressor of E1A-stimulated genes
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Acceleration GO process Gene Symbol Sequence Code Gene Name
MIN Cell differentiation PAFAH1B1 200816_s_at a platelet-activating factor acetylhydrolase IB subunit alpha
EARLY p-value: 8.41E-03 DDX47 220890_s_at hqp0256 protein
12 HRS VEGF 210512_s_at vascular endothelial growth factor
VEGFC 209946_at vascular endothelial growth factor C
RUNX1 209360_s_at runt-related transcription factor 1
Cell Cycle GAD045A 203725_at growth arrest and DNA-damage-inducible, alpha
p-value: 1.83E-04 NOL1 214427_at nucleolar protein 1
PAFAH1B1 200816_s_at a platelet-activating factor acetylhydrolase IB subunit alpha
PNN 212037_at pinin, desmosome associated protein
VEGF 210512_s_at vascular endothelial growth factor
VEGFC 209946_at vascular endothelial growth factor C
CCNH 204093_at cyclin H
NOLC1 211951_at nucleolar and coiled-body phosphoprotein 1
Acceleration GO process Gene Symbol Sequence Code Gene Name
MIN RNA metabolism BCAS2 203053_at breast carcinoma amplified sequence 2
EARLY p-valye: 2.27E-14 C2F 209233_at C2f protein
24 HRS SYNCRIP 209025_s_at NS1-associated protein 1
NOL5A 200875_s_at nucleolar protein (KKE/D repeat)
DHX15 201385_at DEAD/H (Asp-Glu-Ala-Asp/His)box polypeptide 15
DKC1 201478_s_at dyskeratosis congenita 1, dyskerin
DKC1 201479_at dyskeratosis congenita 1, dyskerin
EPRS 200843_s_at glutamyl-prolyl-tRNA synthetase
FTSJ1 205324_s_at homolog of yeast SPB1
PAI-RBP1 217724_at PAI-1 mRNA-binding protein
HARS 202042_at histidyl-tRNA synthetase
HNRPAB 201277_s_at heterogeneous nuclear ribonucleoprotein A/B
HNRPD 209330_s_at heterogeneous nuclear ribonucleoprotein D
HNRPD 221480_at heterogeneous nuclear ribonucleoprotein D
HNRPD 221481 _x_at heterogeneous nuclear ribonucleoprotein D
ARF4 201097_s_at ADP-ribosylation factor 4
ARL1 201669_s_at ADP-ribosylation factor-like 1
CGI-94 218235_s_at CGI-94 protein
FLJ2D485 218984_at hypothetical protein
PPP2CA 208652_at protein phosphatase 2, catalytic subunit, alpha isoform
SRP46 21184_s_at splicing factor, arginine/serine-rich, 46kD
SFRS2 200754_x_at splicing factor, arginine/serine-rich 2
SFRS3 208673_s_at splicing factor, arginine/serine-rich 3
SFRS10 200893_at splicing factor, arginine/serine-rich 10
SNRPF 203832_at small nuclear ribonucleoprotein polypeptide F
TARS 201263_at threonyl-tRNA synthetase
HPRP8SP 215905_s_at U5 snRNP-specific 40 kDa protein
HNRPOL 209067_s_at heterogeneous nuclear ribonucleoptrotein D-like
Acceleration GO process Gene Symbol Sequence Code Gene Name
MIN Cell Cycle TXNL4A 202836_s_at thioredoxin-like protein 4A
EARLY p-valye: 4.77E-04 SORT1 214383_x_at sortilin 1
48 HRS H2AFX 205436_s_at H2A histone family, member X
BIRC5 202094_at baculoviral IAP repeat-containing protein 5
BIRC5 202095_s_at baculoviral IAP repeat-containing protein 5
BIRC5 210334_x_at baculoviral IAP repeat-containing protein 5
MAD2L1 203362_s_at MAD2 (mitotic arrest deficient, yeast, homolog)-like 1
TOPK 219148_at T-cell originated protein kinase
PSMD2 200830_at 26S proteasome non-ATPase regulatory subunit 2
CCNB1 214710_s_at cyclin B1
BCL10 205263_at B-cell CLL/Lymphoma 10
PRC1 218009_s_at protein regulator of cytokinesis 1
CDC20 202870_s_at cell division cycle 20 protein homolog
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Acceleration GO process Gene Symbol Sequence Code Gene Name
MIN DNA Metabolism PARP2 204752_x_at poly [ADP-ribose] polymerase 2
FAST p-value: 1.52E-13 RNASEH2A 203022_at ribonuclease H2 subunit A
48 HRS RAD51AP1 204146_at RAD51-interacting protein
CBX1 201518_at chromobox homolog 1
DNMT1 201697_s_at DNA (cytosine-5-)-methyltransferase 1
FEN1 204768_s_at flap structure-specific endonuclease 1
CBX5 209715_at chromobox homolog 5
POLE3 208828_at DNA polymerase epsilon subunit 3
RFC2 203696_s_at replication factor C subunit 2
RFC3 204127_at replication factor C subunit 3
RFC5 203209_at replication factor C subunit 5
WSB2 213734_at CS box-containing WD protein
RRM2 201890_at ribonucleotide reductase M2 polypeptide
SFPQ 201586_s_at splicing factor proline/glutamine rich
USP1 202413_s_at ubiquitin specific protease 1
KIAA0186 206102_at KIAA0186 gene product
DNA Metabolism MCM2 202107_s_at minichromosome maintenance deficient 2
Cell Cycle MCM3 201555_at minichromosome maintenance deficient 3
MCM6 201930_at minichromosome maintenance deficient 6
MCM7 210983_s_at minichromosome maintenance deficient 7
RAN 200750_s_at GTP-binding nuclear protein Ran
CDC7 204510_at cell division cycle 7-related protein kinase
CDC6 203968_s_at cell division control protein 6 homolog
Cell cycle CCT4 200877_at T-complex protein 1 subunit delta
p-value:4.58E-06 C10orf3 218542_at hypothetical protein FLJ10540
CDC2 203213_at cell division control protein 2 homolog
Cell cycle UBE2C 202954_at ubiquitin-conjugating enzyme E2C
Microtubule-based process ZWINT 204026_s_at ZW 10 interactor
CKS2 204170_s_at cyclin-dependent kinases regulatory subunit 2
STK6 208079_s_at serine/threonine kinase 6
TUBG1 201714_at tubulin, gamma 1
Microtubule-based process TUBB2 213726_x_at tubulin, beta
p-value: 2.80E-08 RAN 200750_s_at GTP-binding nuclar protein Ran
TUBB 204141 _at tubulin, beta polypeptide
TUBA3 209118_s_at tubulin, alpha 3
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Chapter
Conclusions, Discussion and Future 
Prospects
In this thesis advances are presented in the analysis of microarrays by 
introduction or application of a number of statistical and chemometric 
techniques. For instance, the comparison of nonparametric methods (chapter 
3) based on current biological knowledge is an example of the relation 
between statistical methods and biological validation. Another example is 
the application of nonparametric ANOVA as an extension of the 
ANOVA-PCA introduced in chapter 2. From these examples the conclusion 
can be drawn, that additions to a variety of different areas of microarray 
research are shown in this thesis. However, there are evident relations 
between these different topics which tie them together.
As mentioned previously, the topics in the chapters can be roughly 
categorized in three sequential steps, starting after the point of data 
extraction and normalization. The second and third chapter can be viewed as 
a description and introduction of methods giving general -  but improved -  
methods, which explicitly incorporate and use information about the 
experimental design and interfering experimental conditions in the analysis. 
The chapters 4 and 5 present methods which give a more detailed analysis of 
the biological information known about the groups of genes resulting from 
the aforementioned general methods. In the end, chapter 6 shows the direct 
application of microarray analysis methods in hypothesis generation and 
validation in “hands on” research.
In this final chapter, a short discussion is presented, which addresses to 
which extent the problems and goals in the introduction are solved and
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accomplished. Furthermore, the author’s opinion on the future of statistics 
and chemometrics in the analysis of biological data is given.
7.1 Conclusions
Below, the goals and problems as posed in the introduction will be explicitly 
addressed one by one, starting with the two problems, followed by the two 
goals. The problems were formulated as follows:
• Due to the nature of the microarray data new methods will have to be 
found which can handle the amount of data and are able to cope with 
disturbing factors as noise or other systemic effects.
• Second, the decision in biological validation tools is often not checked 
for stability of the results even though large differences could occur 
depending on the chosen cut-offs.
The first problem accentuates the need for methods, which can deal with the 
difficult nature of microarray data. More specifically the noise and other 
disturbing factors which are frequently present in the data are mentioned.
The ANOVA-PCA method described in chapter 2 is a good example of the 
development of such a method which can accomplish this. The method 
allows to separate all effects by modeling them in the ANOVA model. As a 
result one can perform a focused analysis, without the disturbance of 
unwanted systemic effects, which were resulting from the design or nature of 
the experiment.
An alternative approach to the first problem of the analysis of noisy 
microarray data is given in chapter 3. There, non-parametric methods are 
investigated which are less influenced by outliers and are generally more 
robust to disturbances by having less strict assumptions to start with. Of 
course the general idea is that this is also reflected in the sensitivity of the 
findings, but the results show that non parametric methods can be an 
attractive alternative to their parametric counterparts.
The second problem of stability of results from biological validation tools is 
tackled by the GOSpace method from chapter 4. There it is shown that it is 
useful to inspect a range of gene selection cut-offs in order to draw well 
informed biological conclusions which are less dependent of arbitrary
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decisions at the start of the analysis. By drawing enrichment surfaces and 
ROC curves an overview of the biological information space is given, 
solving the problem of stability.
From the problems the goals below were formulated in the introduction:
• Is there a way to extend the explorative analysis of data to the biological 
questions for the experiment and to improve the analysis of large 
microarray datasets in general?
• Is it possible to bring advances in analysis of microarray experiments, 
in stability and other aspects, by applying biological information, which 
is available beforehand from external sources?
The first goal is applicable to and met by all chapters in the thesis; all 
chapters describe new methods or their application and improvements to 
large gene expression datasets.
The second goal is more specific, and is partly met by the work presented in 
chapter 4. As mentioned before, the methods of chapter 4 bring advances in 
stability of biological validation. The improved application of biological 
information in the analysis is tackled in chapter 5, describing the 
combination of preclustering with PCA. The examples show a clear 
improvement of relating newly formed subgroups of genes with important 
factors in the experiment.
The final conclusion can be drawn, that this thesis adds methodological 
contributions to the field of microarray analysis. More specifically, steps are 
made in the areas of pattern recognition, biological validation and the 
integration of biological information in the data analysis.
7.2 Discussion
The first point of discussion here is about the biological level of microarray 
data; at the RNA level of gene expression not all universal knowledge about 
an organism is necessarily present. It could be possible that the explanation 
to answer the questions underlying the disease or biological process which is 
studied, can only be found at a different level in the living organism. For 
instance, regulation can take place at the protein level by phosphorylation or 
even the organization of the DNA in the chromatin instead, which can not be
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deducted from gene expression patterns. Thus, not all biological questions 
can be answered by only using microarrays.
A solution to the more fundamental issue from the previous paragraph could 
be to take measurements at more levels. For example, epi-genetic 
measurements [1], measurements at the RNA level, protein level and 
metabolite level for all data points. Some of the multi-level experiments 
currently performed, will give the bioinformaticians, statisticians and 
chemometricians the daunting task of integrating and relating different types 
of biological data. The assumption for these experiments is that this gives a 
more realistic systems biology approach. In future, data fusion methods to 
accomplish this will have to be generated to explore the feasibility and 
possible benefits. Problems of data fusion will lie in the scaling of the 
different types of data, as well as difference in experimental setup, 
differences in experimental noise and differences in features which are 
measured in the datasets; most of the current platforms are not designed for 
compatibility and will measure different (sub)sets of genes.
Second, the work presented here could be extended on two specific aspects. 
A time-series micorarray dataset was used to perform the research. In the 
analysis the time information was not exploited fully, and it is possible that 
extra information can be gained by methods which do use the time 
component. An example of a method is by Storey et al. [7]. In this method 
splines are used to incorporate time information in the analysis.
Additionally, for the research presented in this thesis, only data generated 
with the Affymetrix platform were used. There is of course another type of 
microarray which is used frequently and it is called the cDNA microarray. 
The cDNA microarray platform has some other characteristics that will not 
be explained here, but in general the methods described in this thesis can be 
applied to the cDNA expression values. For instance, the ANOVA models 
from chapter 2 can even be applied to handle side effects of the cDNA 
method [5].
Third, the fact that we know the coding genes in the genome and can 
measure the expression of individual genes, does not mean that the function 
of the genes is known. As mentioned previously throughout the thesis, the 
biological information available for all measured transcripts is far from 
complete. This is problematic for interpretation of analysis results and poses
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interesting challenges to the scientists working on microarray data analysis.
Finally, there is of course the “soft” human factor which has to be discussed 
after the analyses presented in the previous chapters, which are based on 
“hard” data. Expectations and promises were high at the start of the -omics 
era, but heaps of data do not automatically results in an instant gain of 
knowledge. With the vast amount of data which has already been measured, 
enormous clusterings, gene networks and expression databases can easily be 
built. However, to the human eye and mind it can be difficult to have an 
overview, let alone understand or know which results are important. To some 
extent data analysis can help here, but it is also advisable to pay close 
attention at experimental design in combination of a set of well formulated 
simple research questions before the experiment is being performed. A 
method to focus the analysis of large datasets more to the research question 
at hand, is to link the data with chemometric methods to other measurements 
which give a relevant description of the disease or mechanism which is 
studied.
The solution of the problem of the limited amount of biological information 
will have to come from the biological field. The incorporation of this 
information will become more of the chemometrician’s, biostatistician’s and 
bioinformatician’s line of work in the future. Furthermore, when datasets 
emerge which are measured at various levels in the system, they will require 
an all-encompassing analysis. At the moment functional prediction based on 
prior data is far from where we would like it to be [3].
7.3 The future of chemometrics and statistics in the life sciences
In this thesis the focus was on the questions which can be answered with the 
data, as they are currently available. Nevertheless, like we are sometimes 
contemplating the practice of measuring single genes -  in the not so distant 
past - , future researchers will probably wonder how we were able to conduct 
our research without any functional information about such a substantial part 
of the genome.
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7.3.1 Currently available methods and new developments; problems 
and opportunities
In genomics a lot of techniques are still progressing in their development and 
new applications are found for more developed techniques. For the 
techniques which are becoming commonplace, developments are still 
needed. Even though the transcripts of a large number of genes can be 
measured, advances in the microarray analysis and increase of annotation 
information will make this technique more applicable and interpretable. A 
nice example for this is the re-annotation of chicken microarrays [6]. After 2 
years, one third of the probes on a microarray chip received a different 
annotation because of updated databases. As a result a substantial number of 
probes appeared to be unspecific, which can explain more about the 
expression levels which have been measured with the concerning probes. 
Elaborating on the incomplete annotations, a more directed and systemic 
increase in biological information about genes could be promoted by 
automated functional categorisation. Here the term automated is meant in 
the context of automated performance of experiments (thus not in the sense 
of electronic prediction which could also be envisioned in the field of 
bioinformatics). The experiments could be on a scale like current screening 
assays in pharma. Currently it is not cost effective to think and operate 
research in this fashion, but more and more standard test are already 
performed by robots in certain labs. Efforts in other fields (like for instance 
lab on a chip [2]) could be of great importance here. This involves 
embedding the techniques mentioned in the previous section. A lot of 
techniques which are considered state of the art -and are considered 
difficult, sensitive and dependent on expert skills- should be applied in an 
automated controlled fashion then. Statistics and chemometrics could be 
involved to design the set up of such systems in order to be able to interpret 
the resulting even larger stream of data.
A development in molecular biology which is of particular interest is the 
field of very high throughput sequencing (or “deep sequencing”) of samples. 
Although the high throughput sequencing was originally used for genomic 
DNA sequencing, the technique will be used more and more for different 
purposes. For instance, researchers have used deep sequencing to map 
histone genome-wide histone modifications in epigenetic studies [1]. It is
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possible that in the near future the microarray technique will be in 
competition with high throughput sequencing transcriptome analysis. An 
example for microRNA expression detection in Arabidopsis Thalania with 
deep sequencing can already be given [8]. Next generation sequencing could 
be more cost effective, but still major efforts have to be made in the post 
processing of the sequence data. Another problem to tackle for this 
technique is how to identify low expressed genes when no normalization is 
applied on the samples. A final interesting development worth mentioning 
here, is the application of high throughput technology, which allows for the 
direct sequencing of RNA from samples. Currently the high throughput 
RNA sequencing is being developed, but the post sequencing analysis 
suffers from identical problems as the DNA high throughput sequencing.
Other examples of coming of age problems can be found in the fields of 
proteomics and metabolomics. These techniques currently suffer from two 
major problems: comparability of results between experiments and 
identification of metabolites. Problems will probably be tackled by major 
efforts which are currently ongoing.
Besides coming of age, the problem of lack of knowledge about fundamental 
characteristics of the enormous amount of gene expression data which is 
currently being generated should be tackled as well. A first example of such 
a fundamental characteristic is the knowledge about time scale of effects of 
interest. This is of major importance to the design of experiments and the 
algorithms which are used in the analysis. More knowledge about time scale 
of effects, or interactions between effectors which behave on different 
timescales, will improve the results of analyses. This is desirable, because 
mechanisms like age, the circadian rhythm, the diurnal cycle, the nutritional 
state, the physiological state -o r for humans the mood (psychological state)- 
are interfering with in vivo experiments at the moment. Gaining knowledge 
about these effects will be of great importance to the conclusions drawn 
from the components of an organism at different levels (proteins, mRNA and 
metabolites). With microarray analysis we are looking at snapshots which 
might contain the disturbing noise of the cyclic mechanisms mentioned here. 
A second fundamental characteristic of the data for which basic knowledge 
should be improved is the complexity of the diseases and biological 
mechanisms which are studied. A large number of experiments have been
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designed to find single biomarkers with the assumption that these 
biomarkers exist, only to find out that the number of involved genes and 
processes is larger than anticipated. If this knowledge is not updated and 
applied in the design of future experiments, one will always be stuck at the 
level of exploratory research.
A final example of a field where improvements can be made, is in the 
understanding of complex interactions between organisms. For instance the 
human can be thought of as a human-microbe hybrid, and the health of this 
“super organism” will be affected by intrinsic properties such as human 
genetics, diurnal cycles, age and lifestyle choices (food, drink and drug 
intake). But these factors will influence the acquisition of a healthy and 
stable gut microflora as well. Alterations in this “super organism” will be 
manifest in the metabolite complement within its serum and urine 
samples [4].
7.3.2 The ideal future perspective
In a “perfect” world, a patient feeling ill visits the doctor. There the patient 
will give a small sample of blood or urine followed by a readout of a chip, 
which has continuously monitored basic data like blood pressure, heart rate 
and temperature. Within a couple of minutes the exact illness and treatment 
are returned to the patient, independent of how vague the patients complaints 
may have been.
The situation described is a fast accurate diagnosis based on historic data 
and resulting in a treatment for a specific individual patient. The prediction 
or classification is based on multiple markers generated from a predictive 
model which was generated and validated fully at all possible levels. The 
model was based on a large network of known feed forward, feed backward 
relations between DNA folding, RNA transcripts, proteins and metabolites. 
Furthermore, the model and treatment are adapted based on the genetic 
predisponition of the patient.
To get anywhere near to this situation, there is still a long way to go. Setting 
aside, whether it would be ethically desirable to monitor one’s health 
continuously. In my mind, statistical methods will be involved in the process 
of getting us there, by means of models for classification, predictions or for 
instance accurate estimates of risks based on prior knowledge. At the
152
CHAPTER 7. FUTURE PROSPECTS
moment the question is whether we still need better methods and models, 
better data or better understanding of the systems underlying the data. My 
guess is that we will have more and more new measurements to relate and 
investigate. Results and analysis are intertwined and dependent on one 
another. More prior knowledge will give us better models, which render 
more prior knowledge, and so on. Therefore, the life sciences will need to 
develop an even more collaborative nature to get the anticipated results.
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Summary
Chapter
In this thesis work is presented on the statistical analysis of microarray data. 
Methods from the fields of statistics and chemometrics are adapted and 
combined to improve microarray analysis. A microarray dataset of 
mesenchymal stem cells was used in all the chapters of the thesis. The 
dataset was designed to investigate the effect of different treatments on 
osteogenesis. The gene expression was measured at several time points for 
the stem cells.
Methods which can cope with disturbing factors as noise and other systemic 
effects are presented in chapters 2 and 3. In chapter 2 the method 
ANOVA-PCA is applied to the mesenchymal dataset. The ANOVA was used 
to remove unwanted systemic effects and PCA was used to summarise and 
investigate the interaction effect components from an ANOVA model. It was 
shown that the interpretability of ANOVA models was improved by 
performing ANOVA-PCA. The visualisation of the results with biplots give 
information about effects of specific treatments on genes over time. Results 
on particular genes are in agreement with literature.
Even though the benefits of performing ANOVA were shown in chapter 2, 
the components calculated in the ANOVA model can be influenced by 
outliers and large numbers of noisy non-expressed genes. Because 
nonparametric methods are less effected by these factors, several methods to 
perform nonparametric ANOVA are applied to the stem cell dataset. The 
results are compared with normal ANOVA. With the comparison, significant 
differences are found between the estimates of main effects and interactions. 
Furthermore, the ANOVA method which consisted of the combination of
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rank transformed data and the median as location parameter gave the best 
representation of current biological knowledge.
The comparison of statistical methods based on current biological 
knowledge is presented in chapter 4 and chapter 5. There, methods are 
shown which introduce biological annotation information into statistical 
analyses to improve the interpretation. In chapter 4 advances on the current 
practice of enrichment analysis are shown. With the representation of 
enrichment results for multiple gene selection a more robust estimate of 
association of expression data with GO annotation is generated. Moreover, 
the application of ROC plots is used to assess the agreement of experimental 
results with current biological knowledge in chapter 4.
The biological information is exploited even further in the preclustering 
analysis in chapter 5. By grouping heterogeneous profiles in clusters per 
functional biological category, important relationships between profiles in 
the data and these categories can be identified. The relationships would 
otherwise be obscured. The patterns present in the newly formed subgroups 
are visualised with PCA. The improvements are shown for both the 
mesenchymal stem cell dataset and a well known yeast cell cycle dataset.
A more detailed description of biological findings for the mesenchymal stem 
cell dataset is given in chapter 6. Part of the biological findings are based on 
hypotheses generated from work in the previous chapters. Besides this, the 
biological questions from the stem cell experiment directed research in this 
thesis, by posing problems which needed to be solved. Finally, the 
conclusions and future developments of the thesis are summarised in chapter 
7.
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Samenvatting
Chapter ______
In dit proefschrift wordt werk aan de statistische analyse van microarray data 
gepresenteerd. Methodes uit de chemometrie en statistiek zijn aangepast en 
gecombineerd om de analyse van microarrays te verbeteren. In alle 
hoofdstukken van dit proefschrift is een microarray dataset gebruikt welke 
genexpressie meet in mesenchymale stamcellen. De dataset was ontworpen 
om voor verschillende behandelingen van deze cellen het effect op 
osteogenese te onderzoeken. De genexpressie in de cellen is gemeten op 
meerdere tijdspunten.
In de hoofdstukken 2 en 3 worden methodes gepresenteerd die zorgen dat de 
analyse van de data minder door verstorende factoren zoals ruis en andere 
experimentele effecten verstoord wordt. In hoofdstuk 2 werd dit bereikt door 
ANOVA-PCA toe te passen op de mesenchymale stamcel dataset. ANOVA 
werd gebruikt om ongewenste effecten te verwijderen, en de PCA werd 
gebruikt om de interactie effect componenten van het ANOVA model te 
onderzoeken en samen te vatten. Er werd aangetoond dat de 
interpreteerbaarheid van ANOVA modellen verbeterde door ANOVA-PCA 
toe te passen. Verder gaven de visualisaties van de resultaten in biplots 
informatie over het effect van de specifieke behandelingen op genen over de 
tijd. De resultaten kwamen voor specifieke genen overeen met wat bekend is 
in wetenschappelijke literatuur over de betreffende genen.
Ondanks de voordelen van het toepassen van ANOVA (hoofdstuk 2), blijkt 
dat de componenten die berekend werden in het ANOVA model beïnvloed 
kunnen worden door uitbijters en door grote aantallen genen die eigenlijk 
helemaal niet tot expressie zijn gekomen en ruis genereren. Omdat
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niet-parametrische methodes minder last van deze factoren zouden moeten 
hebben, zijn verscheidene methodes voor niet-parametrische ANOVA 
toegepast in hoofdstuk 3. De resultaten weren vergeleken met normale 
ANOVA. Met deze vergelijken werden significante verschillen gevonden 
tussen normale en niet-parametrische ANOVA voor de geschatte 
hoofdeffecten en interacties. Bovendien gaf een specifieke ANOVA methode 
de beste representatie van de biologische kennis die over de data bekend 
was. Deze methode gebruikte rang transformatie van de data en verder de 
mediaan als locatie parameter.
De vergelijking van de prestaties van statistische methodes op basis van 
beschikbare biologische kennis is van toepassing op het werk wat 
gepresenteerd wordt in de hoofdstukken 4 en 5. In deze hoofdstukken 
worden methodes uitgelegd welke ontwikkeld zijn om biologische kennis in 
de data analyse met te introduceren. In hoofdstuk 4 werden verbeteringen op 
de huidige toepassing van verrijkingsanalyses besproken. Door de resultaten 
van meerdere genselecties te onderzoeken werd een meer robuuste 
representatie van de relatie tussen GO annotatie en genexpressie 
gegenereerd. Bovendien werden in hoofdstuk 4 ROC plots toegepast om de 
overeenkomst tussen de experimentele resultaten en de huidige biologische 
kennis te bepalen.
Biologische informatie wordt nog beter gebruikt in hoofdstuk 5. Belangrijke 
relaties tussen profielen in de data en functionele categorieen konden worden 
gevonden door heterogene profielen te verdelen in clusters binnen elke 
functionele biologische categorie. Anders zouden deze relaties verborgen 
blijven. PCA werd gebruikt om de patronen van de nieuwe subgroepen te 
visualiseren. Voor zowel de mesenchymale stamcel dataset als een bekende 
celcyclus dataset voor gist werden gebruikt om de verbeteringen aan te 
tonen.
Uiteindelijk wordt een meer gedetailleerde beschrijving van biologische 
vondsten gegeven in hoofdstuk 6. Gedeeltelijk zijn de biologische 
ontdekkingen in dit hoofdstuk gebaseerd op hypotheses gegenereerd naar 
aanleiding van werk in de voorgaande hoofdstukken. Daarnaast hebben de 
biologische vragen die ontstonden bij de mesenchymale stamcel dataset 
richting gegeven aan het onderzoek in dit proefschrift. In hoofdstuk 7 
worden tenslotte conclusies getrokken en ontwikkelingen voor de toekomst
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bediscussieerd.
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